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Abstract
This thesis describes the development of separate assays to measure coenzyme Q10
(CoQ10) and vitamin K. Coenzyme Q is essential for the mitochondrial electron
transport chain, and vitamin K for the blood coagulation cascade. Vitamin K
deficiency is associated with haemorrhagic disease of the new-born, and CoQ10
deficiency with HMG-CoA-reductase inhibitor (statin) therapy and heart failure.
Coenzyme Q and vitamin K are usually measured by HPLC, using electrochemical
and ultraviolet, and electrochemical and fluorescence detection, respectively.
For vitamin K1, the limit of detection achieved using fluorescence and
electrochemical detection was 0.28 and 0.12 nmol/L, respectively. Sensitivity of
fluorescence detection is improved by using protic solvents in the mobile phase, and
platinum-black catalysed alcohol reduction. The lipophilicity and low endogenous
concentrations of vitamin K1 hinder its measurement, and further work is required to
produce a rapid, reliable and robust assay for its measurement in human plasma.
The limits of detection achieved using fluorescence, ultraviolet and
electrochemical detection to measure CoQ10 were 29, 4.8, and 0.34 nmol/L,
respectively. Plasma CoQ10 is not stable during long term storage at –13 ºC, but at –
80 ºC it is stable for at least 18 months.
The reference interval for plasma total CoQ10 in the New Zealand population
is 0.47 – 1.80 µmol/L. There is no clinical requirement for stratification of the
reference interval according to gender. Coenzyme Q10 in human plasma is
homeostatically controlled, varying little over a two month interval in healthy young
males.
Coenzyme Q10 supplements have significantly different bioavailability, with
the median increase in plasma CoQ10 ranging from 0.14 to 0.59 µmol/L for seven
different supplement brands. There is a large inter-individual variation in CoQ10
absorption, and hence plasma concentrations should be monitored during
supplementation. A plateau in CoQ10 absorption, from a single dose, at approximately
200 mg suggests that the maximum dose ingested at one time should be 200 mg or
less. Q-Gel capsules containing 30 mg of CoQ10 are twice as effective at raising blood
CoQ10 as 100 mg capsules.
Plasma CoQ10 in patients with chronic heart failure are significantly lowered
by approximately 33% when these patients receive Atorvastatin for six weeks. The
Abstract xi
absolute decrease in CoQ10 showed a significant correlation with worsening
endothelial function (r = + 0.548, p = 0.011).
Coenzyme Q9 was shown to be present in human plasma with a reference
interval of 8.8 – 47.0 nmol/L.
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Chapter 1. Introduction
1.1. Introduction
Coenzyme Q (ubiquinone, CoQ) and vitamin K (phylloquinone, vitamin K1, and
menaquinone) are quinones. The electron and proton transfer functions of these
compounds are of fundamental importance to all life forms; ubiquinone in the
mitochondria of eukaryotes, plastoquinone and vitamin K1 (phylloquinone) in the
chloroplast of plants, vitamin K1 in the blood coagulation cascade of animals, and
menaquinone in bacteria. The work described in this thesis started from a previous project
to develop an assay to measure vitamin K1 in the plasma of new born babies, and in human
and cow milk (1). This new test was intended for monitoring and investigating the
prevalence of haemorrhagic disease of the new-born, a condition associated with low
circulating vitamin K. As found in this study it was not practicable to meet the clinical
expectations (measuring low concentrations with small sample sizes) with the analytical
resources available. While this work was in progress there was escalating interest in CoQ.
Although their physiological roles are different, vitamin K and CoQ are chemically similar,
and it was expected that the experience with developing the vitamin K assay could be
adapted to measuring CoQ (1). Thus the work described here emphasises CoQ. With the
increasing popularity of statin therapy, a medication of choice for preventing
cardiovascular disease, a need to monitor the effect of statin therapy on CoQ has arisen.
Coenzyme Q has also become a popular health supplement. There is little reliable data on
the clinical biochemistry of CoQ and the work described here is a contribution to
improving this.
1.2. Quinones
The name “quinone” was given to a compound first described in 1838 (2), which was
obtained by oxidising the natural product quinic acid. This compound is now usually called
“benzoquinone”, and the term quinone is used generically for a whole class of compounds
that can be regarded as derivatives of benzoquinone. Quinones are unsaturated diketones,
and are related to aromatic compounds. There are two isomeric benzoquinones, 1,4-
benzoquinone (Figure 1.1), also called a paraquinone, and a 1,2-benzoquinone (called an
orthoquinone). However, almost all of the biochemically important quinones, and all of
those of clinical importance, are 1,4-quinones. Quinones with condensed ring systems are
common in nature, so as well as benzoquinones, there are naphthoquinones and
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anthroquinones. The basic structures and numbering systems of these are shown in Figure
1.1.
Figure 1.1 The basic structures and numbering systems of common biological
quinones.
Quinones show a characteristic reduction and oxidation (redox) chemistry, and the
biological importance of quinones centres on the resulting electron and proton transfer
functions of these compounds. Oxidation (or reduction) of quinols (or quinones) occurs in
two steps, with one hydrogen ion being abstracted from the quinol (or donated to the
quinone) to form a relatively stable radical, called a semiquinone (Figure 1.2), which is
resonance-stabilised. A second hydrogen ion can be removed (or added) to complete the
oxidation (or reduction) to a quinone (or quinol).
The transfer of electrons during oxidation and reduction of quinones can be used to
quantify them, using electrochemical detection. Semi-quinones have unpaired electrons,
and can therefore be measured with electron spin resonance (ESR).
Figure 1.2 The redox states of quinones.
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Because the reduction of quinones (or oxidation of quinols) involves hydrogen ions, the
potential of the reaction is strongly pH dependent, and can be used to measure pH. The
redox potential of different quinones also depends on their structure and environment.
Naphthoquinones are more stabilised by the condensed ring than benzoquinones and are
weaker oxidising agents. Anthroquinones are weaker still. These differences are significant
for their biological roles and affect the approach to measuring them.
The quinols are aromatic diphenols. The phenolic hydroxyl groups of quinols are weakly
acidic. At high pH phenoxide ions are formed, which are very easily oxidised, and are
sensitive to oxygen.
Methods for measuring quinones in the laboratory are mostly based on either their
spectroscopic properties or on their electrochemical properties. Quinones are typically
coloured compounds with absorbances in the visible region and intense near-UV
absorbance. Quinols, being aromatic compounds, typically absorb at shorter wavelengths
than the quinones but they are usually fluorescent.
The biologically important quinones contain long hydrophobic side chains, giving them
excellent lipid solubility. The chemical structures of some biologically important quinones,
CoQ, vitamin K, and α-tocopherol, are shown in Figure 1.3.
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Figure 1.3 The structures of some biologically important quinones, CoQ10, vitamin
K1, α-tocopherol, and α-tocopherol quinone.
1.2.1. Coenzyme Q
Coenzyme Q10 was first isolated from beef heart mitochondria by Frederick Crane of
Wisconsin, USA, in 1957 (3). Coenzyme Q10 is a 1,4-benzoquinone with a long (50-
carbon) isoprenoid side chain (Figure 1.3). Different CoQ analogues contain various
numbers of isoprenoid units in the sidechain, and the length of this side chain varies
between species, but is predominantly ten units in humans. The dominant CoQ homologue
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in rats is CoQ9 (4), with CoQ10, CoQ8 and CoQ7 also being present in rat plasma although
CoQ7 appears to be of dietary origin (4). Both the reduced (ubiquinol) and oxidised
(ubiquinone) forms of coenzyme Q10 (Figure 1.4) are present in the body, with the
intermediate (semiquinone) form being transient in nature, and unable to be isolated.
Oxidised CoQ10 is reduced to CoQ10H2 in the mitochondria by flavoenzymes such as
mitochondrial succinate dehydrogenase and NADH (5).
Figure 1.4 Coenzyme Q10 and its redox states.
The isoprene side chain gives the molecule excellent lipid solubility and allows its
localisation inside cellular membrane bilayers (Figure 1.5).
Figure 1.5 The location of CoQ10 in the lipid bilayer
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The percentage CoQ10H2 of total CoQ10 in plasma in a healthy individual is about 96% (6).
In human liver, pancreas and intestine, all CoQ10 is CoQ10H2, but in brain and lung most
CoQ10 (80%) is in the oxidised state (7). Coenzyme Q10H2 is easily oxidised in the
presence of oxygen. Therefore, it has been proposed that the ratio of CoQ10H2 to CoQ10
may indicate oxidative stress in the body (8, 9). It is generally assumed that systemic
antioxidant deficiency precedes and predisposes to the deleterious effects of oxidative
stress (10, 11). Kontush et al., (1997) (12) reported that the proportion of CoQ10H2 of total
CoQ10 decreases in the order young adults>aged controls>hyperlipidaemic patients without
complications>hyperlipidaemic patients with complications. However, Lenaz et al., (2002)
(13) proposed that antioxidant defences should actually increase in response to oxidative
stress, as an adaptation to the increased stress. Evidence of an increase in antioxidant
defences is provided in several animal studies where CoQ9 is significantly increased in
response to the pro-oxidant effects of diabetes mellitus (14-16). However, none of these
studies evaluated changes in the CoQ redox state. It is possible that the body adapts to an
oxidative stress by producing more total CoQ, so that while the percentage CoQH2 of total
CoQ decreases, the absolute amount of CoQH2 is similar to that in a healthy individual.
 Additionally, the ratio of CoQ10H2 to CoQ10 changes in a biological sample due to
oxidation of CoQ10H2 by atmospheric oxygen. The percentage CoQ10H2 of total CoQ10 in
plasma has been reported to be between 51 and 96% (4, 6, 17-25). The simple, robust and
well validated method of Tang et al., (2001) (6) suggests that in healthy individuals (n =
25) the percentage of CoQ10H2 is tightly regulated, at 96.3 ± 2.0 %. It is possible that the
reports of lower percentages of CoQ10H2 in healthy individuals are actually a result of
sample handling, especially when some methods recommend analysis of one sample at a
time (23, 24).  Therefore, strict sample handling is required to ensure that the measured
ratio is the actual ratio and not an artefact of sample handling.
1.2.2. Roles of CoQ10
1.2.2.1. Electron transport chain
The best-known role of coenzyme Q10 is to transfer electrons between complexes I and II,
and complexes III and II in the mitochondrial electron transport pathway, which ultimately
produces adenosine triphosphate (ATP) (Figure 1.6). Peter Mitchell received the Nobel
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Prize in 1978 for his contribution to the understanding of biological energy transfer
through the formation of the chemiosmotic theory, which includes the vital protonmotive
role of CoQ10 in energy transfer systems (26).
The overall reaction of the electron transport pathway is the reaction 2H+  + ½O2 → H2O,
which is made to occur in small steps so that most of its energy can be converted into
storage instead of being released to the environment as heat. The electrons are passed
through the respiratory chain while the protons escape into the aqueous surroundings.
These protons are returned only after the electrons reach the end of the respiratory chain,
when they neutralise the negative charges created by the final addition of the electrons to
the oxygen molecule.
The electron transport begins when a hydride ion (H:-) is removed from NADH to
regenerate NAD+, and the hydride ion is converted into a proton and two electrons (H:- →
H+ + 2e-). These two electrons are passed into the first of many electron carriers embedded
in the inner mitochondrial membrane. At this stage the electrons are at very high energy,
and their energy is gradually reduced as they pass along the sequence of more than fifteen
different electron carrier molecules in the respiratory chain. The electrons pass through
metal atoms and cytochromes via 1-electron transfers. Different metal atoms are tightly
bound in a different way to a protein, which alters the electron affinity of the bound atom
so that electron transfer occurs. The simplest of the electron carriers is CoQ, which, via the
semiquinone intermediate, can pick up or donate either one or two electrons. Coenzyme Q
temporarily picks up a proton from the medium along with each electron that it carries, and
functions as a mobile electron carrier.
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Figure 1.6 The mitochondrial electron transport chain. Coenzyme Q10 is indicated as
Arrows indicate direction of electron flow through this pathway. Fe-S = the iron-
sulfur protein, FMN = flavin mononucleotide, NADH = nicotinamide adenine
dinucleotide, b = cytochrome b, C 1 = cytochrome C1, C = cytochrome C, FAD =
flavin adenine dinucleotide, a-Cu = copper associated with cytochrome a, a3-Cu =
copper associated with cytochrome a3, ADP = adenosine diphosphate, ATP =
adenosine triphosphate.
Coenzyme Q is also present in protein-bound form in complex III, where it is necessary for
the function of the “Q-Cycle” of electron transfer, linked to proton translocation inside the
complex. This cycle (Figure 1.7) involves the Rieske iron-sulfur centre, cytochromes b566
and b560, cytochrome c1 and ubiquinones (27).
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Figure 1.7 The Q-cycle, showing the transfer of electrons in complex III of the
mitochondrial electron transport chain. The Qp site is the first quinone-binding site,
and the Qn site is the second quinone-binding site. Cytc = cytochrome C, Cyt b =
cytochrome b. UQH2 = reduced CoQ, UQ- = semiquinone, UQ = oxidised CoQ. FeS is
the Rieske protein. (Figure adapted from (28)).
Coenzyme Q has also been shown to be a native constituent of a lysosomal electron
transport chain, which promotes proton translocation across the lysosomal membrane (29).
Lysosomes are membrane-bound cytoplasmic organelles involved in intracellular protein
degradation, and the lumina of the lysosome is acidic. The role of CoQ10 in this organelle
may therefore be to pump protons to regulate the luminal pH (30).
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1.2.3. Concentration of CoQ in plasma and tissue
The range of CoQ10 plasma concentrations reported in healthy people falls within 0.22 –
2.31 µmol/L (6, 25, 31-35). The presence of CoQ9 in plasma is controversial, but has been
reported to be around 46 nmol/L (20). Coenzyme Q9 is used as an internal standard in
some assays for plasma CoQ10, and hence it is desirable to confirm the concentration of
endogenous CoQ9, to ensure that endogenous CoQ9 does not affect estimation of plasma
CoQ10.
The presence of both CoQ10 and CoQ9 in human and rat tissues has been reported, with
CoQ10 in humans being present in the highest concentrations in heart, kidney and liver.
Coenzyme Q9 contributes only 2-5% of total CoQ in humans (Table 1.1) (7).
Table 1.1 Distribution of CoQ9 and CoQ10 in human and rat tissues (from (7)).
Tissue Rat Human
CoQ9
(µmol/kg)
CoQ10
(µmol/kg)
CoQ9
(µmol/kg)
CoQ10
(µmol/kg)
Heart 254.0 ± 23.3 19.6 ± 2.0 3.1 ± 0.4 132.0 ± 10.7
Kidney 155.8 ± 14.2 25.5 ± 2.2 4.1 ± 0.3 77.0 ± 7.6
Liver 164.6  ± 18.6 24.7 ± 2.3 2.3 ± 0.3 63.6 ± 4.7
Muscle 53.6 ± 7.0 3.6 ± 0.3 1.3 ± 0.1 46.0 ± 5.0
Brain 47.0 ± 4.1 21.9 ± 1.7 1.3 ± 0.1 15.5 ± 1.2
Pancreas 46.8 ± 4.0 3.2 ± 0.3 2.0 ± 0.3 37.9 ± 3.2
Spleen 28.8 ± 2.5 10.7 ± 0.9 0.9 ± 0.1 28.5 ± 4.2
Lung 21.3 ± 1.8 2.8 ± 0.3 0.8 ± 0.1 9.1 ± 0.9
Thyroidea 54.7 ± 4.7 7.6 ± 0.9 1.5 ± 0.3 28.6 ± 2.3
Thymus 31.4 ± 2.8 8.3 ± 0.8 n.d. n.d.
Testis 40.7 ± 3.6 5.4 ± 0.6 0.5 ± 0.1 12.2 ± 1.3
Intestine 64.0 ± 9.1 22.0 ± 1.9 0.6 ± 0.1 13.3 ± 1.9
Colon 59.7 ± 4.9 9.7 ± 0.8 0.5 ± 0.1 12.4 ± 2.2
Ventricle 69.9 ± 6.2 6.1 ± 0.6 n.d. 13.7 ± 0.9
The values are means ± SD (n = 6). n.d. = not determined.
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In rats, although CoQ9 constitutes 92% of total CoQ in the liver, heart, and skeletal muscle,
only 67% of total CoQ in the brain is CoQ9 (7, 36, 37).
The proportion of CoQH2 in tissues has been shown to be negatively correlated with CoQ
content (38). In rats under mitochondrial impairment, CoQ redox control is tissue specific
(38). In rats, the highest concentration of CoQ9H2 is found in the liver (85%) and the
lowest amount in the brain (28%) (37). In mice, the highest amounts of CoQ9H2 are present
in the heart (89%), liver (61%), and brain (58%), with only 35% of CoQ9 in muscle being
CoQ9H2 (39). In mice, the percentage of CoQ10H2 is very similar to that of CoQ9H2 (39). In
contrast to humans where 95% of plasma CoQ10 is CoQ10H2 (6), in rats 50% of plasma
CoQ is CoQH2 (37).
1.2.4. CoQ and antioxidant activity
CoQ was initially thought to be a mitochondrial reactive oxygen species (ROS) generator
(40), only to be later gradually accepted as an antioxidant. While evidence for the
antioxidant function of CoQ is now overwhelming, a definitive role for CoQ in
mitochondrial oxygen radical generation has not been directly demonstrated.
The earliest observations of an antioxidant function of CoQ10H2 date back to the sixties,
and show that this substance could, like α-tocopherol, protect against the light-catalysed
peroxidation of mitochondrial lipids (41). These observations have been extensively
confirmed during the last two decades. Coenzyme QH2 is the only lipid-soluble antioxidant
synthesised by animal tissues in vivo. Coenzyme Q10H2 can act as an antioxidant directly,
by preventing initiation and propagation of mitochondrial lipid peroxidation, or indirectly,
by recycling α-tocopherol. Coenzyme Q10H2 can also protect against oxidative damage to
other important cellular macromolecules such as proteins and DNA.
The reactivity of CoQ10H2 with peroxyl radicals is much slower than that of α-tocopherol,
and because CoQ10H2 is a highly hydrophobic molecule located in the middle of the
phospholipid bilayer, it has considerably less intramembrane mobility than α-tocopherol,
which would tend to decrease its radical scavenging potential. Therefore, this suggests that
α-tocopherol, rather than CoQ10H2, acts as the direct scavenger of peroxyl radicals within
the mitochondrial inner membrane.
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Supporting the hypothesis that CoQ10H2 recycles α-tocopherol, several in-vivo
observations have shown that levels of CoQ10 correlate with the concentration of α-
tocopherol (18, 42, 43). Electron spin resonance studies have shown that in homogeneous
solutions (44), as well as cellular membranes (45), the presence of CoQ10 can prevent
oxidation of α-tocopherol. The ability of CoQ10 to regenerate α-tocopherol may also
explain why an increase of vitamin E has been reported after CoQ10 supplementation in
mice (36, 46) and rats (47), although this effect of CoQ10 supplementation on vitamin E
was not seen in humans (48). Simultaneous supplementation with vitamin E and CoQ10 has
been shown to result in lower increases in plasma CoQ10 levels (31) of up to 50%. The
decreased absorption is dependent on the dose of vitamin E given being less when lower
concentrations of vitamin E are administered (49). This effect of co-supplementation with
vitamin E on CoQ10 levels may be due to CoQ10 regenerating α-tocopherol, since a
decrease in CoQ10H2 has been observed when vitamin E was supplemented . Additionally,
it is possible that there is competitive absorption, transport, and/or uptake between CoQ10
and vitamin E in the gut (49), or that the plasma concentrations are regulated at the
lipoprotein level, since plasma low-density-lipoprotein-cholesterol (LDL-cholesterol) and
plasma total CoQ10 concentrations correlate (12, 18, 22, 33, 43, 50, 51).
1.2.5. Biosynthesis of CoQ10
In mammals, CoQ is synthesised by the body via stepwise addition of isoprenoid units to
generate a decaprenyl unit, which is then added to a quinoid moiety that has been derived
from tyrosine or phenylalanine (Figure 1.8). The biosynthetic pathway by which the
isoprenoid units are added to build the sidechain is the mevalonate pathway. The
mechanism of intracellular transport of CoQ10 from the site of biosynthesis to the site of
action has not yet been established.
Vitamin B6, as pyridoxal 5´-phosphate, is required for the initial transamination step,
which produces 4-hydroxyphenylpyruvic acid from tyrosine. Thus an adequacy of vitamin
B6 is essential for the synthesis of CoQ10 (52).
Figure 1.8 The biosynthesis of CoQ.
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1.2.6. Dietary CoQ
Coenzyme Q10 is also obtained from the diet. A proposed pathway of dietary CoQ10
absorption and elimination is shown in Figure 1.9. Dietary-derived CoQ10
accumulates first in liver before it is detectable in other peripheral tissues (46, 53).
CoQ10 is absorbed at a constant (zero-order) rate in the gastrointestinal tract with an
absorption time of 6.2 hours per 100 mg, and then distributed sequentially to (1)
chylomicrons and tissues, which rapidly absorb the chylomicron-packaged CoQ10, (2)
the liver, and (3) a compartment representing very low-density lipoproteins (VLDL)
and tissues, which rapidly absorb the VLDL-packaged CoQ10 (54). The half-life of
CoQ10 is approximately 33 hours (55). Laaksonen et al., (1995) (56) reported that the
LDL-cholesterol fraction was the major vehicle for endogenous/supplemented
ubiquinone during all three supplementation phases, containing 46 to 62% of the
serum CoQ10. Coenzyme Q10 was not detected in lipoprotein-deficient serum either
before or during the supplementation periods, indicating that all endogenous and
exogenous CoQ10 is carried in circulating lipoproteins (57). Supplemental CoQ10 is
rapidly reduced to maintain the CoQ10 to CoQ10H2 ratio to that already present (58,
59).
Figure 1.9 Absorption of dietary CoQ10 from the intestines. After absorption
CoQ10 is transported by chylomicrons to the liver. VLDL then initiates
movement from liver to peripheral tissues. VLDL = very low-density
lipoproteins, LDL – low density lipoproteins, HDL = high-density lipoprotein.
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Vitamin E has a similar absorption pattern and is transported from liver to blood via
transport proteins. It has not yet been established whether transport proteins are
required for CoQ10 to be moved from liver to the bloodstream.
In terms of elimination of CoQ10 from the body, faecal elimination has been proposed
to involve 62.5% of it, with the main elimination occurring via bile . Bile contains bile
acids (derivatives of cholesterol synthesised in the hepatocyte that are conjugated to
either glycine or taurine), which are facially amphipathic, enabling them to emulsify
lipid aggregates, and solubilise and transport lipids in an aqueous environment.
Small amounts of CoQ10 are excreted in the urine, with Okamoto et al., (1985) (4)
reporting CoQ10 levels in urine to be in the range 23 – 98 µmol/kg of creatinine. Daily
urinary excretion levels of CoQ10 were therefore estimated to be 20 – 128 µg (23 –
148 nmol), based on the daily urinary excretion levels of creatinine in normal subjects
(4).
Supplemental CoQ10 is generally well tolerated. Forty percent of treated patients with
Huntington’s disease receiving 1200 mg/day reported minor side effects (including
headache, heartburn, fatigue, and increased involuntary movements) that may or may
not have been directly related to the supplemental CoQ10 (60).
1.2.7. Dietary sources of CoQ10
Coenzyme Q10 is found in the mitochondria of every eukaryotic cell, based on which
it was also named ‘ubiquinone’. Hence, dietary CoQ10 is found in many sources, but
is most concentrated in sources containing high levels of mitochondria such as meat.
Meat has been reported to provide 64% of total dietary CoQ10 in the Danish diet (61).
Weak positive associations between cholesterol-adjusted serum CoQ10 and the
average daily consumption of meat and meat products (43) have been shown. Intake
of eggs, vegetables and roots are also positively associated with plasma CoQ10 (33).
Conversely, intake of fish and dairy products has been shown to have a negative
association with plasma CoQ10 (33). In all, dietary intake of CoQ10 has only a
marginal effect on plasma CoQ10 concentrations (33), and hence it is very difficult to
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accurately estimate the effect of the diet on CoQ10 levels. It is unlikely that
vegetarians would be deficient in CoQ10, since it is synthesised by the body.
1.2.7.1. Absorption of dietary and supplemental CoQ
It can be expected that absorption of CoQ10 from the gastrointestinal tract will be slow
due to its high molecular weight and lipophilicity. Maximum plasma concentrations
occur approximately six hours after ingestion of a CoQ10 supplement (48, 62-64).
CoQ10 supplements have been shown to have varying bioavailability (48, 62-66). This
can be due to the form of CoQ10 (reduced or oxidised), or due to excipients in the
supplement.
The absorption of nutrients often diminishes with increasing dose due to saturation of
the transport system in the intestine. Upon supplementation, a dose-dependent
increase in plasma CoQ10 level has been observed up to a daily dose of 200 mg, which
resulted in a 6.1-fold increase in plasma CoQ10 levels (31). Laaksonen et al., (1995)
(56) supplemented eight healthy male participants (22-49 years old) for one week at
60, 120, and 240 mg, and reported an increase in mean serum CoQ10 concentrations of
85, 180, and 362% respectively. Zita et al., (2003) (67) reported that expressing the
change in serum CoQ10 concentration as a function of dose shows that each mg of a
30 mg and a 100 mg dose increases serum CoQ10 concentration by about 0.03 µmol/L
and 0.02 µmol/L respectively. Kurowska et al., (2003) (63) reported that the
absorption (defined as percent of initial dose present in the plasma at tmax assuming a
2.5 litre total plasma volume) of both a reduced CoQ10 formulation and a commercial
grade oxidised formulation was 1.2 and 0.7 % respectively.
The oxidised and reduced forms of CoQ10 may be differentially absorbed due to their
different lipophilicities. While the oxidised form of CoQ10 has a substantial
hydrophobicity and tendency to aggregate, the reduced form is more hydrophilic.
Kurowska et al., (2003) (63) compared a commercial grade CoQ10 powder with a
‘bio-transformed’ CoQ10H2 supplement, obtained by fermentation of a soy-based,
CoQ10 rich media with bakers yeast. They reported enhanced bioavailability of the
CoQ10H2 supplement (63). Miles et al., (2002) (64), also reported a 25% higher
bioavailability of CoQ10H2 as compared to a supplement containing solubilised
oxidised CoQ10, although this increase was not significant.
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Turunen et al., (1999) (68) administered CoQ10, acetylated CoQ10, and succinylated
CoQ10 (Figure 1.10) to 6-week old male rats for three weeks via the diet. Uptake of
CoQ10 into the blood was 40% and 70% greater in rats given the succinylated and
acetylated forms, respectively (68). All three forms of CoQ10 increased total CoQ10 in
the liver (about 100%) and the spleen (about 130%) to the same extent (68). Neither
CoQ10 nor its esterified forms were taken up into the kidney, heart, muscle or brain
(68). Therefore, esterification of CoQ10 increases the uptake of dietary CoQ10 into
blood, but derivatisation does not contribute to its elevation in the various organs (68).
In the blood, about 5% of the total uptake of CoQ10 could be identified as the
derivative (using HPLC), but in liver and spleen, no succinylated or acetylated forms
were detected (68). Therefore, esterases present in blood and tissues efficiently
hydrolyse the derivatised forms of CoQ10 (68).
Figure 1.10 The structures of CoQ10H2, succinylated CoQ10 and acetylated
CoQ10, the bioavailability of which was compared by Turunen et al., (1999) (68).
Excipients used in CoQ10 supplements include soybean oil which has been reported to
increase the bioavailability of CoQ10 above that seen in CoQ10 supplements
formulated with other inert substances (69, 70). Additionally, emulsifying agents have
been added to supplements to increase the dispersion of CoQ10. The concentration of
emulsifying agent is crucial. Surfactants, as emulsifying agents, at concentrations
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below their critical micelle concentration (CMC), can increase the solubility and
dissolution rate of drugs from dosage forms and thus the drug becomes available for
absorption (71, 72). In addition, surfactants can penetrate and disrupt the normal
structure of biological membranes resulting in increased membrane permeability.
However, surfactants above their CMC solubilise and retain the drug thereby causing
an overall reduction in the amount of drug released and absorbed (71). Below the
CMC individual lipid molecules predominate. Nearly all the lipid added above the
CMC spontaneously forms micelles.
Emulsifying agents that have been added to CoQ10 supplements include polysorbate-
80 (polyoxyethylene (20) sorbitan monooleate), a non-ionic surfactant and emulsifier
capable of forming micelles, and lecithin, a liposome forming phospholipid. Animal
experiments have shown that lecithin increases the bioavailability of CoQ10 over that
of a powder formulation (73). However, Weis et al., (1994) (62) found no significant
difference between a reference formulation and two formulations with
micelle/liposome forming additives (polysorbate 80/lecithin) in humans (n = 10).
Only the soybean oil formulation significantly increased bioavailability (62). In the
study of Weis et al., (1994) (62), the exact ingredients in the reference formulation
were not given which makes it difficult to compare this study with animal studies. It is
possible that the concentrations of lecithin and polysorbate-80 were not ideal for
aiding bioavailability in the study of Weis et al., (1994) (62), especially since the
emulsifying agents significantly lowered the bioavailability of the CoQ10 as compared
to an identical formulation without any emulsifying agents. Further studies examining
the exact effect of excipients are required.
Topical application of CoQ10 (as a 0.05% CoQ10 containing cream) significantly
increases CoQ10 in the sebum without significantly affecting the stratum corneum or
plasma concentration of total CoQ10 or vitamin E (74).
There is large inter-individual variability in absorption of CoQ10 from supplements,
and this variability has been reported for many different formulations of CoQ10
supplement (48, 62, 63, 67, 75). Zita et al., (2003) (67) found that in the  group
supplemented with 30 mg CoQ10 daily for 2 months, 25 of 28 men showed an increase
in plasma CoQ10 concentration (increase ranged from –0.56 to 1.95 µmol/L). In the
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group supplemented with 100 mg daily for 2 months, 32 of 36 men showed an
increase (increase ranged from –0.66 to 5.34 µmol/L) (67). In the studies of
Kaikonnen et al., (1997) (48) and Weis et al., (1994) (62), the bioavailabiilty of
CoQ10 varied more between subjects than between preparations.
Correlating demographic variables with changes in plasma CoQ10 concentration after
supplementation may help explain the large inter-individual variation in absorption.
However, there is little information available on such correlations, and that which is
available is contradictory. For example, Zita et al., (2003) (67) reported that the
change in CoQ10 concentration was not dependent on baseline CoQ10 concentration,
age or body weight. However, Wolters et al., (2003) (43) reported that, after
supplementation, changes in cholesterol-adjusted CoQ10 concentrations were
inversely correlated to the baseline values. This aspect of supplementation deserves
more attention as knowledge of what affects absorption may aid determination of the
optimal dosage to supplement and also aid in the comparison of results from different
study populations. Krone et al., (2001) (76) proposed that one possible explanation
for the variable absorption of CoQ10 between human subjects is Candida colonisation
of the gastrointestinal tract. Uptake and utilisation of supplemental CoQ10 by this
yeast could diminish availability for the human subject. The normal endogenous CoQ
in this yeast is CoQ9, but Krone et al., (2001) (76) showed that growth of the yeast is
enhanced in the presence of CoQ10, suggesting CoQ10 is biologically functional in this
yeast. Many common medical treatments including antibiotics and anti-
hyperchlorhydric agents (antacids and proton pump inhibitors) increase the risk of
gastrointestinal tract Candida colonisation and hence may affect absorption of
supplemental CoQ10.
While the concentration of CoQ10 in erythrocytes (which do not contain
mitochondria) is not dependent on the concentration of CoQ10 in plasma, the platelet
concentration follows the increase in plasma concentration after CoQ10
supplementation, and the exogenous CoQ10 enters the mitochondria in platelets (59).
This suggests that CoQ may enter inner cell membrane compartments, but not outer
cell membrane compartments (59). A CoQ derivative that contains a CoQ analogue
covalently coupled to an alkyltriphenylphosphonium cation has been developed (77)
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which targets the CoQ analogue to the mitochondria. Oral administration of this
compound to mice resulted in its accumulation in heart, brain, liver, and muscle (78).
In a case of severe CoQ10 deficiency, described as a rare encephalomyopathy (due to
defects in either mitochondrial or nuclear DNA), where three siblings had severe
neurohormonal and muscular symptoms, CoQ10 supplementation led to a dramatic
improvement in the childrens’ health (79). This improvement suggests that CoQ10 was
distributed to its proper localisation in subcellular organelles and membranes, and that
the uptake of dietary CoQ10 does occur when there is a deficiency in the target organs.
The effect of CoQ10 supplementation on tissue levels of CoQ is most easily studied in
animal models. CoQ10 supplementation increases CoQ10 in mice and rats in both
plasma (36, 37, 46, 47, 49, 80) and tissues including spleen (49), liver (37, 46, 49, 80)
and kidney (46, 80). Heart muscle mitochondria (36), skeletal muscle mitochondria
(36, 80),  liver mitochondria (36, 46, 49, 80), mitochondria of spleen (49) and
mitochondria of kidney (80) have also shown an increase in CoQ10 with CoQ10
supplementation. Using older mice (24 months old), Lass et al., (1999) (46) reported
no increase in CoQ10 in heart or skeletal muscle. The increase in CoQ10 in the brain
may be dose-dependent since both no increase (36, 81, 82) and an increase (47, 80)
have been reported. Kamzalov et al., (2003) (36) reported an increase in CoQ10 in
brain mitochondria only in rats fed high dose CoQ10 (654 mg/kg/day). The uptake of
CoQ into tissues may therefore be dependent on the age of the animal and the dose
administered.
Many of the reported animal studies are difficult to extrapolate to humans since
impractically high doses of CoQ10 are often supplemented. It has been suggested that
uptake of CoQ10 by tissues such as heart, skeletal muscle and brain is low or
negligible unless the endogenous levels fall below a critical physiological threshold,
which is known to occur during aging (37, 81, 83). The most accurate way to measure
uptake of supplemental CoQ by tissues is also arguable since the CoQ concentration
is 4-250 times higher in mitochondria than in the tissue homogenate (36). Therefore,
while the concentration of CoQ in the mitochondria may increase substantially,
homogenisation of tissue may suggest the increase in CoQ concentration in the whole
tissue is minor. Thus, measurement of CoQ in tissue mitochondria may give a more
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sensitive and accurate assessment of tissue uptake than measuring total tissue
homogenates (80).
Finally, although rats and mice contain predominantly CoQ9, supplementation with
CoQ10 may also increase CoQ9. An increase in CoQ9 after CoQ10 supplementation has
been reported in plasma (80), spleen (49) and liver (49). An increase in CoQ9 in
mitochondria has been reported in mitochondria of heart muscle (36), skeletal muscle
(36, 80), kidney (80), and liver only in rats fed a high dose of CoQ10 (654 mg/kg/day)
(36). Ibrahim et al., (2000) (49) reported a decrease in CoQ9 in muscles and no
change in CoQ9 in serum, kidney or heart after CoQ10 supplementation. Similarly,
Kwong et al., (2002) (80) reported no change in CoQ9 in liver and kidney. The effect
of CoQ10 supplementation on CoQ9 concentrations in the brain are controversial with
reports of an increase in cerebral CoQ9 (47), no change in brain CoQ9 (36), and an
increase in CoQ9 in brain mitochondria only in rats fed a high dose of CoQ10 (654
mg/kg/day) (36). The increase in CoQ9 during CoQ10 supplementation may be due to
the in vivo modification of the isoprene moiety, and/or the antioxidative protection of
mitochondrial CoQ9 by exogenous CoQ (84).
1.2.8. Effect of supplementation on oxidation resistance
There is conflicting evidence on the effect of supplemental CoQ10 on oxidation
resistance mainly because there is no easy way to measure oxidation resistance.
Because the reduced form of CoQ10 has antioxidant capacity, and since
supplementation with the oxidised form of CoQ10 does increase levels of CoQ10H2
(58, 59), it is reasonable to assume that supplemental CoQ10 increases oxidative
resistance of plasma. However, despite there being many methods available for
determining the oxidative resistance of plasma, none provide clear answers. For
example, Kaikonnen et al., (1997) (48) reported that after 2 months of
supplementation, none of the CoQ10 supplements they tested increased the oxidative
resistance of the VLDL + LDL-cholesterol fractions suggesting the measurement
techniques used to determine oxidative resistance of the VLDL + LDL-cholesterol
fraction may have lacked sensitivity. Because CoQ10 is an endogenous substance, it is
difficult to achieve multiple fold elevations in its content in lipoproteins, which could
lead to a lack of measurable increase of oxidative resistance or a decrease in plasma
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malonaldehyde (a degradation product of lipid peroxidation) concentration. Also, the
oxidative resistance may not increase with an increase in CoQ10 concentration
because the exogenous CoQ10 may play a pro-oxidative role. If the antioxidant role of
CoQ10 is mainly that of regenerating α-tocopherol, then a low plasma α-tocopherol
concentration may limit the increase in oxidative resistance due to increased CoQ10.
Autooxidation of the CoQ semiquinone intermediate in the electron transport chain is
the major source of mitochondrial oxidants. However, CoQ10 supplementation in rats
does not appear to have an effect on the rate of mitochondrial H2O2 generation (80).
Additionally, CoQ10 supplementation does not result in a decrease of antioxidative
enzymes in skeletal muscle and liver homogenates in rats (80). Plasma homocysteine
content, and the ratio of reduced to oxidised glutathione, may be appropriate indices
of in-vivo oxidative stress (80). After 13 weeks of CoQ10 supplementation in rats, no
change in the level of plasma reduced glutathione and methionine was observed.
However, plasma oxidised glutathione content was decreased by about 60% resulting
in an increase of about 2-fold in the ratio of reduced to oxidised glutathione (80).
There was also a 25% decrease in cysteine–glycine, and a 45% decrease in
homocysteine. CoQ10 supplementation may therefore attenuate oxidative stress by
altering the plasma aminothiol redox balance towards a more reductive, and less pro-
oxidative, environment (80).
1.2.9. Factors affecting levels of CoQ10
1.2.9.1. Genetic/ethnic and gender influences
There are relatively few reports of genetic and ethnic influences on CoQ10. A very
rare primary CoQ10 deficiency due to an autosomal recessive disorder has been
reported on several occasions worldwide, and is detected in early
childhood/adolescence. This disorder has a clinical spectrum that encompasses three
major phenotypes:
1) A myopathic form, characterised by exercise intolerance, mitochondrial
myopathy, myoglobinuria, epilepsy and ataxia, which was first reported by
Ogasahara et al., (1989) (85).
2) A generalised infantile variant with severe encephalopathy and renal disease
(Rötig et al., 2000) (79).
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3) An ataxic form, dominated by ataxia, seizures, and cerebellar atrophy (Musumeci
et al., 2001) (86).
Significant differences in CoQ10 with respect to gender have been documented for
human adults (33, 87), with males having approximately 22.9% higher total CoQ10
concentration, or 13.3% higher cholesterol-adjusted CoQ10 concentration, than
females (33). Conversely, a lack of difference between genders in respect to plasma
CoQ10 concentration has been reported (4, 32, 75). The association of gender and
CoQ10 observed in adults does not occur in children (51, 59). It is possible that the
gender difference seen in adults may not be clinically relevant, and perhaps is a result
of higher concentration of lipids in older males (88).  The gender effect may be
compounded by genetic differences since Miles et al., (2003) (87) found no
significant difference between healthy black males and females for CoQ10, CoQ10H2,
or the percentage of CoQ10H2 of total CoQ10. However, healthy white males had a
significantly higher concentration of total CoQ10 and CoQ10H2, and a higher total
CoQ10 to total cholesterol index than healthy white females (87). Additionally,
American blacks had significantly higher concentrations of plasma CoQ10 than whites
in all cases except for the CoQ10H2 to total CoQ10 fraction (87). The total CoQ10 to
LDL-cholesterol index and the total CoQ10 to total cholesterol index were 21 and 25%
higher, respectively, in blacks than in whites (87).
The gender difference in CoQ10 has been extended to supplementation with CoQ10.
Wahlqvist et al., (1998) (75) reported that, 4 hours after administration of
supplemental CoQ10, plasma CoQ10 was significantly higher in men compared with
women. Similarly, Weis et al., (1994) (62) reported a significant difference in
absorption between males and females with the increase in serum CoQ10 levels being
27.7% and 40.6% for females and males respectively. However, because more
females than males in this cohort smoked, it is possible that this significant finding
was due to a type-1 error. It is therefore possible that men have better absorption,
and/or a lower clearance rate for CoQ10 than women but this finding needs to be
confirmed.
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1.2.9.2. Body mass index and plasma lipids
Total CoQ10 levels have been positively correlated with body mass index (BMI) (33,
67) but this correlation has been shown to disappear when levels are adjusted for
cholesterol (43). This is probably because BMI and plasma total cholesterol positively
correlate (89). Plasma CoQ10 is positively associated with plasma total cholesterol
(12, 18, 22, 33, 43, 50, 51) and plasma triglycerides (33, 43, 90). Adjusting CoQ10
concentration for total cholesterol eliminates the correlation of plasma CoQ10 and
triglycerides (43). The correlation of fasting plasma CoQ10 and lipids is expected due
to the hydrophobicity of the CoQ10 molecule.
1.2.9.3. Age
Reports on the correlation of plasma CoQ10 with age are conflicting, possibly because
the age-related CoQ10 changes are dependent on circulating lipids and hence
disappear when CoQ10 concentrations are adjusted for lipids (43). There are reports of
a positive association with age (33, 91, 92) but also of no association, either adjusted
for lipids or not (11, 87). A negative correlation exists between the year of life of
infant and the CoQ10 concentration adjusted for lipids (59).
Young children have increased lipid-adjusted total CoQ10 concentrations compared
with adults (11) and older children (0.1 – 7 years vs 9 – 19 years) (59, 93). Miles et
al., (2004) (11) reported a significant age-related decrease in the CoQ10 redox ratio
after 18 years of age which may be related to the early effects of oxidative stress.
There is a marked increase in plasma CoQ10 during the first few weeks of life (11) and
young children tend to have low CoQ10 redox values (11, 94) suggesting infants may
require weeks or even months to attain a CoQ10H2/CoQ10 ratio within the reference
range for children (11).
A decrease of CoQ10 levels with increasing age has been reported in both human and
rat tissues (95). The exception to this trend is the brain, where no decrease has been
observed in rats, while in humans a decrease is apparent only at 90 years of age (95,
96).  This decrease of tissue CoQ10 with ageing could be due to reduced synthesis, or
age-dependent increases in lipid peroxidation, that can reduce CoQ10 levels (84). It is
not clear whether the decrease in tissue CoQ10 is a result of CoQ10 leaving
mitochondria, or extra-mitochondrial regions. Therefore, whether the observed
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decrease in CoQ10 with age results in a real deficiency syndrome is not clear, since it
may just be a general adaptation to a decreased metabolic rate with age (42).
1.2.9.4. ‘Recreational substances’
The effect of alcohol on CoQ10 is unclear and probably depends on the volume and
duration of alcohol consumption. A weak positive association between cholesterol-
adjusted serum CoQ10 and alcohol has been shown (33, 43), and  serum γ-
glutamyltransferase (a marker of liver damage) was associated with increased plasma
CoQ10 levels (33). In cirrhotic patients and in chronic alcoholics, plasma CoQ10 levels
have been shown to be decreased (97).
The effect of smoking on CoQ10 is also controversial. As in the case of alcohol, the
effect probably depends on the number of cigarettes smoked and the number of years
of smoking. Smoking has been shown to positively associate with CoQ10 (33, 67)
whereas smoking did not have a significant effect on CoQ10 in the studies of
Lagendijk et al., (1996) (22) and Miles et al., (2003) (87), plasma CoQ10 levels being
adjusted for lipids in the study of Lagendijk et al.,(1996) (22). Zita et al., (2003) (67)
suggested that the higher CoQ10 concentration in smokers may be due to increased
oxidative stress and hence an increased demand for CoQ10 in smokers. However,
Lagendijk et al., (1996) (22) reported no significant difference in plasma
concentrations of CoQ10H2, CoQ10, or the CoQ10H2/CoQ10 ratio between male
smokers and non-smokers. In contrast to these studies, plasma CoQ10 was found to be
reduced amongst smokers by Kontush et al., (1997) (12).
1.2.9.5. Exercise
The effect of intense exercise on CoQ10 is difficult to determine since it is not clear
whether plasma levels reflect tissue levels of CoQ10. A negative association between
intense exercise and plasma CoQ10 has been reported (33). In rats, exercise training
resulted in tissue-specific increases in the mitochondrial CoQ content (98), with the
concentration being significantly increased in red quadriceps and soleus muscles as
well as in white and brown adipose tissue (98). The ratio of CoQ9 to CoQ10 in rats is
not significantly influenced by exercise training (98).
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1.2.9.6. Medications
The effect of medications on CoQ10 has mainly focused on HMG-CoA reductase
inhibitors (statins). Statins are currently indicated for nearly all dyslipidaemias
associated with coronary artery disease (99). Statins partially inhibit the enzyme 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase which catalyses the
rate limiting step in cholesterol biosynthesis (Figure 1.11) resulting in lower
intracellular cholesterol levels and a secondary up-regulation of LDL-cholesterol
receptor expression, leading to increased LDL-cholesterol clearance (100, 101).
Statin-induced reductions in cardiovascular disease risk are greater than can be
explained by lipid lowering effects alone, and clinical benefits of statins that are LDL-
cholesterol-independent (globally termed pleiotropic effects) include anti-thrombotic,
anti-oxidant, anti-proliferative, anti-inflammatory, vasodilatory and plaque stabilising
effects (102).
Acetyl-CoA
   HMG-CoA reductase
HMG-CoA
 Statins
Mevalonate
                   Coenzyme Q10
Farnesyl-pyrophosphate
Cholesterol
Figure 1.11 The site of action of statins in the mevalonate pathway.
Statin therapy is associated with a reduction in plasma CoQ10 concentrations of up to
54% (103-108). This reduction is thought to be due to competitive inhibition of
HMG-CoA reductase or to a decrease in circulating LDL-cholesterol (109).
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In view of the controversy as to whether decreased plasma CoQ10 concentrations are
indicative of decreased tissue CoQ10, and because statins are relatively new drugs, the
long-term consequence of CoQ10 lowering by statins is not currently known. Two
studies have shown a CoQ10 decrease in blood, myocardium and skeletal muscle in rat
and hamster (110, 111) during statin therapy whereas in another study, patients with
hypercholesterolaemia given simvastatin for four weeks had a reduced serum level of
coenzyme Q10 but increased tissue CoQ10 concentration (57). Statin therapy has been
associated with muscle pain and fatigue in approximately 13.6% of New Zealanders
on simvastatin (112). This side effect of statin therapy may be due to a statin-induced
CoQ10 deficiency (106). Further investigation of the role of CoQ10 in muscle pain
experienced in some patients on statin therapy is necessary.
1.2.9.7. Disease
The literature on endogenous CoQ10 levels and the incidence of disease or ill-health,
and on the effect of supplemental CoQ10 on disease and ill-health, is limited. There
are many reports of associations of CoQ10 and disease, but most need confirming with
large, well planned clinical trials.
Coenzyme Q10 deficiency has been reported in patients with cancer (113), patients
with Steinert’s myotonic dystrophy (114), children with Prader-Willi syndrome (115),
patients on haemodialysis (116), patients with phenylketonuria consuming natural
protein-restricted diets (117), and patients with hyperthyroidism (35). An altered
redox state has been shown for platelet CoQ10 in Parkinson’s patients (118). Miles et
al., (2004) (90) reported that a comparison of groups with minimal-risk and high-risk
of developing the metabolic syndrome revealed an increased ratio of CoQ10H2 to
CoQ10 in the high-risk group. Total CoQ10 to total cholesterol index, total CoQ10 to
LDL-cholesterol index, and total CoQ10 to triglyceride index are significantly higher,
higher and lower respectively in subjects with the metabolic syndrome as opposed to
those without (119).
Folkers (1996) (120) suggests that a cause of cancer may be a deficiency of one or
more of the DNA bases (thymidine, guanine, adenine, and cytosine) that require
vitamin B6 for their biosynthesis. Vitamin B6 is also necessary for CoQ10 synthesis
such that a deficiency of CoQ10 may correlate with, but not be causative for, cancer.
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Supplemental CoQ10 has reportedly been beneficial in patients with breast cancer
(121, 122), diabetes (123), patients on haemodialysis (123), patients maintained on
continuous ambulatory peritoneal dialysis (123), and patients with chronic stable
angina pectoris (124). Supplemental CoQ10 reportedly improves in-vivo cardiac and
skeletal muscle bioenergetics in patient’s with Friedreich’s ataxia (125), aids patients
with Kearns-Sayre syndrome (126), provides mild symptomatic benefit in patients
with Parkinson’s disease (127) and increases sperm cell motility in patients with
idiopathic asthenozoospermia (128). In hypertensive patients, CoQ10 supplementation
decreases the need for antihypertensive therapy and significantly reduces both systolic
and diastolic blood pressure (129-131).
Coenzyme Q10 has often been associated with heart disease since the heart is a site of
major energy expenditure and is critical to life. A deficiency of plasma CoQ10H2 and
total CoQ10 in patients with ischaemic heart disease has been recorded (132, 133).
CoQ10 supplementation has been used for the treatment of mild congestive heart
failure in Japan since 1974. Whether CoQ10 supplementation does improve health of
patients with heart failure or cardiomyopathy is controversial, particularly because
clinical studies exploring the effect of CoQ10 supplementation on heart failure differ
in the dose of CoQ10 given (low doses were given up until the 1990s when it was
discovered that high doses of supplemental CoQ10 are well tolerated), the duration of
supplementation, the severity of heart failure when supplementation was initiated, the
number of subjects enrolled in trials, and the measured endpoints. A positive effect of
CoQ10 supplementation in patients with heart failure (134-143) has been reported
more often than a neutral effect (144-146). Large, multicentre, and well designed
studies on the efficacy of CoQ10 supplementation in heart failure and cardiomyopathy
are required, but these are difficult to conduct because funding is not easily
forthcoming for trials on non-patentable, over-the-counter therapies. One study, called
‘Q-SYMBIO’, a randomised double-blind multicentre trial with CoQ10 as an
adjunctive therapy in chronic heart failure, is currently under way (147).
It is clear that further work is necessary to confirm the effect of disease on CoQ10, and
the efficacy of CoQ10 supplementation on disease.
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1.2.10. Determination of CoQ10
In an early report of measurement of CoQ10, Kröger et al., (1978) (148) used a dual
wavelength spectrophotometer (in the ultraviolet region) to determine simultaneously
menaquinone and CoQ10 in both the reduced and oxidised forms. The method was
used to determine CoQ in mitochondria and sub-mitochondrial particles of bacteria,
cell-free bacterial homogenates and purified preparations of bacterial membranes.
Extraction of quinones from aqueous suspensions of membrane preparations was
carried out with light petroleum in the presence of methanol. The quinone forms of
CoQ and menaquinone were determined using the absorbance difference caused by
reduction to the quinol by potassium borohydride. The quinols were measured by
recording the oxidation reaction with oxygen under alkaline conditions. Besides using
dual-wavelength spectrophotometry, the difference in the spectra of extracts (reduced
by potassium borohydride vs untreated or oxidised) was evaluated using the same
wavelength-pairs as proposed for dual-wavelength recording.
Recently, Hagerman et al., (2003) (149) reported an assay for the measurement of
plasma CoQ10 based on the binding of CoQ to a CoQ binding peptide (149). The 14-
amino acid binding peptide was chemically synthesised, and conditions for
immobilising the peptide on microfuge tubes were established (149). CoQ10 was
selectively bound to the immobilised peptide, eluted, and determined
spectrophotometrically (149). The limit of detection was 0.25 – 5 nmol CoQ, and
recoveries ranged from 99-102% of the values obtained with HPLC (149). This assay
allows high sample throughput using Elisa plates, but relatively long sample
preparation times are required. The assay has been applied to measure CoQ6 in yeast,
but was not adapted to measure CoQ in human plasma or tissues.
High-performance liquid chromatography (HPLC) has been the most commonly used
method for determination of tissue and plasma CoQ in human and rodent samples.
Ultraviolet detection lacks sensitivity to measure the ratio of CoQ to CoQH2, but has
been used to measure total CoQ (4, 32, 35, 150-152). Electrochemical detection after
HPLC has been the preferred detection method to determine the ratio of CoQ to
CoQH2 (6, 18, 20-25, 39, 59, 153, 154) although simultaneous detection using
ultraviolet and electrochemical detection has also been used to measure this ratio
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(155-158). The results presented by Daines (2001) (1) suggest that fluorescence
detection may be sufficiently sensitive to measure the ratio of CoQ10 to CoQ10H2 in
plasma samples. Reduction of endogenous CoQ10 to the fluorescent CoQ10H2 after
separation on an analytical column is necessary, and the most efficient method of
achieving this reduction (electrochemical, chemical, or platinum-black catalysed
alcohol reduction) is discussed in Chapter 2.
Some assays have required a concentration step after liquid-liquid extraction (using
evaporation to dryness and reconstitution of the residue), to measure total CoQ by
ultraviolet or diode-array detection (4, 32, 150, 152), or to measure the ratio of CoQ
to CoQH2 using electrochemical detection (20, 21, 24, 59, 153, 154, 158), or when
using a combination of electrochemical and ultraviolet detection (155, 157). Less
complex assays that do not require concentration of the extract have been reported for
measuring total CoQ with ultraviolet detection (35, 151), and the ratio of CoQ to
CoQH2 using electrochemical detection (6, 18, 22, 23, 25, 39).
1.2.11. Stability of CoQ
Reports on the stability of CoQ10 in plasma, standards, and extracts are difficult to
interpret because they do not always give full experimental details, eg what
anticoagulant was used, whether the sample was protected from light, and, in the case
of plasma, what the total volume of plasma in each aliquot was. Light protection is
critical (24). The aliquot volume may affect the stability of CoQ10 in plasma because
the surface area (exposed to light and air) is often proportionally higher for smaller
sample volumes.
1.2.11.1. Photostability of CoQ
Coenzyme Q10 is photochemically degraded so its stability under full laboratory
lighting is unclear. Tang et al., (2001) (6) suggest that CoQ10 is stable (variation <
2%) under normal laboratory lighting for at least 7 hours at room temperature when a
pool of plasma is exposed. However, Kaikkonen et al., (1999) (24) suggest that 10%
of CoQ10 degrades during exposure to light during extraction, evaporation and
reconstitution. These results suggest that laboratories setting up an assay to measure
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CoQ10 should confirm whether or not samples need to be protected from light during
the selected extraction procedure.
1.2.11.2. Heat stability of CoQ
CoQ10 is not stable at temperatures above 40 ºC during evaporation of solvents under
a stream of nitrogen, as shown by peaks of decomposed products after samples had
been exposed to a 40 ºC water bath (34).
1.2.11.3. Stability of CoQ in plasma and plasma extracts
There is no clear data on the stability of CoQ10H2 in extracts of plasma or tissues, with
reports of it being stable for 2 hours (155) and 4 hours (39). Reports of stability for
times intermediate between these two are also available (18, 156, 157). Discrepancies
may be due to extraction procedure, light exposure, volume stored and assay
sensitivity.
Tang et al., (2004) (39) provide evidence that CoQ10H2 is more stable in 1-propanol
extracts than in the tissue itself since, in a 1-propanol extract stored on ice for 4 hours,
CoQH2 remained stable, while >50% of the tissue CoQH2 oxidised in the same time
frame. The use of cold 1-propanol therefore seems to prevent tissue ubiquinols from
oxidation (39). This finding is supported by Leary et al., (1998) (153) who reported
that methanol-water extracts of tissue CoQH2 remain unchanged when kept on ice for
3 hours.
Anticoagulants markedly affect the stability of CoQ10H2, with the ratio of CoQ10H2 to
CoQ10 decreasing 30% in whole blood specimens containing EDTA (stored in open
Vacutainers at 4 ºC for 7 hours) in contrast to remaining stable in lithium heparinised
blood samples stored in the same way for the same length of time (159). The ratio of
CoQ10H2 to CoQ10, is reasonably stable in lithium heparinised plasma for up to 24
hours at 4 ºC when oxygen contact is limited, (i.e. whole blood stored in closed
Vacutainers) (159). The CoQ10H2 to CoQ10 ratio in lithium heparinised plasma stored
in closed containers at 4 ºC decreases by approximately 6 and 28% after 48 and 72
hours, respectively (159). However the volume stored and protection from light are
not discussed. In contrast, in heparinised plasma stored at room temperature, the
CoQ10H2 to CoQ10 ratio is reportedly stable for only 30 minutes, with a 39% increase
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in CoQ10 after 24 hours at room temperature (154). Whether or not this sample was
exposed to the light is not mentioned and oxygen contact is not discussed.
Lagendijk et al., (1996) (22) and Kaikonnen et al., (1999) (33) reported
approximately 20% loss of CoQ10H2 in EDTA plasma on ice for 3 hours, but this was
not compared with the stability of CoQ10H2 in lithium heparin plasma stored under the
same conditions.
Mosca et al., (2002) (151) showed that total CoQ10 in lithium heparinised plasma
stored at or below 22 ºC for  up to 4 days was stable. However the volume stored and
whether the samples were protected from light was not reported.
1.2.11.4. Stability of CoQ during freeze-thaw cycles
Knowledge of the stability of CoQ10 during freezing is important, to validate sample
storage. Standard CoQ10H2 is stable at –20 ºC for several weeks (155). CoQ10H2 in
EDTA plasma is not stable at –20 ºC, with a 60% loss occurring within one month
(158). Addition of butylated hydroxytoluene accelerates this loss, and addition of
reduced glutathione delays but does not inhibit it (158).
Plasma total CoQ10 has been shown to be stable during repeated freeze-thaw cycles (7
cycles) to –80 ºC (n = 5), although a non-significant (p = 0.080) decrease was
apparent (mean concentration 0.80 and 0.72 µmol/L before and after freeze-thawing,
respectively) (24). Yamashita and Yamamoto (1997) (23) reported that one freeze-
thaw cycle does not significantly alter CoQ10H2 or CoQ10 in plasma samples, but that
freeze-thawing should be minimised when measuring this ratio (24).
Coenzyme Q10 in both heparinised and EDTA plasma is stable at –80 ºC for 3 years
(24). Tissue CoQ probably has similar stability to that in plasma. Tang et al., (2004)
(39) reported that CoQ9H2, CoQ9, CoQ10H2, and CoQ10 in mouse tissue were stable at
–80 ºC over 3 months.
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1.3. Vitamin K
Vitamin K was discovered by Henrik Dam in the late 1920s (160) when he was investigating
the role of cholesterol by feeding chickens a cholesterol-depleted diet. After several weeks on
a cholesterol depleted diet, the chickens developed lengthened blood clotting times, anaemia
and haemorrhage, defects that were not reversed when pure cholesterol was added to the
chickens diet. Hence, Dam was led to conclude that a second compound, termed the
‘coagulation vitamin’ had been extracted from the food along with cholesterol. The new
vitamin received the letter K because these initial discoveries were reported in a German
journal in which it was designated as Koagulations vitamin. Edward Adelbert Doisy, of St
Louis University carried out much of the research that lead to the discovery of the structure
and chemical nature of vitamin K. Dam and Doisy shared the 1943 Nobel Prize for medicine
for their work on vitamin K.
Vitamin K is the family name for a series of fat-soluble compounds. These all have a
common 2-methyl-1,4-naphthoquinone nucleus but differ in the structure of a side chain at
the 3-position (Figure 1.12). Vitamin K1 is synthesised by plants and has a phytyl side chain
with only one double bond. Vitamin K1 is present in biological samples as oxidised K1 (K1
naphthoquinone), reduced K1 (K1 naphthoquinol), and the epoxide metabolite (161). Only the
trans-isomer of vitamin K1 is biologically active. However, the cis-isomer is present at about
10-20% in synthetic preparations (162). Menaquinone comprises a group of structures that
are synthesised by bacteria. Each menaquinone structure has a side-chain with a varied
number of isoprene units. These structures are designated menaquinone-n (MK-n) according
to the number (n) of prenyl units. Some bacteria also synthesise menaquinones in which one
or more of the double bonds is saturated.
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Figure 1.12 The structures of vitamin K1 naphthoquinone, vitamin K1 naphthoquinol,
vitamin K1 epoxide, and menaquinone.
The 2-methyl-1,4-naphthoquinone nucleus (common name menadione) does not occur in
nature but does possess biological activity in vertebrates because of their ability to add a
geranylgeranyl side chain at the 3 position (thus turning it into menaquinone-4). In this way,
menadione can be thought of as a provitamin. Menadione, as water soluble salts, is used as a
feed supplement in animal husbandry and therefore may indirectly enter the human food
chain presumably as preformed menaquinone-4 present in meats.
The body obtains vitamin K1 from the diet with the majority being obtained from leafy green
vegetables and four vegetable oils (soybean, cottonseed, canola and olive) that contain high
amounts (163). Menaquinone is present in meats but is also synthesised by bacteria in the
colon and absorbed into the body. There is some evidence in rats of tissue-specific formation
of menaquinone-4 from vitamin K1 as a metabolic transformation that does not require
bacterial transformation to menadione as an intermediate (164).
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1.3.1. Absorption of dietary vitamin K
Dietary vitamin K is absorbed in the proximal intestine by the bile salt-mediated pathway that
operates for dietary lipids (165). Upon oral consumption, radiolabelled vitamin K is absorbed
from the small intestine, becomes associated with chylomicrons in blood, and disappears
from circulation at the same rate as chylomicrons (166). Vitamin K is transported with
lipoproteins (167). It has been estimated that healthy adults absorb approximately 80% of an
oral dose of vitamin K1 given in its free form (165).
The liver plays an exclusive role in the metabolic transformations that lead to the excretion of
vitamin K from the body. Tracer experiments with labelled vitamin K1 have shown that a
sizeable fraction of a single dose is rapidly catabolised and excreted in either the urine (20%
within three days) or bile (40-50%) (165).
1.3.2. Role of vitamin K
The precise function of vitamin K was not discovered until 1974 when Stenflo et al., (1974)
(168) isolated the vitamin K-dependent coagulation factor, prothrombin, from cows that had
received a high dose of the vitamin K antagonist, warfarin. It was shown that normal
prothrombin contained 10 unusual amino acid residues which were identified as γ-
carboxyglutamate (Gla). Prothrombin isolated from warfarin-treated cows has normal
glutamate (Glu) at the Gla-positions and is designated as descarboxyprothrombin (168). The
extra carboxyl group in Gla made clear that vitamin K plays a role in the carboxylation
reaction during which Glu is converted into Gla (168).
The essential biochemical role of vitamin K is in the post-translational chemical modification
of a group of proteins that have calcium-binding properties collectively called the vitamin K-
dependent proteins, or Gla-proteins. These proteins are synthesised in the liver and comprise
protease clotting factors II, VII, IX, and X. These factors are procoagulants which arrest and
prevent bleeding. Vitamin K acts as a cofactor for the specific carboxylation reaction that
transforms selective Glu residues in zymogens to Gla residues, revealing active protease
clotting factors.  The Gla residues are efficient chelators of calcium ions. In the presence of
Gla and calcium ions, these proteins bind to the surface of membrane phospholipids of
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platelets and endothelial cells where, together with other cofactors, they form membrane-
bound enzyme complexes.
 Some vitamin K-dependent proteins are synthesised in other tissues including the bone
protein, osteocalcin, and matrix Gla protein, suggesting a link between vitamin K deficiency
and bone health. The importance of vitamin K in bone maintenance is revealed by the
osteoporosis and fractures resulting from long-term use of warfarin (the mechanism of which
is discussed below) which inhibits the bone-building effect of vitamin K (169).
Within the body, vitamin K is cycled between the naphthoquinone, the epoxide and the
naphthoquinol forms (Figure 1.13). It is during the conversion between the naphthoquinol
and epoxide forms (catalysed by vitamin K γ-glutamyl carboxylase) that Glu residues on
zymogens are carboxylated to become Gla residues. Warfarin is a coumarin drug that inhibits
the recycling of vitamin K in the body (Figure 1.13). This is achieved by inhibition of the
enzymes that catalyse the conversion of vitamin K epoxide to the naphthoquinone (vitamin K
epoxide reductase) and which catalyse the reduction of the vitamin K naphthoquinone to the
naphthoquinol (vitamin K reductase). Plasma concentrations of phylloquinone epoxide are
increased when patients are on warfarin treatment (170), and phylloquinone epoxide is
converted to vitamin K1 via reduction (171). Dietary sources of vitamin K can be converted
into the naphthoquinol form via an NADH-dependent pathway, a step that is not inhibited by
warfarin.
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Figure 1.13 The vitamin K epoxide cycle. Enzyme (1) is vitamin K γ-glutamyl
carboxylase, (2) is vitamin K epoxide reductase, and (3) is vitamin K reductase. PIVKA
II = proteins in vitamin K absence, as described later.
1.3.3. Reference range and factors affecting vitamin K levels
Vitamin K values in a population are distributed log-normally (161, 172) with no significant
difference between genders (172). A moderately strong correlation between age and serum or
plasma vitamin K has been reported (172). Reference ranges reported for plasma vitamin K
vary significantly (Table 1.2). This variation may be due to differences in assays to measure
plasma vitamin K or due to genetic or environmental differences. As discussed below, the
plasma vitamin K concentration is probably dependent on the diet. Different assays give
different estimates of plasma vitamin K because of differences in the extraction and reduction
(where fluorescence detection is used) techniques as is discussed in section 1.2.4. There are
no clear trends to explain the large range of values for vitamin K shown in Table 1.2, except
that the three reports of higher concentrations of plasma vitamin K (161, 173, 174) use
photochemical, platinum oxide catalysed, and platinum black catalysed reduction of vitamin
K, and not zinc reduction. Whether this is an actual result or an artefact is not clear.
Dithiol
Vitamin K
Quinol Vitamin K
Epoxide
Vitamin K
Quinone
Prothrombin Precursor (Glu) Native Prothrombin (Gla)
PIVKA-II
Warfarin
Warfarin
NADH
NAD+
Disulfide
Dithol
Disulfide
Dietary Sources
O  + Co2 2
1
2
3
2
i l
Chapter 1 38
Table 1.2 Reported reference ranges for vitamin K
Publication Measuring n Male/Female
(Age (years))
Vitamin K
(nmol/L)
Comments
(161) n.s. 40 5.8 mean
2.0 – 17.3
range
(175) K1 15 10 F
5 M
(51-81)
0.83 mean
(175) K1 16 15F
1M
(69-86)
0.22 mean Osteoporotic patients
(171) K1 22 6M
16F
1.24 mean
0.20 – 4.70
range
(175) K1 6 M 0.95 mean
0.51 – 2.09
range
(175) K1 16 F 1.55 mean
0.20 – 4.70
range
(172) n.s. 50 29M
21F
(24-87)
0.55 median
0.14 – 2.17
range
(172) n.s. 29 M 0.57 median
0.15 – 2.19
range
(172) n.s. 21 F 0.52 median
0.12 – 2.21
range
(173) K1 5 M 6.52 mean
1.55 – 18.4
range
The mean (range) for
K1 in 5 people was
3.55 (1.55 – 6.43)
nmol/L, except one
person had a value of
18.4 nmol/L
(176) K1 298 (7-19) 0.6 mean
0.09-2.22
range
(177) K1 263 M and F
(68.5 ± 6.3)
0.7 mean
0.17-2.34
interfractile
interval
(2.5 – 97.5%)
(174) K1 4.0 ± 2.4
(mean ± SD)
(174) K1 1.38 ± 0.25
(mean ± SD)
Osteoporotic patients
treated with
menaquinone-4
n.s.= not stated
As stated previously, the actual concentration and form of vitamin K is probably dependent
on the diet (173). Vitamin K1 and menaquinones-4,5,6,7, and 8 are present in plasma, but the
common hepatic forms (menaquinones-9-13) are not (173, 174, 178). Longer chain
menaquinones, especially menaquinones-10 and menaquinone-11 are found in large amounts
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in the healthy human liver (179) and are probably derived from the intestinal flora via the
portal vein (179). The absence of these menaquinones in the plasma might be a consequence
of a different route of absorption (for example, the possibility of a portal route for long-chain
menaquinones versus a lymphatic route for vitamin K1), but might suggest that, once in a
target tissue, the long-chain menaquinones, which are extremely lipophilic, are not easily
mobilised (178).
Vitamin K deficiency is not common in healthy adults. However, a deficiency may arise if
broad-spectrum antibiotics are consumed. Several mechanisms have been proposed to
account for antibiotic-associated hypoprothrombinemia, including eradication of
gastrointestinal bacteria, direct inhibition of vitamin K-dependent coagulation, and indirect
inhibition of coagulation (180). Deficiency may also occur if absorption of vitamin K1 from
any source is incomplete.
The concentrations of menaquinones-10, 11, and 12 are significantly lower in livers of
patients with chronic hepatitis and cirrhosis which may be one cause of haemorrhagic
tendency in liver disease (179).
1.3.3.1. Vitamin K in bone health
Vitamin K deficiency has been associated with bone defects. A high prevalence of low
vitamin K status (as determined by a high serum undercarboxylated osteocalcin
concentration) has been reported in elderly women in Japan (181), but no correlation between
low vitamin K status and low bone mineral density was observed. Reduced plasma
concentrations of vitamin K1 and menaquinones-7 and 8 have been reported in patients with
recent femoral fractures or prior vertebral compression fractures (182, 183). Serum
concentrations of vitamin K1 and menaquinones-7 and 8 in elderly women after hip fracture
were found to be significantly lower than those in age-matched healthy controls (184).
In osteoporotic patients treated with menaquinone-4, plasma menaquinone-4 is significantly
elevated and levels of vitamin K1 and menaquinone-7 are significantly lowered (174).
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1.3.3.2. Vitamin K in haemorrhagic disease of the new born
The major concern with vitamin K deficiency is focused on new born babies, where a
deficiency of vitamin K can lead to uncontrolled bleeding and haemorrhage. This is
commonly called haemorrhagic disease of the new born (HDN). This disease is life-
threatening and is the reason infants are often given supplemental vitamin K at birth.
1.3.4. Measurement of vitamin K
For several decades after its discovery in the late 1920s, the vitamin K deficient chick model
was the only method for quantifying vitamin K in various foods (185). The chicks were made
vitamin K deficient and subsequently fed with known amounts of vitamin K-containing food.
The extent to which blood coagulation was restored by the diet was taken as a measure of its
vitamin K content.
The concentration of vitamin K in plasma is difficult to assess, partly because vitamin K is
present in blood at very low concentrations. Additionally, there are many different forms of
vitamin K present in plasma, vitamin K1, vitamin K1 epoxide (present at around 32 pmol/L
(171)), and menaquinones (present at 0 – 11.4 nmol/L). Most published methods to determine
vitamin K in plasma (or serum) use HPLC, with a preliminary extraction of vitamin K from
plasma and an extract purification step before analysis (Appendix 3). Extraction procedures
commonly use liquid-liquid extraction, followed by solid-phase extraction, and concentration
of the sample (172, 186). Detection of vitamin K after HPLC is most commonly achieved
using fluorescence detection (161, 170-174, 176, 177, 179, 186-196). Early reports of HPLC
measurement of vitamin K utilised ultraviolet detection (161, 197-199), although sensitivity
was not high. Fluorescence detection has markedly better selectivity and sensitivity for
vitamin K1 than ultraviolet detection (161). Electrochemical detection has also been utilised
for determination of vitamin K after HPLC separation (175, 200, 201). There is one report of
the use of gas chromatography to measure vitamin K in plant material after HPLC separation
(202), and another reporting the use of GC/MS for measurement of plasma vitamin K after
HPLC (203).
Other methods of quantifying vitamin K include conventional coagulation assays (time for
blood to clot) to detect overt vitamin K-deficient states (and hence associated risk of
uncontrolled bleeding) (204). A more sensitive assay, known as PIVKA II, or proteins in
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vitamin K absence, involves immunoassay of under-carboxylated prothrombin (factor II),
where an increase is related to the degree of functional vitamin K deficiency (205). Another
test for vitamin K status measures urinary Gla, whose excretion is decreased in vitamin K
deficiency (206).
1.3.4.1. Reduction
There is a need to reduce vitamin K before fluorescence detection since the naphthoquinone
does not fluoresce. The most common reduction method for vitamin K is to use zinc metal in
the presence of zinc ions (195) (Equation 1.1).
Zn → Zn2+ + 2e-
2H+ + 2e- + K1 → K1H2
Zn + 2H+ + K1 → Zn2+ + K1H2
1.1
One disadvantage of zinc reduction in a column is that zinc particles in the reducing column
are consumed by oxygen and analyte reduction, such that the resulting smaller zinc particles
are able to pass through the filter frits on the column, and enter the HPLC system. This limits
the useful life of the reducing column and can damage the HPLC system (186).
Vitamin K can be reduced by electrochemical (coulometric) reduction, but the coulometric
reduction has low efficiency (approximately 60%) (171), because of residual oxygen. The
oxygen can be scrubbed using a zinc metal-packed reactor (171) (Equation 1.2). Removal of
oxygen is also essential for elimination of fluorescence quenching.
Zn + O2 + 2H+ → Zn2+ + H2O2
Zn + H2O2 + 2H+ → Zn2+ + 2H2O
1.2
Vitamin K can also be reduced via platinum catalysed alcohol reduction (1, 173, 174, 179,
186, 193) (Figure 1.14).
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Figure 1.14 The platinum-catalysed reduction of vitamin K by alcohol.
If the reduction of vitamin K by platinum-black catalysed alcohol reduction is shown to be
equally or more efficient than that by coulometric or zinc reduction, it should be utilised,
since there is no requirement to replace the platinum often, or to include additives in the
mobile phase. The assay is therefore simplified.
1.3.4.2. Internal standard
Internal standards are very important in the quantification of plasma vitamin K with HPLC
since the recoveries achieved are commonly low and variable (Appendix 3). The internal
standard is required to show the same analytical behaviour as the analyte and to not be
endogenously present in the specimen being analysed. The internal standards that have been
used in vitamin K assays are shown in Table 1.3.
Table 1.3 The internal standards that have been used in vitamin K assays.
Publication Measuring in Internal standard
(197) Human and
cow milk
Vitamin K1 epoxide
(171) Plasma Dihydro vitamin K1
(172) Plasma Vitamin K1(25)
(173) Plasma Menaquinone-3
(186) Plasma Menaquinone-4
(176) Plasma 2´,3´-dihydrophylloquinone
R
O
O
R C
H
OH
H
R
OH
OH
R C
H
O
Vitamin K quinone Alcohol Vitamin K hydroquinone Aldehyde
+ +
Pt/Al2O3
catalyst
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1.3.5. Stability of vitamin K
Vitamin K1 is stable in breast milk for at least 5 months at –20 ºC (197) and in infant formula
in the dark at room temperature for 12 months (197). Boiling does not affect vitamin K1 in
cows milk (197).
Vitamin K is photochemically degraded and K vitamins (menaquinone-3-10) at low
concentration (0.1 ng/mL) in clear Pyrex tubes decompose almost completely (3-9%
remaining) when allowed to stand in light for 1 day. In contrast, 95% of the K vitamins
remain intact in a brown Pyrex tube (173).
Saponification cannot be used when extracting vitamin K because of the instability of vitamin
K1 during alkaline hydrolysis (191).
1.4. Research described in this thesis
The quinones CoQ and vitamin K are of fundamental importance to all life forms specifically
because of their electron and proton transfer functions. The initial focus of the work reported
in this thesis was to develop an assay to determine vitamin K1 in plasma of new born babies
in order to clarify the mechanisms behind vitamin K and haemorrhagic disease of the new
born. The clinical requirements of the vitamin K assay were that:
1) Both plasma vitamin K1 and menaquinone-4 be quantified.
2) The limit of detection in plasma be lower than 0.2 nmol/L, which represents a low-normal
plasma concentration.
3) The coefficient of variation be less than 10% at a plasma concentration of 0.2 nmol/L.
4) The sample volume required for the assay be as low as possible and not more than 500 µL
(for a 2.7-3.6 kg baby the recommended maximum blood withdrawal at any one time is
2.5 mL (207) of which approximately 1 mL will be plasma).
5) The assay be as simple, robust, and inexpensive as possible.
6) The assay have the shortest turn-around time possible making it suitable for use in
newborns with HDN.
Development of an assay for vitamin K that meets these requirements was initiated by Daines
(1) using HPLC with fluorescence detection, and platinum-black catalysed alcohol reduction
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of vitamin K. In this thesis (Chapter 7) it is shown that these clinical requirements for a
vitamin K assay cannot be met using existing fluorescence technology.
During work on the vitamin K assay, demand from clinicians for an assay to measure plasma
CoQ10 increased. With the exploding use of statin drugs for cardiovascular disease, the need
to measure CoQ10 and to investigate the effect of statins on CoQ10 increased. Additionally,
public knowledge of CoQ10 has increased substantially and an Internet search for coenzyme
Q can reveal all manner of claims for the health benefits of CoQ10 supplementation. Scientific
testing of these claims requires a reliable method for measuring CoQ10 in plasma.
The work of Daines (2001) (1) provided evidence that fluorescence detection of CoQ10H2
should provide sufficient sensitivity to measure endogenous CoQ10 and CoQ10H2 in a single
HPLC run, after separation on the analytical column and platinum-black catalysed alcohol
reduction.
The clinical requirements of the assay for plasma CoQ10 were that the assay:
1) Be capable of measuring total plasma CoQ10 and possibly plasma CoQ10 and CoQ10H2.
2) Be rapid, reliable, robust and inexpensive.
3) Have a limit of detection corresponding to a plasma concentration of not greater than 0.2
µmol/L.
4) Have a coefficient of variation between assays of less than 10% at the low-normal
concentration (0.2 µmol/L).
 After development of a suitably validated assay (presented in Chapter 3), clinical
biochemical data for CoQ10 was required such as the biological variability in healthy
individuals and the reference interval in the healthy population. This is presented in Chapter
4. The relative absorption from different CoQ10 supplements and the dose-response to a
CoQ10 supplement are presented in Chapter 5.
1.5. Research hypotheses
The studies described in this thesis form part of the research and development programme of
Canterbury Health Laboratories, and were intended to underpin both clinical research and
service development. This section outlines research hypotheses that the research group
aspires to address. Although only a few of these hypotheses are directly addressed in this
Chapter 1 45
thesis, much of the work described is aimed at developing the tools and background
information, that are necessary to test the wider hypotheses.
1.5.1. Clinical research on CoQ
? CoQ10 can be limiting in human tissues, and an insufficiency causes cellular dysfunction.
? Muscle tissue, with its high energy requirement, will be particularly susceptible to CoQ10
insufficiency.
? CoQ10 insufficiency will exacerbate cardiovascular disease.
? Statin therapy can cause CoQ10 insufficiency and this is a factor in the muscular side-
effects of statin therapy.
1.5.2. Laboratory assessment of CoQ status
? Circulating plasma CoQ10 concentrations are a measure of CoQ10 sufficiency.
? The healthy New Zealand population has a range of plasma CoQ10 concentrations, and it
is possible to define a lower limit below which clinical insufficiency can be presumed.
? The intra-individual variation in plasma CoQ is less than the inter-individual variation,
and relatively small changes in plasma CoQ concentrations are clinically significant.
1.5.3. Clinical research on vitamin K
? Some groups in the New Zealand population have a sub-clinical deficiency of vitamin K.
? High risk groups include the newborn, lactating mothers and the elderly.
1.5.4. Laboratory assessment of vitamin K status
? Vitamin K is present as multiple active species and measuring one of these is not a
sufficient guide to vitamin K status.
? Vitamin K status may be better assessed by measuring metabolic markers of vitamin K
status rather than the vitamin itself.
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1.5.5. Analytical development
? Coenzyme Q10 and vitamin K concentrations can be determined by measuring the
ultraviolet absorbance of the quinone forms, the fluorescence of the quinol forms, or their
redox properties.
? The ultraviolet absorbance of the quinones will not provide sufficient sensitivity for
measuring plasma concentrations of vitamin K1, CoQ10 and CoQ10H2 in human samples,
but fluorescence detection will provide the necessary sensitivity.
? Catalytic reduction using an in-line platinum-black reactor in an HPLC system will
convert the quinones to quinols more efficiently and robustly than alternative techniques
in common use.
? Electrochemical detection is an alternative sensitive method for measuring CoQ and
vitamin K.
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Chapter 2. Redox Properties and Effect of Solvents on the Fluorescence of Coenzyme Q and Vitamin K,
and Stability of Coenzyme Q10 in Plasma
2.1. Introduction
The chemical properties of CoQ and vitamin K, particularly their photosensitivity and easy
oxidation, combined with their low concentrations in plasma, make them difficult to
measure. Both CoQ and vitamin K are most commonly measured with HPLC, using
fluorescence and electrochemical detection for vitamin K, and ultraviolet and
electrochemical detection for CoQ. Both CoQ10 and vitamin K1 are present in plasma in the
quinol and quinone forms. Because these compounds are present at such low
concentrations, maximum assay sensitivity is achieved when their total concentrations are
measured, by reducing or oxidising samples before analysis. The quinone form is most
stable with the quinols being readily oxidised by atmospheric oxygen. Therefore, it is more
practical to measure the quinone when measuring total concentrations.
As outlined in Chapter 1, Section 1.4, it was hypothesised that use of fluorescence
detection after HPLC would provide sufficient sensitivity to measure plasma vitamin K1
and menaquinone-4, as well as plasma total CoQ and possibly the ratio of CoQ10 to
CoQ10H2. Only the quinols of vitamin K and CoQ are fluorescent and hence their reduction
before fluorescence detection is essential.
Fluorescence response is determined by the solvent that fluorescence is occurring in, due to
interactions of the solvent with the excited fluorophore. To optimise assay sensitivity,
knowledge of the solvent in which the highest fluorescence occurs is important. The
compound 4-methoxy-1-naphthol is a vitamin K1 analogue that does not contain the
hydrophobic side-chain, and CoQ0H2 is identical to CoQ10H2 but without the hydrophobic
side-chain. Investigation of the effect of solvent on fluorescence of these two compounds
as well as the parent compounds allowed insight as to the role of the hydrophobic
sidechain on fluorescence response in different solvents.
Knowledge of the stability of an analyte, especially during storage, is essential since this
determines how often a routine assay must be run as well as the practicalities of sample
handling during clinical trials.
Experiments designed to address these issues are presented in this Chapter.
Chapter 2 67
2.2. Redox properties of CoQ and vitamin K
The reduction/oxidation (redox) potential (E1/2) for the reversible CoQ10-CoQ10H2 redox
couple is 0.1 V at pH 7.4. The redox equilibrium involves 2 protons (Equation 2.1), and is
pH-dependent (∆E1/2/∆pH = -0.059).
CoQ + 2H+ + 2e- → CoQH2 2.1
Coenzyme Q10 and CoQ10H2 have different retention times on reversed-phase C18
columns, since the reduced form contains a more polar head group. An oxidation or
reduction step before or during HPLC is therefore necessary when measuring total CoQ10.
The reduction potential (E0) for vitamin K1 is 0.363 volts. The redox equilibrium involves
2 protons (Equation 2.2).
Vitamin K + 2H2 + 2e- → Vitamin KH2 2.2
Vitamin K1 is present in biological samples as oxidised K1, reduced K1 and the epoxide
metabolite (1) (Figure 1.12). The vitamin K1 epoxide metabolite is reduced to vitamin K1.
In HPLC the detection method determines the form (reduced or oxidised) that the analyte
needs to be in. The extinction coefficients for CoQ10 and CoQ10H2 are 14020 and 3940 at
absorbance maxima of 275 and 290 nm, respectively. For vitamin K1 the extinction
coefficient is 18600 at an absorbance maximum of 243 nm in ether. Hence, CoQ10 absorbs
light more strongly than CoQ10H2 and the ultraviolet detection of CoQ10 is more sensitive
when oxidised CoQ10 is measured.
It is difficult to completely eliminate oxygen during sample preparation and therefore it
usually results in oxidation of CoQ10H2, and probably vitamin K. Thus, measurement of
the ratio of reduced to oxidised CoQ10 requires strict sample handling, to ensure the ratio is
not an artefact of sample handling.
In the case of vitamin K, extraction procedures are complex (as discussed in Chapter 7)
and it can be assumed that reduced vitamin K is oxidised during extraction. Indeed, Kroger
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et al., (1978) (2) report that menaquinol is autooxidised to menaquinone during a
methanol/light petroleum liquid-liquid extraction, followed by evaporation and
reconstitution in n-heptane and ethanol.
Early methods to detect CoQ10 involved long and tedious extraction techniques before
HPLC separation and detection, such that the majority of CoQ10 was in the oxidised form
by the time it was quantified (3, 4). Additionally, the commonly used hexane and ethanol
extraction reportedly results in conversion of CoQ10H2 to CoQ10 (5) whereas 2-propanol,
which along with 1-propanol is now commonly used in single-step extractions of CoQ10
from plasma, protects CoQ10H2 from oxidation (5). Therefore, with the advent and
popularity of a single step dilution for extraction of CoQ10, it became a necessity to include
a specific step to ensure that all CoQ10 is in the oxidised form when ultraviolet detection
was to be used to measure total CoQ10. CoQ10H2 oxidation has been achieved using
autooxidation under alkaline conditions (6), ferric chloride (7), gold (II) chloride (8),
cupric sulfate (9), potassium hexacyanoferrate (III) (4), and cupric chloride (10). The
oxidation by silver oxide (11) is unreliable because the complete separation of the oxidant
(which is necessary before measurement) is difficult to achieve (2). However, 1,4-
benzoquinone oxidises CoQ10H2 efficiently and rapidly and can be left in the sample
during HPLC analysis (12) without interferance.
The work of Daines (2001) (13) suggested that fluorescence detection should allow
measurement of plasma total CoQ10. Because of the sensitivity of vitamin K1
naphthoquinol and CoQ10H2 to oxygen, it is desirable that the reduction step be integrated
into the HPLC set-up, eliminating avenues for oxidation.
Zinc reduction is most commonly used before fluorometric detection of vitamin K during
HPLC (14-23). The zinc powder filled columns require frequent repacking due to the zinc
particles being consumed by oxygen and the analyte reduction (24), and the presence of
zinc ions in the mobile phase. Platinum-black catalysed reduction of vitamin K by alcohols
has also been reported (13, 24-28) and has the advantage that platinum-black-filled
columns do not require frequent repacking (13), and, aside from requiring an alcohol, there
is no requirement for additives in the mobile phase.
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Vitamin K1 has also been reduced using sodium borohydride. The reaction is temperature
dependent, occurring more completely as the temperature increases, up to 50 ºC (29).
Photoreduction of quinones has also been reported (30) in a post-column reactor of an
HPLC system during which the analyte is reduced to the corresponding quinol while
methanol (the hydrogen atom donor) is oxidised to formaldehyde.
Reduction of CoQ10 before HPLC with electrochemical detection has been reported. This
on-line reduction of CoQ10 has been achieved using electrochemical cells (9, 31-35) and
chemical reduction (36-39). The method of Leary et al., (1998) (38) uses zinc catalysed
reduction in a post-column reactor consisting of a column (20 × 4.6 mm stainless steel) dry
packed (under vibration) with zinc particles. The method of Yamashita et al., (1997) (37)
utilises a reduction column (IRICA RC-10) immediately prior to the analytical cell. The
method of Wang et al., (1999) (36) uses a complex set-up for automated pre-column
reduction of CoQ10 with sodium borohydride which is made fresh by the automated system
every three samples, and injected into the extract. Wakabayashi et al., (1994) (39) report
the use of a post-column platinum catalyst for reduction of CoQ. This consisted of a
stainless steel column (10 × 4.6 mm) packed with catalyst (5% on alumina, 10 µm), and
placed between the analytical column and the detector (39). The reduction ability of the
platinum catalyst was unchanged by successive injections of biological samples (39).
Reduction of CoQ10 to obtain a CoQ10H2 standard is necessary when measuring the ratio of
CoQ10H2 to CoQ10 (4, 9, 37, 39, 40). The most common reducing agent used to obtain a
pool of standard reduced CoQ10 is sodium borohydride (4, 9, 37, 39, 40). Tang et al.,
(2004) (9) mixed sodium borohydride and CoQ (at a ratio of 23 nmoles of CoQ to 250
nmoles of sodium borohydride) for 30 minutes in the dark at room temperature, whereas
Yamashita et al., (1997) (37) mixed sodium borohydride and CoQ for 5 minutes in the
dark at room temperature. Excess sodium borohydride can be removed from the sample by
washing with water (37). The disadvantages of using sodium borohydride as a reducing
agent are that (a) it reduces methanol and to a lesser degree ethanol resulting in hydrogen
bubbles, and (b) it has limited solubility in non-polar solvents. Tetrabutylammonium
borohydride has increased solubility in organic solvents, offering more flexibility.
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Sodium dithionite has also been used as a reducing agent for obtaining CoQ10H2 (38, 41-
43). Lang et al., (1986) (41) mixed sodium dithionite and CoQ10 for 30 minutes in the dark
at room temperature, before extracting CoQ10H2 with hexane, evaporating the hexane and
reconstituting the CoQ10H2 in ethanol.
Using an electrochemical cell, Gohil et al., (1987) (44) obtained CoQ10H2 by setting up a
loop consisting of a pump and a guard cell, with the potential on the guard cell set to –1000
mV. A CoQ standard was pumped through the loop system in the dark for approximately 3
hours. The conversion rate of CoQ10 to CoQ10H2 was approximately 99% (44).
2.2.1. Oxidising plasma CoQ10H2 for measurement of total CoQ10
In an attempt to simplify the assay of Mosca et al., (2002) (12) where an aqueous solution
of 1,4-benzoquinone is added to plasma before liquid-liquid extraction with 1-propanol,
the 1,4-benzoquinone was added to 1-propanol as a stock solution.  This was diluted with
1-propanol and used as the extraction solvent to oxidise and extract CoQ10 from plasma in
a single step. This simplification was found to work effectively in terms of efficient
oxidation of plasma CoQ10H2 and efficient extraction of CoQ10 from plasma.
An investigation of the practicalities of this simplification involved determining the
stability of the standard solution of 1,4-benzoquinone in 1-propanol (5 mmol/L) over time.
2.2.1.1. Experimental
A 5 mmol/L solution of 1,4-benzoquinone in 1-propanol was stored protected from light at
–13 ºC. At various time points between 0 and 60 days, an aliquot was diluted to 33.3
µmol/L and the absorbance at 243 nm (the absorption maxima) was determined.
2.2.1.2. Results
The 1,4-benzoquinone standard solution decomposed by approximately 10% and 20% after
10 and 20 days storage, respectively (Figure 2.1). Therefore, this standard solution needs to
be made fresh at least every week when stored at –13 ºC.
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Figure 2.1 The change in absorbance over time of a benzoquinone standard solution
(5 mmol/L) stored at –13 ºC.
2.2.2. Reducing CoQ10 and vitamin K1 for fluorescence detection -
comparison of reduction efficiency of an electrochemical cell, zinc, and
an alcohol in the presence of platinum-black.
The efficiency of reduction of CoQ10 and vitamin K achieved with electrochemical
reduction, zinc and alcohol (in the presence of platinum-black) was compared. Sodium
borohydride reduction was not used due to reduction of the alcohol producing gas in the
HPLC system. Additionally, de Barros et al., (1994) (45) examined the extent of
decomposition of sodium borohydride in absolute ethanol after time. After a decrease of
35.5%, the content of sodium borohydride almost stabilised in the interval of 2.5 – 6 hours.
The reducing power of sodium borohydride in absolute ethanol therefore decreases with
time and fresh solutions need to be made regularly.
Coenzyme Q0 (CoQ0) and 4-methoxy-1-naphthol were also included in this experiment, as
inclusion of CoQ0 would allow insight into the effect of the hydrophobic side chain on
reduction and fluorescence, and 4-methoxy-1-naphthol is an intrinsically fluorescent
vitamin K analogue, without the side chain.
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2.2.2.1. Experimental
The mobile phases used are outlined in Table 2.1. Fluorescence detection was used to
estimate the reduction achieved for both CoQ10 (excitation 290 nm, emission 370 nm) and
vitamin K1 (excitation 249 nm, and emission 408 nm). For electrochemical reduction of
both CoQ10 and vitamin K1 the electrochemical cell was set to a potential of –800 mV.
Table 2.1 The mobile phases used for comparison of reduction efficiency of CoQ10
and vitamin K1.
Reduction method CoQ10 Vitamin K1
Platinum-black 30/70 methanol/ethanol (v/v) 100% methanol
Electrochemical 30/70 methanol/ethanol (v/v), 15
mL/L glacial acetic acid and 50
mmol/L sodium acetate trihydrate
100% methanol, 15 mL/L glacial
acetic acid and 50 mmol/L
sodium acetate trihydrate
Zinc 30/70/0.55
methanol/ethanol/aqueous
solution of 2 mol/L zinc chloride;
1 mol/L glacial acetic acid, and 1
mol/L sodium acetate (v/v/v)
99.45/0.55 methanol/aqueous
solution of 2 mol/L zinc
chloride; 1 mol/L glacial acetic
acid, and 1 mol/L sodium acetate
(v/v)
An ethanolic standard of vitamin K1 (5 nmol/L, 200 µL) was injected. For CoQ10, a 10
µmol/L standard in 1-propanol was injected (200 µL). The analytical column used for both
CoQ10 and vitamin K1 was a Phenomenex Luna C18(2) column, (250 × 4.6 mm, 5 µm).
2.2.2.2. Results
The reduction of CoQ10 by an electrochemical cell was not as efficient as that by a zinc or
alcohol with platinum-black as a catalyst. However electrochemical reduction of CoQ10
was more consistent than zinc reduction (Table 2.2). This supports the findings of Haroon
et al., (1987) (14)  who reported that 95% of injected quinones (K-vitamins) could be
reduced to their corresponding hydroquinones by zinc metal compared to 60% reduction
with electrochemical cells. In situations where an electrochemical detector is connected to
a dual-cell analytical cell, a lower limit of detection and more accurate assay could be
obtained using a platinum-black catalysed alcohol reduction system.
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Electrochemical reduction of vitamin K was poor and zinc reduction was not as efficient
for vitamin K1 as it was for CoQ10 (Table 2.2).
Table 2.2 The percentage reduction (± SD) of CoQ10 and vitamin K achieved using
three different methods of reduction (n = 3).
Reduction method CoQ10 Vitamin K1
Alcohol with platinum-black catalysis 100 ± 1.0 100 ± 2.45
Electrochemical 84 ± 3.8 40 ± 1.2
Zinc 100 ± 11.1 92 ± 6.7
The electrochemical reduction of Vitamin K is inefficient because of residual oxygen in
the system. In fact complete removal of oxygen is essential for both efficient
electrochemical reduction and elimination of fluorescence quenching (46, 47). It can be
hypothesised that insertion of a platinum-black filled reactor prior to the injector in the
HPLC system would remove oxygen from the mobile phase and increase the efficiency of
electrochemical reduction of vitamin K1.
2.2.3. Reduction of quinones to determine the effect of solvent on
fluorescence
Before the effect of solvent on fluorescence could be quantified, a reliable and efficient
method to reduce CoQ10, CoQ0, and vitamin K1 was required. As already discussed,
sodium borohydride does reduce CoQ10 and vitamin K1, but it has limited solubility in non-
polar solvents and degrades in methanol and (to a lesser degree) ethanol. Thus solutions
need to be made fresh regularly.
Electrochemical reduction of CoQ10, as described by Galinier et al., (2004) (5) did not
produce CoQ10H2. Briefly, 100 mL of 100 µmol/L CoQ10 in 1-propanol was recycled
through an electrochemical cell set to a potential of –1000 mV. All parts of the system
were protected from light using aluminium foil. There was no evidence of formation of
CoQ10H2 as determined by measuring the change in absorbance of the solution at 275 nm
(Amax for CoQ10).
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Tetrabutylammonium borohydride in 1-propanol (approximately 19 mmol/L) was used to
reduce CoQ10, CoQ0, and vitamin K1. This concentration was determined to be the
minimum concentration at which all CoQ10, CoQ0 and vitamin K1 was reduced. A small
volume of the tetrabutylammonium borohydride solution was freshly made each time it
was required and each sample was reduced just before measurement to ensure minimal
oxidation of CoQ10H2 occurred before analysis.
Reduction of the quinones by tetrabutylammonium borohydride was most probably
complete since (a) the results for the replicates were similar, (b) the results showed similar
trends to that obtained using HPLC, where a different reduction system was employed, and
(c) similar results were obtained for vitamin K1 and its analogue 4-methoxy-1-naphthol,
which did not require reduction to fluoresce. These results are presented in section 2.3.4.3.
When using HPLC to determine the effect of solvent on fluorescence, vitamin K1 and
CoQ10 were reduced by alcohol using platinum-black as a catalyst. Heptane was used in
the mobile phase to reduce peak tailing. Standards contained 20% methanol. Most peaks
had secondary peaks at the end (Figure 2.2) – this may have been due to analyte absorbing
onto the surface of the platinum-black, so that when the mobile phase (with a higher
eluting power) moved through the reactor the absorbed analyte was washed off (Figure
2.2). This suggests that the reactor is contributing to the chromatography and confirms the
findings of Usui, (1989) (25).
Figure 2.2 The peak tailing observed with the platinum-black reactor, the solvent is 1-
propanol. Arrow points to the secondary peak.
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Some solvents (for example, acetonitrile) affected the performance of the reactor which
consequently affected the results depending on the sequence of solvents run. This is a
disadvantage of using this method to investigate the effect of solvent on fluorescence.
2.2.4. Hydrodynamic voltammograms
For analysis of a compound by electrochemical detection, it is first necessary to confirm
the potentials required to reduce or oxidise the compound under the conditions (solvent,
column, electrochemical cells) to be used in the method. Therefore, hydrodynamic
voltammograms of both CoQ10 and vitamin K1 were obtained. For CoQ10, the standard
solution  was 0.2 µmol/L in 1-propanol/water 9/1 v/v and for vitamin K1 it was 5 nmol/L
in ethanol. Injection volume was 50 µL. The potential at the final electrode was altered by
50 mV increments until the graph of applied potential vs peak height reached a plateau
(Figures 2.3 and 2.4).
Figure 2.3 Hydrodynamic voltammogram for CoQ10.
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Figure 2.4 Hydrodynamic voltammogram for vitamin K1.
For electrochemical detection of CoQ10, it is therefore possible to set the first of the
analytical cells on the electrochemical detector to a potential below 300 mV, at which no
CoQ10 will be oxidised but any impurities that are oxidised at or below 300 mV will be.
The impurities oxidised by the first cell will therefore not be detected by the second cell
which is set to 550 mV. This ‘screening’ process results in cleaner chromatograms.
2.3. Absorbance and fluorescence of CoQ10, and vitamin K1
2.3.1. Absorbance of Vitamin K1 and CoQ10
Ultraviolet detection in HPLC has been utilised to measure total CoQ10 (3, 4, 12, 48-50). A
preliminary absorbance scan serves to determine (a) the wavelength at which maximal
absorption occur, and (b) alternative wavelengths that may be used if there are interfering
compounds detected at the wavelength of maximal absorption.
2.3.1.1. Absorbance scans of CoQ10 and vitamin K1
The absorbance scans of CoQ10 and vitamin K1 in 1-propanol and ethanol, respectively,
show the absorbance maxima for CoQ10 to be at 275 nm (Figure 2.5) and for vitamin K1 to
be at 330 nm (Figure 2.6).
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Figure 2.5 Absorbance scan of CoQ10 in 1-propanol. Concentration is 100 µmol/L.
The absorbance maximum of 1.42 occurred at 275 nm.
Figure 2.6 Absorbance scan of vitamin K in ethanol. Concentration is 500 µmol/L.
The absorbance maximum of 1.7 occurred at 330 nm.
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2.3.2. Fluorescence of CoQ10H2, CoQ0H2, vitamin K1 naphthoquinol, and 4-
methoxy-1-naphthol.
Fluorescence of CoQ10H2 has been reported (51), but fluorescence detection of CoQ10H2
after HPLC has not. In contrast, fluorescence detection of the vitamin K naphthoquinol
after HPLC is the most commonly used detection method (1, 14, 15, 17-29, 52-55).
2.3.3. Effect of solvent on fluorescence
In fluorescence, spectral shifts occur due to the general effect of solvent polarity, specific
fluorophore-solvent interactions, and charge separation in the excited state.
Polar solvent molecules decrease the energy of the excited state by stabilising it (the
fluorophore) thereby shifting the emission to lower wavelengths (bathochromic shift). In
general, only fluorophores which are themselves polar display a large sensitivity to solvent
polarity. Non-polar fluorophores, such as unsubstituted hydrocarbons, are much less
sensitive to solvent polarity.
The dipole moment determines the asymmetry of a charge distribution and is defined as the
product of the total amount of positive or negative charge and the distance between their
centroids. Upon absorption of an exciting photon, a dipole moment is created in the
fluorophore (usually of different magnitude and direction from the ground state dipole).
The orientation of this dipole moment relative to the nuclear framework, and its
magnitude, will be determined by the nature of the substituents on the molecule. The
dielectric constants and dipole moments for some solvents that are compatible with HPLC
are shown in Table 2.3.
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Table 2.3 The dielectric constants and dipole moments for some solvents that are
compatible with HPLC.
Solvent Structure Polarity
index
(according to
Snyder)
Dielectric
constant
(20 or 25 ºC)
Dipole
moment
(according to
Debye)
Heptane C7H16 - 1.9 0
Hexane C6H14 0.0 1.9 0
1-Butanol CH3(CH2)3OH 3.9 17.8 1.66
Acetonitrile CH3CN 6.2 37.5 3.44
1-Propanol CH3(CH2)2OH 4.3 20.1 1.68
2-Propanol CH3CH(OH)CH3 4.3 18.3 1.66
Ethyl acetate CH3COOC2H5 4.3 6.0 1.78
Ethanol C2H5OH 5.2 24.3 1.70
1.4-Dioxane C4H8O2 4.8 2.2 0.40
Tetrahydrofuran C4H8O 4.2 7.4 1.63
Methanol CH3OH 6.6 32.6 1.70
Intermolecular interactions can cause important changes in the excited state decay
mechanism. Additionally, the external solvent parameters (for example, viscosity of the
solvent) can influence the rate of intermolecular processes especially in the case where
efficient charge separation or internal nuclear motions are involved.
Absorption occurs with the solvent in the arrangement characteristic of the ground state of
the molecule. However, before fluorescence occurs, the solvent molecules relax into a new
arrangement, which is preserved during the subsequent radiative transition (56). Therefore
excitation spectra change very little with different solvents.
Investigation of the effects of solvent on CoQ10 and vitamin K1 fluorescence is important
since an increase in the fluorescence yield gives an increase in sensitivity. However, the
solvent that gives the best fluorescence yield may not be the most favourable for the
chromatographic separation. Therefore a compromise between the best solvent for
chromatography and the best solvent for sensitivity may be necessary.
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2.3.4. Determination of the effect of solvent on fluorescence of CoQ10H2,
CoQ0H2, vitamin K1 naphthoquinol and 4-methoxy-1-naphthoquinol.
2.3.4.1. Aim
The aim of this work was to determine the effect of different solvents on the fluorescence
of CoQ10H2, vitamin K1 naphthoquinol, CoQ0H2 and 4-methoxy-1-naphthol (Figure 2.7).
Another aim was to determine whether the side-chains of CoQ10H2 and the vitamin K1
naphthoquinol are implicated in the fluorescence response to solvents.
Figure 2.7 The structures of CoQ10H2, CoQ0H2, vitamin K1 naphthoquinol, and 4-
methoxy-1-naphthol.
2.3.4.2. Experimental
Fluorescence was measured using a Cary Varian Eclipse fluorescence spectrophotometer.
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Vitamin K1, CoQ10, and CoQ0 were reduced by tetrabutylammonium borohydride, as
described in Section 2.2.3. Fresh solutions of tetrabutylammonium borohydride
(approximately 19 mmol/L) in 1-propanol were made by addition of 1-propanol (300 µL)
to tetrabutylammonium borohydride (approximately 0.0015g). The mixture was left to
stand for 5 minutes to ensure complete dissolution of the tetrabutylammonium
borohydride.
For CoQ10 and CoQ0, the standard solutions were 100 µmol/L in 1-propanol. The
borohydride solution (50 µL) was added to a quartz curvette followed by 750 µL of
standard. After shaking for approximately four seconds, 2200 µL of the solvent under
study was added to the curvette. After inversion of the curvette three to five times, it was
positioned in the fluorometer with the cell holder set at 25 ºC. After five minutes an
excitation scan (260 – 320 nm, emission set to 370 nm) and an emission scan (320 – 450
nm, excitation set to 290 nm) were obtained. Duplicate samples were scanned for each
solvent tested. A blank consisting of 750 µL 1-propanol, 50 µL of tetrabutylammonium
borohydride solution and 2200 µL of the solvent being tested was scanned for excitation
and emission as per the samples. The resulting spectrum was subtracted from the sample
spectra.
For vitamin K1, the standard solution was 500 µmol/L in 1-propanol. The standard (5 µL)
was added to 50 µL of borohydride solution in a curvette. After shaking for approximately
4 seconds, 2945 µL of the solvent to be tested was added to the curvette and the curvette
mixed by inversion three to five times. The curvette was placed in the cell holder (held at
25 ºC) for 5 minutes before readings were taken. Excitation (230 – 270 nm, emission at
408 nm) and emission (360 – 490 nm, excitation set to 249 nm) spectra were scanned on
duplicate samples and on a blank (5 µL 1-propanol, 50 µL borohydride solution, and 2945
µL appropriate solvent). The blank spectra were subtracted from the sample spectra.
For 4-methoxy-1-naphthol the standard solution was 100 µmol/L in 1-propanol. To 55 µL
of standard, 2945 µL of the solvent being tested was added. After inversion three to five
times, the curvette was placed in the cell holder (at 25 ºC) and excitation (230 – 270 nm,
emission at 408 nm) and emission (360 – 490 nm, excitation set to 249 nm) spectra were
scanned. Duplicate samples were analysed, and a blank (55 µL 1-propanol and 2945 µL of
the appropriate solvent) was run. The blank spectra were subtracted from sample spectra.
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The mean of the duplicate spectra was calculated using the fluorometer software. The
resulting data were fitted to a Gaussian curve of wavenumber versus peak height. The
maximum peak height and corresponding wavenumber were then determined from this
curve using the non-linear regression function in SigmaStat (SPSS, Chicago, Inc).
The effect of solvent on fluorescence of CoQ10 and vitamin K1 was also investigated on-
line, with HPLC and fluorescence detection (Shimadzu RF-551, Spectrofluorometric
detector). Standards (50 µmol/L) were injected in 20/80 (v/v) methanol/solvent of interest,
with a mobile phase of 20/80 (v/v) heptane/methanol. The flow rate was 0.1 mL/minute,
with no analytical column. Injection of 400 µL of standard gave a 4-minute plateau of
fluorescence, the height of which related to the fluorescence intensity of the standard in
each solvent.
2.3.4.3. Results
For CoQ10H2, the highest fluorescence intensity was observed in the aprotic solvents ethyl
acetate, dioxane, acetonitrile and tetrahydrofuran, when measured with a fluorometer
(Table 2.4) and HPLC (Table 2.7). Acetonitrile could not be tested in the HPLC system
since it ‘poisons’ the platinum-black reactor (13). A slight bathochromic shift was
observed in the emission maxima for CoQ10H2 with the aprotic solvent 1-butanol (Table
2.4, Figure 2.8). Kruk and Strzalka (1993) (51) also reported that the emission band of
CoQ10H2 (at 371 nm) was not sensitive to solvent polarity (Table 2.5) and hypothesised
that the methoxy groups of CoQ10H2  may form additional hydrogen bonds with protons in
the protic solvents. Since this quenches the fluorescence, maximum fluorescence occurs in
aprotic solvents.
Supporting this hypothesis further is the fact that the fluorescence response of CoQ10H2
and CoQ0H2 in the various solvents was very similar suggesting that the isoprenoid side-
chain of CoQ10H2 does not contribute to the fluorescence response. Additionally, there was
no correlation between the dielectric constant (r = -0.22, p = 0.524) and CoQ10H2
fluorescence, or the dielectric constant and the CoQ10H2 Stokes shift (r = -0.19, p = 0.573).
This hypothesis also provides an explanation as to why much higher concentrations of
CoQ0H2 and CoQ10H2 were required for investigation of their fluorescence as compared to
vitamin K1 naphthoquinol.
Chapter 2 83
Table 2.4 Fluorescence response of CoQ10H2 and CoQ0H2 in various solvents as determined using a fluorometer (data are mean ± SE)
Coenzyme Q10H2 Coenzyme Q0H2
Solvent Emission
Maxima
(wavenumber,
cm-1)
Emission
Response
(± SE)
R2 for Fit Emission
Maxima
(wavenumber,
cm-1)
Emission
Response
(± SE)
R2 for Fit
Methanol 27072 ± 10 9.57 ± 0.04 0.988 27410 ± 12 14.91 ± 0.08 0.985
Ethanol 26997 ± 12 11.50 ± 0.06 0.985 27323 ± 14 17.04 ± 0.11 0.979
1-butanol 25853 ± 24 14.35 ± 0.13 0.939 24473 ± 57 33.57 ± 0.56 0.885
2-butanol 26830 ± 11 6.58 ± 0.03 0.985 27106 ± 13 7.54 ± 0.04 0.981
1-propanol 27029 ± 10 11.65 ± 0.05 0.988 27663 ± 16 16.88 ± 0.13 0.978
2-propanol 26924 ± 12 12.19 ± 0.06 0.983 27627 ± 14 18.06 ± 0.12 0.981
Acetonitrile 26885 ± 8 19.29 ± 0.07 0.993 27199 ± 11 23.63 ± 0.12 0.987
Hexane 27130 ± 10 12.15 ± 0.05 0.990 27670 ± 15 15.61 ± 0.11 0.978
Heptane 26979 ± 13 8.94 ± 0.05 0.980 27518 ± 14 15.85 ± 0.10 0.980
Dioxane 26683 ± 9 20.76 ± 0.07 0.991 26926 ± 12 35.78 ± 0.17 0.985
Ethyl Acetate 26768 ± 8 21.55 ± 0.07 0.992 27014 ± 14 21.78 ± 0.12 0.980
Tetrahydrofuran 26693 ± 8 24.48 ± 0.09 0.992 27174 ± 17 19.85 ± 0.14 0.969
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Table 2.5 The absorption maxima (Amax), emission maxima (Emmax), and fluorescence
quantum efficiency (Φ), with excitation set to 290 nm of CoQ10H2 in various solvents,
from Kruk and Strzalka (1993) (51).
Solvent Amax Emmax Φ
Methanol 290.1 371.0 0.003
Ethanol 290.3 371.0 0.004
Ethylacetate 291.4 371.0 0.032
Hexane 291.0 369.5 0.033
50 % Methanol in H2O 288.0 370.5 0.012
25 % Methanol in H2O 289.0 371.0 0.01
Figure 2.8 Emission scan of CoQ10 in various solvents using excitation at 290 nm. See
colour code below for corresponding solvents.
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As expected, the fluorescence responses of vitamin K1 and 4-methoxy-1-naphthol in various
solvents were similar, and were highest in protic solvents such as ethanol and 1-propanol
(Figure 2.9 and Table 2.6). The exception was with tetrahydrofuran and dioxane in which 4-
methoxy-1-naphthol showed high fluorescence but vitamin K1 naphthoquinol did not. The
emission maxima shifted slightly toward shorter wavelengths with aprotic solvents. These
results support the hypothesis of Kruk and Strzalka (1993) (51), who investigated the effect of
solvent on the fluorescence intensity of the chemically similar plastoquinol-9 and α-
tocopherol quinone. They reported that the fluorescence quantum efficiency changed
significantly in solvents of different polarities, being highest in ethanol and lowest in hexane
(51). Kruk and Strzalka (1993) (51) hypothesised that, in a solution of an apolar solvent, the
absorption is to S1 which is non-fluorescent or from which fluorescence has a low efficiency.
However, in solvents of high polarity, if the energy distance between S1 and S2 is low, the
latter state is more strongly stabilised and its energy is lower than that of S1 (51). The
molecule, after absorption to S1 followed by thermal deactivation to S2, will emit energy in
the form of fluorescence (emission from S2 is highly efficient) (51). In such a case, the
absorption remains unaffected by a change in the solvent polarity from non-polar to polar,
whereas the quantum efficiency of the fluorescence strongly increases and a long-wavelength
shift in the emission maxima occurs (51). This hypothesis is further supported by the
significant correlation between vitamin K1 fluorescence and dielectric constant (r = + 0.67, p
= 0.047), and between the vitamin K1 Stokes shift and dielectric constant (r = + 0.65, p =
0.031). The fluorometer results for vitamin K1 agree with those obtained using the HPLC
method. A quenching of vitamin K1 fluorescence by dichloromethane as an HPLC solvent has
been reported previously (47).
Colour code for
Figures  2.8 and 2.9
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The fluorescence of 4-methoxy-1-naphthol was higher in aprotic solvents than that of vitamin
K1 (Table 2.6), which may be either due to interactions of the phytyl side-chain on vitamin
K1, or due to the methoxy group on 4-methoxy-1-naphthol reacting with the solvents. There
was a shift to shorter wavelengths for the emission maxima of 4-methoxy-1-naphthol in the
aprotic solvents hexane, heptane, dioxane, ethyl acetate and tetrahydrofuran (Table 2.6).
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Table 2.6 Fluorescence response of reduced vitamin K1, and 4-methoxy-1-naphthol in various solvents, as determined using a
fluorometer (data is mean ± SE).
Vitamin K1 naphthoquinol 4-methoxy-1-naphthol
Solvent Emission
Maxima
(wavenumber,
cm-1)
Emission
Response
(± SE)
R2 for Fit Emission
Maxima
(wavenumber,
cm-1)
Emission
Response
(± SE)
R2 for Fit
Methanol 22889 ± 8 79.56 ± 0.32 0.989 24617 ± 7 176.41 ± 1.20 0.993
Ethanol 23044 ± 9 191.98 ± 0.82 0.987 24800 ± 6 221.28 ± 1.18 0.995
1-butanol 23269 ± 9 76.22 ± 0.35 0.986 24798 ± 7 175.43 ± 1.02 0.994
2-butanol 23058 ± 9 5.99 ± 0.03 0.985 24798 ± 8 4.65 ± 0.03 0.992
1-propanol 22933 ± 8 183.43 ± 0.74 0.989 24862 ± 1 335.83 ± 2.77 0.996
2-propanol 23004 ± 9 137.56 ± 0.61 0.987 24840 ± 6 236.24 ± 1.22 0.995
Acetonitrile 23521 ± 10 119.53 ± 0.64 0.980 25027 ± 6 204.68 ± 0.88 0.996
Hexane 23359 ± 8 2.80 ± 0.01 0.989 25658 ± 4 125.27 ± 0.25 0.999
Heptane 23507 ± 8 6.05 ± 0.02 0.986 25608 ± 5 146.48 ± 0.34 0.999
Dioxane 23177 ± 38 0.29 ± 0.01 0.813 25780 ± 4 236.87 ± 0.48 0.999
Ethyl Acetate 24152 ± 10 1.90 ± 0.01 0.981 25874 ± 5 4.71 ± 0.01 0.999
Tetrahydrofuran 23275 ± 30 4.28 ± 0.05 0.861 25779 ± 5 230.31 ± 0.5 0.999
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Figure 2.9 Emission scan for vitamin K1 in various solvents. See colour code (below
Figure 2.8) for corresponding solvents.
Table 2.7 Fluorescence peak height for CoQ10H2 and vitamin K1 naphthoquinol as
determined using HPLC (mean ± SD).
Solvent Coenzyme Q10 Vitamin K1
Methanol 24.0 ± 1.5 436
Ethanol 25.9 ± 0.4 620
1-Butanol 16.9 ± 1.8 459
1-Propanol 17.0 ± 2.2 443
2-Propanol 12.8 ± 5.0 501
Dioxane 35.4 ± 0.1 195
Ethyl Acetate 26.8 ± 0.6 162
Tetrahydrofuran 11.2 ± 4.7 268
In the HPLC study, repeat measurements were not obtained for vitamin K1 due to the
solvents affecting the performance of the reactor, which consequently affected the results
depending on the sequence of solvents run.
Wavelengh (nm)
230 240 250 260 270
-60
-40
-20
0
20
40
60
80
100
Fl
uo
re
sc
en
ce
 re
sp
on
se
Chapter 2 89
The results presented here apply directly to the fluorescence detection of CoQ10 and
vitamin K1 after HPLC. Therefore, the presence of 2 and 27% 1-propanol in the vitamin K1
and CoQ10 solutions, respectively (or 20% methanol in the case of the HPLC experiment)
for all solvents tested is not expected to be a problem. It was anticipated that biological
samples injected into the HPLC would be, for example, 1-propanol extracts of CoQ10. A
more accurate estimate of the effect of solvents on fluorescence would have been obtained
if pure solvents were used. However, because the primary aim of this project was to
develop or improve HPLC assays for CoQ10 and vitamin K, this investigation of solvent
effect on fluorescence was tailored to give results relevant to the aim of the project as
opposed to an exact chemical demonstration of the effect of solvent on fluorescence.
It is possible that the tetrabutylammonium borohydride used to reduce the quinones
increases the pH of the final solution, favouring formation of the semi-quinone form which
would have different fluorescence properties to the quinol form. Additionally, a basic
solution may cause a bathochromic shift in the emission maxima and affect the
fluorescence yield. de Barros et al., (1994) (45) reported that fluorescence of primin
(Figure 2.10), after reduction with sodium borohydride, was just below 80% of the relative
fluorescence intensity when no acid was added, and the relative fluorescence intensity
increased on addition of 0 – 40 µmoles of acid in 10 µmol/L, but plateaued after 40 µmol/L
(45). For lapachol (Figure 2.10) (87 µmol/L) reduced with borohydride, the relative
fluorescence intensity was 75% with no acid and increased with up to 60 µmol/L acid
added, then plateaued with addition of extra acid (45).
Figure 2.10 The stuctures of primin and lapachol which were reduced by borohydride
by de Barros et al., (1994) (45).
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However, in the present investigation, the pH of the solution after addition of
tetrabutylammonium borohydride was close to seven (as tested using Litmus paper),
suggesting that the concentration of tetrabutylammonium borohydride added did not alter
the pH significantly.
2.4. Stability of Coenzyme Q10 during extraction and frozen storage
An important factor to consider when setting up a clinical assay is the stability of the
analyte. This determines the practicalities of sample collection (how soon after collection
of the sample must the analyte be measured?), extraction (will the analyte degrade before it
is purified?), and logistics (can the sample be stored until a time suitable for analysis?). In
the case of routine laboratory analysis, stability of the analyte during long term frozen
storage is generally not an issue. However, where clinical studies are being conducted,
long-term storage may be necessary.
There is a lack of good analytical data recording the stability of CoQ10. Most reports that
do discuss stability of CoQ10 in whole blood, EDTA and lithium heparinised plasma, and
in solvent extracts of plasma neglect to mention whether the sample was stored in the light
or the dark. This is important given that CoQ10 is photochemically decomposed (57). It is
also possible that the volume of sample stored affects stability, as other antioxidants
present in plasma may protect CoQ10 from degradation. It is evident that CoQ10H2, and
probably CoQ10, is more stable in heparinised than EDTA plasma (32, 58). The exact
mechanism for this is not known. Many of the reports on the stability of CoQ10 were
carried out using EDTA plasma.
It has been known since the 1960s that ultraviolet light and sunlight destroy CoQ10 (57).
Some methods for measurement of plasma CoQ10 recommend that samples be protected
from light whenever possible to avoid photochemical decomposition of CoQ9 and CoQ10
(4, 31, 33, 36, 41, 59). Kaikkonen et al., (1999) (10) investigated the effect of light on the
stability of CoQ10 in plasma. Samples (n = 8) were either covered with aluminium foil or
exposed to light during sample pre-treatment. Plasma total CoQ10 was 10.1% lower in the
samples kept in the light during the long extraction procedure (consisting of evaporation
and reconstitution) and this effect was independent of plasma CoQ10 concentration and
proportionally similar for all samples (10).
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The stability of CoQ10 during long term storage has not been well documented. Edlund
(1988) (33) reported that CoQ10H2 (and presumably total CoQ10) was stable in plasma
stored at –70 ºC for at least 5 months, but storage at -20 ºC resulted in oxidation of
CoQ10H2. It has also been reported that CoQ10H2 (and presumably total CoQ10) is stable for
at least 12 months (32, 60) in plasma stored at –75 ºC and –80 ºC respectively. On a
limited number of samples (n = 8), Kaikkonen et al., (1999) (10) reported that total CoQ10
is stable in lithium heparinised plasma stored for 3 years at –80 ºC.
2.4.1. General methods
2.4.1.1. HPLC assay for total CoQ10
In the following experiments, the concentration of total CoQ10 was measured using HPLC
with electrochemical detection as described in Chapter 3, Section 3.6.2.
2.4.2. Short-term total CoQ10 stability
2.4.2.1. Aim
To investigate the photostability of total CoQ10 in standard solution and plasma.
2.4.2.2. Experimental
Aliquots (25 µL) of plasma (containing 0.38 µmol/L CoQ10) and standard CoQ10 in 1-
propanol (3.0 µmol/L) were stored in clear plastic Eppendorf tubes on the bench
(approximately 21 ºC) either in the light (under fluorescent lighting) or protected from light
(wrapped in aluminium foil). After 0, 2, 4, 6, 34, and 48 hours, duplicate aliquots of
standard or plasma were extracted by addition of 225 µL 1-propanol, then subjected to
HPLC analysis.
2.4.2.3. Results
Coenzyme Q10 is light sensitive being almost completely decomposed after 24 hours
exposure to light (Figures 2.11 and 2.12). This degradation did not occur when samples
were kept protected from light (Figures 2.11 and 2.12). Therefore keeping samples
protected from light during long extraction procedures (> 2 hours) is desirable. These
results support the statement by Kaikkonen et al., (1999) (10) that samples for plasma total
CoQ10 measurement can be pre-treated in normal laboratory lighting conditions. It is
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probable that the lag time in CoQ10 degradation in the presence of light is due to a free
radical reaction. During sample analysis an autosampler that keeps samples in the dark is
important.
Figure 2.11 The CoQ10 concentration of a plasma sample (initial CoQ10 concentration
0.38 µmol/L) over time during exposure to (squares) and protection from (circles)
light.
Figure 2.12 The CoQ10 concentration of a standard solution of CoQ10 in 1-propanol (3
µmol/L) over time, exposed to (squares) and protected from (circles) light.
Time (hours)
0 10 20 30 40 50
C
oQ
10
 c
on
ce
nt
ra
tio
n 
(µ
m
ol
/L
)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Time (hours)
0 10 20 30 40 50
C
oQ
10
 c
on
ce
nt
ra
tio
n 
(µ
m
ol
/L
)
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Chapter 2 93
2.4.3. Long-term stability of total CoQ10 at –13 ºC
2.4.3.1. Aim
To determine the stability of total CoQ10 at –13 ºC in serum, and EDTA and lithium
heparinised plasma samples (stored aliquots > 1 mL).
2.4.3.2. Experimental
Lithium heparinised plasma, EDTA plasma, and serum samples were obtained from 10
staff at Canterbury Health Laboratories (written informed consent was obtained from all
volunteers). Blood specimens were centrifuged within 1 hour of collection, and the plasma
or serum stored at 4 ºC until HPLC analysis (within 4 hours of collection).
After measuring baseline total CoQ10 samples were stored in the dark at –13 ºC for 12
months. After this time samples were thawed, and total CoQ10 was measured again using
the same methodology.
2.4.3.3. Results
There was a significant decrease in the percentage of total CoQ10 in the plasma samples
after storage at –13 ºC for 12 months, with the mean (± SD) percentage of CoQ10 left in
each sample type being 40 ± 13, 63 ± 25, and 54 ± 19 for EDTA, serum, and lithium-
heparinised plasma, respectively (Figure 2.13).
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Figure 2.13 The concentration of total CoQ10 in lithium heparinised plasma, EDTA
plasma and serum samples before (black) and after (grey) storage at –13 ºC for 12
months. Error bars are standard deviations. (n = 10).
2.4.4. Long-term stability of total CoQ10 at –80 ºC
2.4.4.1. Aim
To investigate the stability of total CoQ10 in lithium heparinised plasma samples stored at –
80 ºC for 18 months.
2.4.4.2. Experimental
Baseline (fasted) samples (n = 70) were obtained from healthy males for a study
investigating the bioavailability of CoQ10 supplements (Chapter 5, section 5.4). Blood
specimens were centrifuged and plasma removed within 1 hour of collection. Plasma
(lithium heparinised) was immediately stored at –80 ºC, and total CoQ10 was analysed
within 4 months of collection.
Immediately after analysis, samples were returned to –80 ºC. Eighteen months after the
initial analysis of total CoQ10, samples were thawed, and total CoQ10 measured again using
identical methodology.
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2.4.4.3. Results
There was no change in the total CoQ10 concentration of the samples after 18 months of
storage (mean ± SD 1.25 ± 0.63 vs 1.33 ± 0.78 µmol/L before and after storage,
respectively) at –80 ºC. This result is consistent with the findings of Kaikkonen et al.,
(1999) (10).
2.4.5. Stability of total CoQ10 in glass and plastic containers
2.4.5.1. Aim
To test whether CoQ10 may be absorbed by plastic or plasticisers when stored in plastic
containers.
2.4.5.2. Experimental
Aliquots of fresh plasma (300 µL) were added to glass and plastic (polycarbonate) tubes.
Aliquots were left at room temperature or immediately frozen to –13 ºC. Duplicate samples
stored in glass and plastic were assayed for total CoQ10 after standing protected from light
at room temperature for 2 hours. After 24 hours under the same conditions, a further set of
aliquots in glass and plastic (in duplicate) were assayed for total CoQ10. Total CoQ10 was
assayed after 18 and 90 days.
2.4.5.3. Results:
There was no difference in total CoQ10 concentration of plasma stored in either glass or
plastic tubes (Table 2.8) for up to 90 days.
Table 2.8 The concentration of CoQ10 in plasma stored in glass and plastic tubes for
varying lengths of time.
Storage
Time (days)
Storage
Temperature (ºC)
Total CoQ10 in Glass
Tubes (µmol/L)
Total CoQ10 in Plastic
Tubes (µmol/L)
0.08 21 0.59 0.61
1 21 0.54 0.57
18 -13 0.69 0.67
90 -13 0.50 0.49
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2.5. Discussion
Both CoQ10 and vitamin K are lipophilic. Thus when extracting them from plasma, lipids
are co-extracted. Sample clean-up steps are often costly in terms of time and resources and
may lead to degradation of the analyte. Hence, any advance in measurement techniques
that allows measurement of the analyte in a less pure, or less concentrated, extract is
welcomed.  If co-extracted compounds co-elute with the analyte during HPLC and are
detected by the detector (hence interfering with chromatography), altering detector settings
may make it possible to ‘screen out’ these interfering compounds. This requires knowledge
of the properties of the analyte under the detection method being used. For example, when
measuring CoQ10 by electrochemical detection, because the potential required to oxidise
CoQ10 is high (550 mV) and very little, if any, CoQ10 is oxidised at potentials lower than
350 mV, an electrochemical cell prior to the analytical electrochemical cell in the HPLC
system can be set to a potential of 350 mV resulting in oxidation of any interfering
compounds that are oxidised at or below this potential. Once oxidised, these compounds
will then not be detected by the analytical electrochemical cell and hence will not appear
on the chromatogram.
Endogenous vitamin K is present in plasma at very low concentrations. Therefore, any
factor that can increase sensitivity of an assay for vitamin K is important. Use of a mobile
phase containing a protic solvent increases the fluorescence yield and hence the sensitivity
of the fluorescence assay. Furthermore, use of a platinum-black filled reactor to catalyse
reduction of vitamin K by an alcohol present in the mobile phase may increase the
sensitivity, and will certainly increase the reproducibility of an assay for vitamin K as
opposed to using zinc reduction. The platinum-black reactor does not require frequent
repacking, or additives in the mobile phase as is required for zinc reduction.
Fluorescence detection of coenzyme Q10 after HPLC has not been reported. Results
presented in Section 2.4.1 show that the fluorescence yield of coenzyme Q10 is low, which
may be due to quenching of fluorescence in protic solvents. Because of this fact, higher
fluorescence yields were found in aprotic solvents for CoQ10 and CoQ0. For platinum-
black-catalysed reduction of CoQ10 by an alcohol, a protic solvent is required in the mobile
phase. Hence fluorescence detection of CoQ10 in biological samples is not as effective as it
is for vitamin K.
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Knowledge of the temperature and light stability of an analyte is essential when carrying
out routine measurement in biological samples. Protection of samples from light during
analysis can waste time if this precaution is not required. However, inaccuracies in
determination of the actual concentration due to sample handling may give erroneous
results. Stability results for vitamin K were not able to be obtained due to the inability to
develop an acceptable assay for measuring vitamin K in biological samples. Stability
results for CoQ10 show that there is no need to protect samples from light during
extraction, as long as the time that samples are exposed to light is kept to a minimum, and
is no longer than 2 hours. Additionally, CoQ10 is not stable during storage at –13 ºC for 12
months, but it is stable during storage at –80 ºC for at least 18 months. Preliminary
evidence shows that CoQ10 has similar stability when stored in either glass or plastic tubes,
and is not absorbed onto plastic.
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Chapter 3. Determination of Coenzyme Q10
3.1. Introduction
A rapid and reliable assay to quantify plasma CoQ10 was required in order for testing of
research hypotheses (Chapter 1, Section 1.5). These hypotheses included that CoQ10 can be
limiting in human tissues, and an insufficiency causes cellular dysfunction, that muscle
tissue, with its high energy requirement, will be particularly susceptible to CoQ10
insufficiency, that CoQ10 insufficiency will exacerbate cardiovascular disease, and that
statin therapy can cause CoQ10 insufficiency and this is a factor in the muscular side-
effects of statin therapy.
Plasma coenzyme Q10 (CoQ10) is usually determined using high-performance liquid
chromatography (HPLC), with ultraviolet (UV) or electrochemical detection. An assay for
CoQ10 was required at Canterbury Health Laboratories to enable monitoring of plasma
CoQ10, in patients receiving statin therapy. It was not a requirement that the assay be
capable of quantifying both reduced and oxidised forms of CoQ10, since this ratio changes
readily in the presence of atmospheric oxygen. Sample handling is critical when measuring
the ratio of CoQ10 to CoQ10H2 in plasma, to avoid a change in the ratio from the in-vivo
situation. The requirement for strict sample handling makes measuring the ratio
inappropriate in a routine diagnostic test.
Measurement of total CoQ10 is less subject to artefactual interference from sample
handling and is less demanding on detector sensitivity since only 4% of CoQ10 is in the
reduced form requiring a detection limit of 22.5 nmol/L in plasma. While measurement of
the CoQ10H2 to CoQ10 ratio was not a priority, the possibility of measuring it was not
totally neglected.
Desired attributes of a routine assay are that sample turnaround time is short and assay
costs are low. Therefore, extraction of the analyte from the biological matrix should be
simple and rapid, the equipment used should be inexpensive and robust, and the solvents
used should be easily obtainable and inexpensive.
There are four important steps to consider when developing a routine test to quantify a
blood analyte by HPLC. The first step is to make sure that the desired detection method is
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sensitive enough to measure the analyte at the expected concentrations. The second step is
the extraction of the compound from the biological matrix, the third is the development of
the chromatography system and the final step is to confirm that the method gives accurate
and reproducible values for the analyte and to build in quality assurance factors to ensure
consistency of the method over time.
When setting up an assay for an analyte, it is important to critically review other published
assays for that analyte. From this review, either a novel assay can be developed or a
reported assay can be set up and improved if necessary. As discussed in Chapter 1, the
large majority of assays for CoQ10 in biological samples utilise HPLC. A summary of (a)
extraction procedures that have been used to extract CoQ10 from biological samples
(Appendix 1), and (b) HPLC systems that have been used to measure CoQ10 in extracts
(Appendix 2) is attached.
Two fast and reliable HPLC assays for the determination of plasma CoQ10, one using
electrochemical detection (1) and the other ultraviolet detection (2),  were used as the basis
for work presented in this Chapter. The initial expense and general lack of availability of
electrochemical detectors as opposed to ultraviolet detectors makes them less desirable.
Fluorescence detection has not been reported for detection of CoQ10 despite being the most
commonly used detector for measurement of the chemically similar analyte, vitamin K. As
has been discussed (Chapter 1, Section 1.4), it was deduced from work by Daines (2001)
(3) that fluorescence detection should offer sufficient sensitivity to measure the
endogenous CoQ10 to CoQ10H2 ratio. It is important to also consider the analytical qualities
(such as the sensitivity and specificity) of detection methods before deciding which
detector to use.
Three methods of detection (electrochemical, fluorescence, and ultraviolet) of CoQ10 (after
HPLC assay) were compared to clarify the advantages and disadvantages of each method.
Using the results from this investigation, as well as the equipment initially available, steps
were taken to set up an assay to measure plasma total CoQ10 using ultraviolet detection.
After setting up the assay using ultraviolet detection, an electrochemical detector became
routinely available, and hence the transfer and modification of the method to use
electrochemical detection is discussed. Finally, the reproducibility and accuracy of the two
methods are compared with each other and that of similar reported assays.
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3.2. Detector
It was anticipated that, by analogy with the sensitivity gained when using fluorescence
detection to measure vitamin K (4-23), fluorescence detection could be useful for
measuring both plasma total CoQ10 and the plasma CoQ10 to CoQ10H2 ratio. Only CoQ10H2
fluoresces (24). Because CoQ10H2 is easily oxidised in the presence of air, reduction on-
line in the HPLC is desired. As discussed in Chapter 2, CoQ10 can be quantitatively
reduced by zinc, or alcohol in the presence of platinum-black as a catalyst, and both these
reduction systems can be incorporated into an HPLC system with relative ease. It was
proposed that a plasma extract could be injected into the HPLC system, CoQ10 and
CoQ10H2 separated on the analytical column, and the reduction device placed between the
column and the detector, to reduce the endogenous CoQ10 to CoQ10H2 for detection. For
measurement of total CoQ10 using fluorescence detection, the reduction device could be
placed before the analytical column, and total CoQ10 measured, as CoQ10H2. Alternatively,
an oxidising agent could be added to the plasma extract before HPLC and the reduction
device placed after the analytical column but before the detector, to reduce CoQ10 for
detection.
As discussed in Chapter 2, oxidised CoQ10 absorbs radiation more intensely than CoQ10H2,
with the molar absorptivities being 14,020 and 3,940 respectively. Because CoQ10 is
present in plasma in both the reduced and oxidised state, plasma CoQ10 must be oxidised
during the sample preparation process before ultraviolet detection, and total CoQ10 is
subsequently measured.
Electrochemical detection measures the change in potential as electrons are lost or gained
during oxidation or reduction. Most commonly, the loss of electrons during oxidation of
CoQ10 is measured at the analytical electrochemical cell. While requiring more equipment,
the most simple HPLC set-ups using electrochemical detection utilise three
electrochemical cells, in the oxidation - reduction - oxidation, or reduction – reduction -
oxidation mode (1, 25-29). Total CoQ10 can be measured by placing the first
electrochemical cell before the analytical column. Both CoQ10H2 and CoQ10 can be
measured simultaneously by placing the first electrode after the analytical column, as the
column separates these two forms of CoQ10. If a fourth electrochemical cell is available,
the assay may be improved by placing the fourth electrode between the pump and the
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injector, to oxidise any electroactive components present in the mobile phase. Some
reported methods for electrochemical detection of CoQ10H2 and CoQ10 employ just one
electrochemical cell for detection, with a non-electrochemical reduction step being added
to the HPLC procedure (30-32). For example, the method of Leary et al., (1998) (32) uses
zinc catalysed reduction in a post-column reactor. The zinc reactor reportedly performs
adequately for 2 weeks of successive runs before requiring replacement of the zinc filling
(32). The method of Yamashita et al., (1997) (31) utilises a reduction column (IRICA RC-
10) immediately prior to the analytical cell. The method of Wang et al., (1999) (30) uses a
complex instrumentation for automated precolumn reduction of CoQ10 with sodium
borohydride, which is made fresh by the automated system every three samples and
injected into the extract. This sodium borohydride reduction requires duplicate injection of
each sample when measurement of the ratio of CoQ10H2 to CoQ10 is required, and
therefore is not efficient in terms of time. Edlund, (1988) (26) also reports the use of
sodium borohydride to reduce all CoQ10 pre-column for measurement of total CoQ10 with
electrochemical detection. As discussed in Chapter 2, the reduction of CoQ10 by an
electrochemical cell is not as efficient as that by zinc or by alcohol in the presence of a
platinum-black filled reactor. Therefore, use of a reduction system such as alcohol and
platinum-black, or zinc, prior to electrochemical detection may result in a lower limit of
detection due to the more efficient reduction.
3.2.1. Extraction
When using liquid-liquid extraction, the degree to which sample dilution can be tolerated
depends on the sensitivity and specificity of the detector for the analyte.
For measurement of total CoQ10, the limit of detection does not need to be as low as when
measuring both CoQ10 and CoQ10H2 simultaneously, so a more dilute extract can be made.
Additionally, a more sensitive detector means that a more dilute sample can be made and
the limit of detection will still be acceptable. With electrochemical detection, it is possible
to set up multiple electrochemical cells to work in a ‘screening’ fashion, so that only
compounds able to undergo reversible redox reactions at the potentials applied are detected
at the final analytical cell. This results in cleaner chromatograms.
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All assays for measurement of CoQ10 use liquid-liquid extraction from plasma (or tissues).
In some cases the liquid extract is injected directly, in others it is purified before injection,
and in others it is purified on-line in the HPLC system (Appendix 1).
Direct extraction of plasma CoQ10 into hexane is not efficient (30). Protein denaturation
with methanol before hexane extraction has been reported to be inefficient by some (1), but
has apparently given 100% recovery for others (31). Similarly, extraction with hexane after
precipitation with ethanol has been reported to be an efficient extraction procedure in some
instances (1, 33) but has apparently given only 76 ± 36% recovery for others (34).
However, the lower efficiency reported by Finckh et al., (1995) (34) may be due to the
evaporation procedure used during extraction. The efficiency depends on the ratio of
plasma to solvent and also the ratio of methanol or ethanol (protein precipitation solvent)
to hexane. The disadvantage of a direct hexane extraction is that when the extract is
injected into the HPLC, the hexane reduces the retention of CoQ on a reversed-phase
analytical column. To overcome this problem, either small injection volumes are used (31)
or the hexane is evaporated and the residue reconstituted in a more appropriate solvent for
reversed-phase chromatography (28, 29, 32-41). Reconstitution of the dry hexane extract
requires a solvent that is compatible with the HPLC system and efficiently extracts CoQ10
from the dry lipid smear on the side of the vessel.
When measuring the ratio of CoQ10 to CoQ10H2, the use of hexane extraction, evaporation
under nitrogen and reconstitution has been reported (28). However some reports suggest
that this concentration process alters the ratio in favour of CoQ10 (25, 31) even when
heparinised plasma (in which the ratio is more stable) is used (31).
Comparison of the recovery obtained when different solvents are used for liquid-liquid
extraction of CoQ10 from plasma indicate that 1-propanol (being the most lipophilic
alcohol that is miscible with water) is an efficient solvent for extraction (Table 3.1) (1, 26,
30, 42, 43). Lower alcohols do not efficiently extract CoQ10 (Table 3.1).
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Table 3.1 Reported recoveries of CoQ10 in liquid-liquid extraction with various
solvents.
Publication Solvent Ratio of plasma
to solvent
Recovery
(mean ± SD) %
(1) 1-propanol 0.11/1 99 ± 3
(42) 1-propanol 0.2/1 96 ± 9.2
(42) 1-propanol 0.3/1 98 ± 3.5
(42) 1-propanol 0.4/1 95.3 ± 4.0
(42) 1-propanol 0.5/1 90.7 ± 10.7
(26) 1-propanol 0.5/1 88
(26) 1-propanol 0.4/1 100.9
(26) 1-propanol 0.3/1 101.37
(1) 2-propanol 0.11/1 89.5
(42) 2-propanol 0.3/1 108.3 ± 14.4
(26) 2-propanol 0.5/1 46
(1) Ethanol 0.11/1 88 ± 4
(42) Ethanol 0.3/1 31
(26) Ethanol 0.3/1 24
(1) 1-butanol 0.11/1 85 ± 5
(1) Acetone 0.11/1 88
(42) Acetone 0.3/1 88
(26) Acetone 0.5/1 36
(26) Acetone 0.3/1 40
(1) Methanol/hexane
(0.2/2.5 v/v)
0.11/1 64 ± 10
(1) Hexane 0.11/1 52 ± 9
(1) Acetonitrile 0.11/1 19 ± 11
(1) Methanol 0.11/1 19 ± 10
(1) Ethanol/hexane 0.11/1 100
To improve the efficiency of extraction of CoQ10 from plasma, the use of the surface-
active agent dodecylsulfate has been reported (38, 43). However, Edlund, (1988) (26)
reported that dodecylsulfate had no effect on extraction.
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The reason why liquid-liquid extraction of CoQ10 from plasma is difficult is that CoQ10 is
lipophilic and associates with lipids in the plasma. Since the extraction solvent needs to be
hydrophobic to extract CoQ10 from plasma, it also extracts some lipids. Saponification can
be used to breakdown triglyceride into glycerol and three molecules of a fatty acid salt.
The fatty acid salt, usually a sodium or a potassium salt, has a hydrophobic tail and a
hydrophilic head. Alkaline saponification of lipids has been used when measuring CoQ10
in foodstuffs (44) but has been reported to cause partial isomerization of CoQ10 to
ubichromenol. In addition, if ethanolic potassium hydroxide is used, an exchange of
methoxy groups of CoQ10 for ethoxy groups occurs even under mild conditions (45, 46).
Greenspan et al., (1988) (47) reported that saponification with potassium hydroxide
resulted in complete loss of CoQ10 although it is possible that the heating step used in their
method contributed to the breakdown and, if the procedure was carried out under full light,
photochemical degradation may have also occurred. The use of enzymatic hydrolysis with
lipase to remove serum lipids has also been reported (48).
Alternatively, purification of liquid-liquid extracts before HPLC analysis has been reported
(41, 49, 50). This purification can eliminate the large solvent front and increase column
lifetime. Thin layer chromatography (39, 51) has been used to purify the extract of plasma
but poor recovery and accuracy were obtained (51). Grossi et al., (1992) (52) and Kaplan
et al., (1995) (41) report solid phase extraction (SPE) for pre-purification, but 2 SPE steps
were required which leads to a long procedure and more variation. Kommuru et al., (1998)
(49) simplified the procedure to only one step of SPE, but the solvent front was very large
(42).
Kaikkonen et al., (1999) (37) compared cartridges and powder (C18 and silica) for SPE of
plasma extracts. Estimates of the total CoQ10 concentration were significantly higher when
samples were purified with cartridges (p = 0.013) but a better CV and shorter sampling
time supported the use of powders in routine analysis. Kaikkonen et al., (1999) (37) also
compared simple hexane extraction followed by evaporation and reconstitution in mobile
phase with hexane extraction followed by SPE. The direct liquid-liquid extraction gave
higher concentrations than the SPE method but this was probably because oxidation with
copper chloride was used before extraction in the direct liquid-liquid extraction method. It
appears that silica and C18 solid phase pre-treatments do decrease the number of unknown
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peaks in the chromatogram compared with a single hexane extraction. However, these
extra steps are not necessary because the extra peaks in the chromatogram do not interfere
with either CoQ10 or the internal standard (37).
A further alternative method of purification of the liquid-liquid extract of plasma is to use
semi-preparative HPLC. For example, Edlund, (1988) (26) reported the use of two
reversed-phase columns with pre-fractionation on the first column. All of the compounds
that were retained strongly on the first column (packed with Spherisorb ODS-2, 100 × 4.6
mm, 3 µm) were washed into a waste container (with a step-gradient of
dichloromethane/methanol (50/50 v/v)) after analysis of each sample, and therefore did not
pass through the second column (packed with Chromspher C18, 100 × 3 mm, 5 µm). This
system therefore incorporated complex column switching and changing of mobile phases.
In the method of Jiang et al., (2004) (42), plasma CoQ10 was extracted into 1-propanol and
the supernatant was purified on-line on a C18 column, before transfer to a reversed-phase
analytical column by a column-switching valve. Determination of CoQ10 was by ultraviolet
detection at 275 nm. The chromatography achieved by Jiang et al., (2004) (42) is visibly
better than that by Mosca et al., (2002) (2) (who injects a 1-propanol extract with no
purification step) due to the presence of fewer impurities and a higher concentration of
CoQ10. The HPLC run time in the method of Jiang et al., (2004) (42) takes 30 minutes per
sample which is twice as long as that in the method of Mosca et al., (2002) (2). The
precision and recovery obtained by Jiang et al., (2004) (42) is similar to that of Mosca et
al., (2002) (2), making it a viable option for measurement of plasma total CoQ10 if the
equipment required for the on-line sample clean up and column switching is available.
Lagendijk et al., (1996) (25) report injection of a 1-propanol extract of plasma into the
HPLC system, which includes a pneumatically activated 2-way valve between the column
and the conditioning cell. The valve allows passage of the mobile phase either through the
coulometric cells or past the coulometric cells directly to the waste container. The 1-
propanol extraction used by Lagendijk et al., (1996) (25) uses a plasma to 1-propanol ratio
of 100 to 333 µL (v/v) as opposed to the method of Tang et al., (2001) (1) in which the
ratio is 100 to 900 µL. There is no requirement for a similar switching device or a
secondary sample clean-up in the method of Tang et al., (2001) (1) because the
concentration of interfering co-extracted material is much lower and the electrochemical
detector is used in a ‘screening’ mode of oxidation-reduction-oxidation.
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3.2.2. Internal standards
Internal standards that have been used in published methods for measurement of CoQ10 are
shown in Table 3.2.
Table 3.2 The internal standards used in various CoQ10 assays.
Publication Measuring Sample type Internal standard
(39) CoQ10 Human plasma CoQ9
(26) CoQ10
CoQ10H2
Human plasma A diethoxy CoQ10
analogue
(40) CoQ10
CoQ10H2
Biological samples Menaquinone-8
(34) CoQ10
CoQ10H2
Human plasma CoQ7, CoQ9, CoQ9H2
(37) CoQ10
CoQ10H2
Human plasma CoQ9
(1) CoQ10
CoQ10H2
Human plasma CoQ9
(53) CoQ10
CoQ10H2
Human plasma Ubiquinol-dicaprilate
(29) CoQ10 Erythrocytes Ubihydrochinone-9
The use of CoQ9 as an internal standard when measuring CoQ10 and CoQ10H2 in human
plasma (1, 37, 39) is controversial as some reports suggest it is endogenously present in
human plasma (54). Tang et al., (2001) (1) reported that analysis of 50 plasma samples (25
from healthy subjects and 25 from patients with various illnesses) identified only one
sample with approximately 25 µg/L CoQ9 from a patient with a rare glycogen storage
disease (Type 1). Measurable CoQ9 was not detected in the plasma samples from the 25
healthy individuals, or the remaining 24 patients (1). This issue is discussed further in
Chapter 6.
Because mouse and rat plasma and tissues contain predominantly CoQ9, this cannot be
used as an internal standard for quantification of mouse and rat CoQ9, CoQ9H2, CoQ10, and
CoQ10H2. Therefore, Tang et al., (2004) (27) report the use of CoQ6 as the internal
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standard when measuring rodent CoQ, as CoQ6 is not present endogenously in mouse
tissue. Similarly, Okamoto et al., (1985) (39) used CoQ11 as the internal standard when
measuring CoQ10 in rat plasma.
3.3. Choice of detector
Things to consider when choosing the detection method include what equipment is already
on hand (costs are reduced if new equipment is not necessary), budget, sensitivity required
and what needs to be measured (for example, total CoQ10 or the CoQ10H2 to CoQ10 ratio).
A comparison of fluorescence, electrochemical and ultraviolet detectors was conducted to
determine the limits of detection for CoQ10 achieved using these three detection methods,
and thereby to establish whether the limits of detection were sufficient for an assay for
total CoQ10 in human plasma. The methods of Tang et al., (2001) (1) and Mosca et al.,
(2002) (2) using electrochemical and ultraviolet detection, respectively, were used as the
basis for the HPLC set-up for this investigation. For fluorescence detection, an
electrochemical cell (placed post-column and pre-detector) was used to reduce CoQ10.
3.3.1.1. Experimental
Standards were CoQ10 dissolved in water/1-propanol mixtures, 1/5 v/v for ultraviolet and
fluorescence detection and 1/9 v/v for electrochemical detection. A saturated aqueous
solution of 1,4-benzoquinone was added before HPLC analysis where ultraviolet detection
was used (50 µL of saturated aqueous benzoquinone solution to 1.20 mL of standard
solution). For ultraviolet detection in plasma, 50 µL was mixed with 12.5 µL of saturated
aqueous 1,4-benzoquinone and 250 µL of 1-propanol; for electrochemical detection, 25 µL
of plasma was mixed with 225 µL of 1-propanol. The mixtures were vortexed for 10
minutes, centrifuged at 8000g for 5 minutes, and the supernatants injected directly into the
HPLC system. Injection (200 µL for ultraviolet and fluorescence detection, 20 µL for
electrochemical detection) was via a Shimadzu SIL-10AXL autoinjector. The basic HPLC
system used for each detection type is described in Table 3.3.
Chapter 3 114
Table 3.3 The mobile phase, flow rate, column and column temperature used with
ultraviolet, fluorescence and electrochemical detection when comparing the three
different modes of detection for CoQ10 analysis.
Detection
Method
Mobile Phase Flow Rate
(mL/min)
Column Column
Temperature (ºC)
Ultraviolet 30/70
methanol/ethanol (v/v)
1 Phenomenex
Luna C18(2)
(250 × 4.6
mm, 5 µm)
45
Fluorescence
and
Electrochemical
30/70
methanol/ethanol (v/v)
15 mL/L glacial acetic
acid, and 50 mmol/L
sodium acetate
trihydrate
0.5 Phenomenex
Luna C18(2)
(250 × 3 mm,
5 µm)
45
For ultraviolet detection, the detector (Linear UVIS 200) was set at 275 nm. For
fluorescence detection, an ESA Guardstat and post-column guard cell (ESA model 5020)
at –800 mV reduced CoQ10. Fluorescence detection (Shimadzu RF-551) was at an
emission wavelength of 370 nm and an excitation wavelength of 290 nm. For
electrochemical detection, an ESA Guardstat and pre-column guard cell (ESA model 5020)
set to +700 mV oxidised CoQ10H2. The electrochemical detector was an ESA Coulochem
III fitted with an analytical cell (ESA model 5011) with the first electrode set to –650 mV
and the second to 550 mV with the range 200 nV.
The limit of detection (LOD) was defined as the concentration at which the signal-to-noise
ratio is three, with baseline noise estimated as the standard deviation of the data points in
sections of clean baseline in chromatograms of standards. LOD was determined using
SigmaStat (SPSS Inc. 1997).
3.3.2. Results
The LOD was calculated for each detection method by taking the average LOD calculated
using standards at 4, 2, 1, 0.5, and 0.1 µmol/L (Table 3.4). Peak and noise height, peak
width and signal-to-noise ratio were determined for each standard and each detection
method (Table 3.4).
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Table 3.4 The detection limits, conditions used to determine these limits, and
chromatogram characteristics for the 1 µmol/L CoQ10 standard using fluorescence,
ultraviolet and electrochemical detection.
Fluorescence Ultraviolet Electrochemical
Water/1-propanol Ratio (v/v) 1/5 1/5 1/9
Injection Volume (µL) 200 200 20
Signal Height 20.9 5.4 611
Noise Height 1.03 0.03 0.58
Signal-to-Noise 20.3 187 1059
Peak Width 43.7 16.5 20.8
Limit of Detection (nmol/L)
(in injected solution)
29 4.8 0.34
Limit of Detection (fmol
injected)
5800 1000 6.8
Limit of Detection (nmol/L)
(in plasma sample)
174 30 3
Using electrochemical detection to detect CoQ10 in a normal plasma sample (CoQ10
content 1.76 µmol/L) there were fewer peaks than with the other detection systems making
it easier to detect and quantify the CoQ10 peak (Figure 3.1). The signal-to-noise ratio was
highest with electrochemical detection (Table 3.4) and equated to a LOD of 0.34, 4.8, and
29 nmol/L for electrochemical, ultraviolet and fluorescence detection, respectively. Thus
the injection volume can be reduced ten-fold to 20 µL when electrochemical detection is
used.
Figure 3.1 A comparison of a plasma extract using ultraviolet (top trace),
electrochemical (middle trace) and fluorescence (bottom trace) detection. Arrows
point to the CoQ10 peaks.
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The LOD for ultraviolet detection agrees well with that calculated from the results of
Mosca et al., (2002) (2) which was 1.23 pmol/L (on column). The limit of quantitation
reported by Mosca et al., (2002) (2) of 1.23 nmol/L appears to actually be an LOD, and the
units a mis-print for ‘pmol/L’.
The LOD reported by Tang et al., (2001) (1) for CoQ10 using electrochemical detection
was 5.79 nmol/L (in plasma) which agrees well with the results presented here.
It was shown in Chapter 2 that electrochemical reduction of CoQ10 is only 84% as efficient
as platinum-black catalysed alcohol reduction. Hence it is probable that the LOD for
fluorescence detection would be lower if platinum-black catalysed alcohol reduction were
used in place of electrochemical reduction. This proposed improvement would not,
however, enable fluorescence detection to be used in a clinical assay. As discussed in
Chapter 2, fluorescence yields are higher in aprotic solvents, but we were unable to
develop practical chromatographic conditions with these solvents and the expected
lowering of the LOD would still not make fluorescence detection a more desirable choice
than ultraviolet or electrochemical detection.
The cleaner chromatograms obtained with electrochemical detection (Figure 3.1) are due to
the screening process whereby only compounds that are able to undergo reversible redox
reactions at the potentials applied are detected at the final electrode. The cleaner
chromatograms contribute to the lower LOD achieved for electrochemical detection.
3.4. HPLC assay for CoQ10 using ultraviolet detection
Results presented in Section 3.3.2 demonstrate that electrochemical detection is
unquestionably the most effective detection method for CoQ10, in that it allows
measurement of the CoQ10H2 to CoQ10 ratio, requires less sample and provides cleaner
chromatography. However, results obtained with ultraviolet detection were acceptable and
in the absence of a ‘spare’ electrochemical detector, an assay using ultraviolet detection to
measure total CoQ10 was set up.
Mosca et al., (2002) (2) reported a simple, rapid and robust method to measure plasma
total CoQ10 using ultraviolet detection. This assay used addition of 1,4-benzoquinone as an
oxidising agent to ensure total CoQ10 is measured. After addition of 1,4-benzoquinone to
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plasma (50 µL of (approximately) 18.5 mmol/L 1,4-benzoquinone per 200 µL plasma),
vortexing and standing for 10 minutes, CoQ10 is extracted from plasma by liquid-liquid
extraction with 1-propanol (1/5 plasma/1-propanol v/v). After vortexing and
centrifugation, 200 µL of the supernatant is injected into the HPLC system. A mobile
phase of 35/65 methanol/ethanol (v/v) is pumped at 1 mL/minute and the extract is
separated on a C18 column (Supelcosil LC 18 (Supelco), 250 × 4.6 cm, 5 µm). The
ultraviolet detector is set to 275 nm. Mosca et al., (2002) (2) suggested that this method
does not require an internal standard because the efficiency of extraction is satisfactory
over a range of concentrations.
As presented in Chapter 2, an attempt to simplify this assay by making an ‘extraction
solvent’ containing 1,4-benzoquinone in 1-propanol was not successful due to the
instability of 1,4-benzoquinone in 1-propanol over time. Various other aspects of this assay
were investigated, in an attempt to increase sensitivity, improve the chromatography, and
generally improve the assay in terms of time and cost required.
3.4.1. Extraction
Because CoQ10 is lipophilic, many lipids are extracted with CoQ10 and it is generally the
lipids in the extract that interfere with the chromatography. The extraction system of
Mosca et al., (2002) (2) uses 1-propanol liquid-liquid extraction of plasma CoQ10, and
direct injection of the extract. This extraction procedure was also used in the method of
Jiang et al., (2004) (42) where the ratio of plasma to 1-propanol of 1 to 3.33 (v/v) resulted
in a more concentrated extract. However further extract purification on-line was necessary.
In terms of chromatography, injecting CoQ10 into the HPLC (equipped with a reversed-
phase column) in a relatively polar solvent (one with less eluting power than the mobile
phase) results in concentration of CoQ10 at the beginning of the analytical column
(stacking). This in turn can improve resolution and peak shape. However, because CoQ10 is
lipophilic, an efficient extraction requires a lipophilic extraction solvent, which leads to a
compromise between extraction solvent, extraction efficiency, injection solvent, and
chromatography. An alternative is to extract with a lipophilic solvent, evaporate, and
reconstitute with a relatively polar solvent, a procedure that is commonly used for related
analytes such as vitamins A, E, and K, but which leads to erratic recoveries. It was
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postulated that this could be because blood lipids have poor solubility in polar organic
solvents such as ethanol and that CoQ10, and presumably related lipophilic solutes,
partition into the extracted blood lipids such that the recovery depends on the lipid content
of the sample. Alternative extraction procedures were investigated to evaluate which
procedure gave both good chromatography and had the minimum concentration of
impurities that interfere with chromatography.
3.4.1.1. Experimental
Unless otherwise stated, the mobile phase was 30/70 methanol/ethanol (v/v). Detection
was with an ultraviolet detector (Linear Uvis200) set to 275 nm.
Olive oil was used as a model triglyceride to test the hypothesis that blood lipids are
responsible for poor recoveries in those procedures based on extraction with hexane,
heptane, or other non-polar solvents, followed by evaporation. A CoQ10 standard in ethanol
(10 mL, 20 µmol/L) was mixed with 1 mL olive oil for 80 minutes in the dark. The two
phases were separated by centrifugation. After 100-fold dilution (with 1/9 (v/v) water/1-
propanol) the concentration of CoQ10 in the olive oil was measured using HPLC with
electrochemical detection, as described in Chapter 3, section 3.6.2. After 10-fold dilution
(with 1/9 (v/v) water/1-propanol) the concentration of CoQ10 in the ethanol layer was
determined using the same methodology. The CoQ10 concentration in the olive oil was 26
times that in the ethanol phase. This suggests that this extraction procedure will not give
efficient recovery of CoQ10, as the CoQ10 will be occluded with the lipids on evaporation.
Thus the recoveries of CoQ10 and related compounds are likely to be erratic in this
extraction procedure depending on the blood lipid concentration. 1-Propanol is the most
polar alcohol that reliably dissolves triglycerides and presumably other blood lipids, and up
to about 15 % water can be added to these solutions before two phases separate. This
constrains the choice of extraction solvent.
Diluting a 100% 1-propanol extract 50/50 (v/v) with acetonitrile, and injecting twice the
injection volume used for the 100% propanol extract resulted in good peak shape and good
resolution but added an extra step to the assay. Extraction of CoQ10 into 40/60 1-
propanol/acetonitrile (v/v) resulted in sharp peaks with good resolution, but the recovery of
the extraction was poor as compared to a 100% 1-propanol extraction. Additionally, a
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minor peak that was found to interfere with the CoQ10 peak when 1-propanol plasma
extracts were injected was still present.
Saponification of lipids has been used when measuring the CoQ10 content of foodstuffs
(44). The saponification used by Mattila et al., (2001) (44) involved adding potassium
hydroxide (KOH) to a homogenate of the foodstuff, ascorbic acid and methanol. This
mixture was heated in a boiling water bath for 10 minutes. After cooling, sodium chloride
was added to avoid emulsion formation, and the CoQ was extracted using n-hexane (44).
To determine whether saponification of plasma lipids affects CoQ10 chromatography, a
CoQ10 standard was subjected to the following conditions. To 200 µL of water was added
575 µL of ethanol and 25 µL of 100 mmol/L CoQ10 stock in 1-propanol. A solution of
KOH (0.2 mol/L in methanol) (200 µL) and 200 µL of phosphoric acid (0.1 mol/L in
ethanol) were added. A control sample containing 200 µL water, 575 µL ethanol, 25 µL
100 mmol/L CoQ10 stock in 1-propanol, 200 µL methanol and 200 µL ethanol was also
made. These solutions were assayed with a 40/60 methanol/ethanol (v/v) mobile phase.
The potassium hydroxide saponification of plasma lipids with subsequent addition of
phosphoric acid in ethanol to precipitate potassium ions lead to a splitting of the CoQ10
peak into two peaks (Figure 3.2), suggesting CoQ10 was degraded by the KOH.
Figure 3.2 A CoQ10 standard without (red) and with (black) potassium hydroxide
saponification. Arrow points to the CoQ10 peak.
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Since potassium hydroxide saponification was not viable, calcium hydroxide
saponification was investigated. Using a sample of pooled plasma, the following two
samples were run: (a) 100 µL plasma, 10 µL of 5 mmol/L 1,4-benzoquinone in 1-propanol
and 490 µL of 1-propanol (normal plasma extraction); (b) 100 µL plasma, 10 µL 5 nmol/L
1,4-benzoquinone in 1-propanol, 490 µL 1-propanol and 15 mg of calcium hydroxide.
After vortexing for 15 minutes, approximately 20 mg of crushed dry ice was added to
neutralise the acid and remove calcium as insoluble calcium carbonate. Finally, 100 µL
was injected into the HPLC system.
This procedure resulted in a single CoQ10 peak with similar recovery to the control.
However, the saponification had a very minor effect on the chromatography, suggesting
that either the interfering compounds are not lipid, or that there was limited saponification
of the lipids. Water present in the plasma may stop saponification of the plasma lipids,
requiring the sample to be heated so that the lipids are hydrolysed. Alternatively, the water
needs to be removed from the samples so that saponification can occur.
Prior precipitation of plasma proteins and removal of water (CoQ10 would remain with the
proteins) could have several advantages for extraction of CoQ10 from plasma. Firstly, water
present in the plasma mixes with the 1-propanol reducing its lipophilicity, and potentially
reducing the extraction efficiency. Secondly, the dilution factor of the extraction would be
lower leading to a more concentrated extract. Thirdly, if ethanol is used to precipitate the
plasma proteins, any plasma constituents that are soluble in ethanol will be discarded with
the ethanol, which would lead to a cleaner CoQ10-containing extract of the protein
precipitate. Finally, if the 1,4-benzoquinone is added to the plasma (to oxidise CoQ10H2)
before protein precipitation with ethanol, residual 1,4-benzoquinone will dissolve in the
ethanol and be removed when the ethanol is discarded.
The use of (a) 5% trichloroacetic acid (TCA) in ethanol, (b) ethanol and (c) 10% TCA in
methanol to precipitate plasma proteins was therefore investigated. In some cases, CoQ10
was extracted from the protein pellet with the mobile phase solvent (30/70
methanol/ethanol v/v) instead of 1-propanol because the eluting power of 1-propanol is too
high to use with the mobile phase when the water is removed from plasma.
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Proteins in plasma were precipitated with 5% TCA in ethanol by adding 20 µL 5 nmol/L
1,4-benzoquinone in 1-propanol to 200 µL plasma, followed by 800 µL 5% TCA in
ethanol. After mixing, centrifugation and removing the supernatant, the protein pellet was
extracted with 250 µL 1-propanol, and 200 µL of the supernatant was injected into the
HPLC. The original supernatant (200 µL) was also injected.
In this procedure, some CoQ10 partitioned into the supernatant during protein precipitation
(as determined by the presence of a CoQ10 peak upon chromatography of the supernatant
obtained during protein precipitation). CoQ10 was therefore lost when the supernatant was
discarded, making this extraction procedure non-viable.
The same procedure with 100% ethanol also resulted in extraction of some CoQ10 into the
ethanol supernatant during protein precipitation making this method also non-viable.
Finally, 500 µL 10% TCA in methanol was added to 250 µL plasma. After vortexing and
centrifugation (5 minutes at 8000g), the supernatant was discarded. The pellet was
resuspended in 250 µL mobile phase (30/70 methanol/ethanol v/v), vortexed and
centrifuged again. Separately, 200 µL of the methanol supernatant and the
methanol/ethanol supernatant were injected into the HPLC system.
This precipitation allowed the water to be discarded and, due to the low solubility of CoQ10
in methanol, the majority of the CoQ10 remained with the proteins (determined from the
lack of a CoQ10 peak in the methanol supernatant) (Figure 3.3). The extraction of CoQ10
from the protein pellet with 30/70 methanol/ethanol (v/v) was, however, incomplete, as
determined by the smaller peak obtained for CoQ10 in this solvent as compared to that
achieved when 1-propanol was used to extract CoQ10 from the precipitate (Figure 3.3). The
incomplete extraction of CoQ10 with 30/70 methanol/ethanol (v/v) was confirmed by a
secondary extraction of the protein pellet (after 30/70 methanol/ethanol (v/v) extraction)
with 1-propanol and the observation of a CoQ10 peak in this secondary 1-propanol extract.
Extraction of CoQ10 from the protein pellet with 1-propanol lead to a more concentrated
extract. However, interfering peaks were still present in the chromatography, at a higher
concentration. Therefore, there was no advantage to this procedure over the more simple
direct 1-propanol extraction, and it was not investigated further.
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Figure 3.3 Chromatogram of the methanol supernatant after precipitation of proteins
(red), the 30/70 methanol/ethanol extract of the plasma proteins (blue), the 1-
propanol extract of the plasma proteins (black), and a normal 1-propanol extract of
plasma (green). Arrows point to the CoQ10 peak in each trace.
The enzymatic hydrolysis of serum lipids with lipase has been used when measuring
CoQ10 in plasma (48). An attempt was therefore made to reduce the number and size of
interfering peaks in the chromatogram by using lipase (Sigma, L-1754) to digest the lipids
present in plasma. One unit of lipase hydrolyses 1 mole (1 microequivalent) of fatty acid in
1 hour at pH 7.2 and at 37 ˚C. One triglyceride contains 3 fatty acids, so that assuming a
plasma concentration of 10 mmol/L triglycerides (equivalent to a very high plasma
triglyceride concentration) means that 200 µL of plasma would contain 6 µmoles of fatty
acid and would therefore need 6 µunits of lipase to break down all the fatty acids in 1 hour.
The lipase used contains 819 units/mg solid, so that adding 200 µL of a 1 mg/mL solution
of lipase to 200 µL of plasma should result in complete breakdown of triglycerides to fatty
acids.
To 200 µL of plasma was added 20 µL of 1,4-benzoquinone (5 µmol/L in 1-propanol).
Ethanol (800 µL) was added to precipitate proteins, the mixture vortexed for 10 seconds,
centrifuged at 8000g for 5 minutes, and the supernatant discarded. The protein pellet was
resuspended in 200 µL of tris buffer (pH 7.6) containing (a) 1 mg/mL lipase and (b) no
lipase. After heating in a waterbath at 37 ˚C for 15 minutes, 1 mL of propanol was added to
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each mixture. The mixtures were vortexed for 10 seconds, centrifuged at 8000g for 5
minutes, and 200 µL of the supernatant injected into the HPLC.
There was minimal change in the chromatogram of lipase-added and lipase-free extracts
(Figure 3.4) suggesting that either lipase was not digesting the lipids (possibly due to the
methodology used) or that lipids are not the cause of interference in the chromatography.
Figure 3.4 Chromatogram obtained with (red) and without (black) lipase added.
Arrows indicate the CoQ10 peak.
3.4.2. Column
The mobile phase and the analytical column packing material separate the compounds in
the injected extract. Together with column length, these factors affect resolution and the
limit of detection by affecting the sharpness and separation of peaks. The column packing
material used most often for measurement of CoQ10 in plasma is C18 (Appendix 2).
Reversed-phase C18 columns contain silica, with octadecyl (C18) groups bound to it, and
retain non-polar compounds, with analytes being eluted faster with non-polar mobile
phases. Normal-phase silica columns contain just silica as the stationary phase, and retain
polar compounds, with more polar mobile phases eluting the analytes. Normal-phase diol
columns contain two vivinal OH groups, and give similar selectivity to silica columns,
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with the added advantage of not being deactivated by small amounts of water. Normal-
phase cyano columns contain a CN group (usually cyanopropyl), which gives unique
selectivity.
When a C18 column was used with a 30/70 methanol/ethanol (v/v) mobile phase and
ultraviolet detection, a small peak co-eluted on the side of the CoQ10 peak. The type of C18
column is also important in chromatography and an attempt was made to resolve the
interfering peak from the CoQ10 peak by changing the type of column.
3.4.2.1. Experimental
Columns (mobile phases) evaluated included silica, diol and cyano (100% heptane and
1/99 1-propanol/heptane), a reversed-phase high carbon-load column (35/65 1-
propanol/acetonitrile, 20/80 heptane/methanol, 10/90 heptane/methanol, 15/85
heptane/methanol, and 70/30 ethanol/methanol) and four C18 columns, Phenyl-hexyl,
Phenomenex Luna C18(2), Merck LiChroCART Supersphere C18 and Supelco Supelcosil
LC18 (70/30 ethanol/methanol).  Where not otherwise stated, the plasma extracts used to
test the performance of the proposed systems were obtained by extracting 100 µL plasma
with 490 µL 1-propanol and 10 µL 5 mmol/L 1,4-benzoquinone in 1-propanol. The
mixture was vortexed for 10 minutes, then centrifuged for 5 minutes at 8000g. The
supernatant (200 µL) was injected directly into the HPLC equipped with an ultraviolet
detector set to 275 nm. Standard solutions of CoQ10 were run on all systems tested to
identify the CoQ10 peak in plasma.
3.4.2.2. Results
Normal-phase columns have been used in the HPLC assay of total CoQ10 (47). To assess
the practicability of using normal-phase columns to measure CoQ10, CoQ10 standards were
made up in heptane, rather than 1-propanol which would elute straight from the columns.
The anticipated advantage of using silica columns and injecting in hexane, is that hexane
has been reported to efficiently extract CoQ10 from plasma when combined with protein
precipitation with methanol or ethanol (31, 33). A silica column retained CoQ10 for at least
an hour when a 100% heptane mobile phase (flow rate 1 mL/minute) was used. However, a
1/99 1-propanol/heptane (v/v) mobile phase (flow rate 1 mL/minute) washed the CoQ10
straight off the column with no retention.
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A diol column retained CoQ10 for around 23 minutes when 100% heptane was used as the
mobile phase (flow rate 1 mL/minute), but the CoQ10 was washed straight off the column
when a 1/99 1-propanol/heptane (v/v) mobile phase (flow rate 1 mL/minute) was used.
Similarly, a cyano column retained CoQ10 for 28 minutes when the mobile phase was
100% heptane (flow rate 1 mL/minute) (although peak shape was poor), and the CoQ10
was washed straight through the column when 1/99 1-propanol/heptane (v/v) was used as
the mobile phase (flow rate 1 mL/minute).
In the method of Greenspan et al., (1988) (47), the percentage of 2-propanol in the heptane
mobile phase was 0.1%. The practicality of using normal-phase columns as part of a
routine plasma CoQ10 assay is limited since methanol or ethanol is required to precipitate
the proteins in the plasma sample and it would not be practical to remove all traces of these
solvents before extraction of the CoQ10 with heptane. The method of Greenspan et al.,
(1988) (47) used methanol for precipitation of proteins but the hexane extract is evaporated
prior to solid phase extraction which is followed by a further evaporation to remove traces
of methanol before the sample is reconstituted in the mobile phase.
It was hypothesised that a reversed-phase high carbon-load C18 column (Phenomenex
Ultracarb ODS(30) column,  150 × 3.2 mm, 5µm), would retain CoQ10 stronger than a C18
column with a lower carbon load, making it possible to add 1-propanol to the mobile phase
while maintaining an acceptable retention time. The anticipated advantage of 1-propanol in
the mobile phase was that resolution and chromatography would be improved. On this
column, a 35/65 1-propanol/acetonitrile mobile phase (flow rate 0.5 mL/minute) gave
longer retention of CoQ10 (16 minutes as opposed to 14 minutes with the longer
Phenomenex Luna C18(2) column (250 × 3 mm, 5µm), and improved resolution of the
CoQ10 peak.
It was further hypothesised that using a heptane and methanol mobile phase with the high-
carbon load reversed-phase column would result in heptane coating the column packing
rather than passing through the column with the methanol. Because CoQ10 is more soluble
in heptane, this should slow elution of CoQ10 through the column. Presuming the
interfering compounds wash through the column with the methanol while the CoQ10 binds
with heptane, the chromatograms would be cleaner. With 20% heptane in methanol (flow
rate 0.5 mL/minute), the CoQ10 peak co-eluted with another compound in plasma, and the
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peak could not be quantified (Figure 3.5). A 10% heptane in methanol mobile phase (flow
rate 0.5 mL/minute) resulted in good separation of the CoQ10 peak with no interference,
but the retention time for CoQ10 was too long at 26 minutes (Figure 3.5). A 15% heptane in
methanol mobile phase (flow rate 0.5 mL/minute) resulted in a retention time of around 15
minutes but there were interfering compounds in plasma (Figure 3.5). Using a 70% ethanol
and 30% methanol mobile phase (flow rate 0.5 mL/minute) with the high-carbon load
column resulted in a retention time of 14 minutes but again the CoQ10 peak was not
resolved from other peaks in the chromatogram (Figure 3.5).
Figure 3.5 CoQ10 peaks on the ultracarbon C18 column, with a mobile phase of 20%
(red), 15% (blue), and 10% (black) heptane in methanol (v/v), and 30/70
methanol/ethanol (v/v) (green). Arrows point to the peak corresponding to CoQ10.
Since other columns were of little use for quantitation of plasma CoQ10, the decision was
made to use a C18 column and investigate chromatography offered by different types of
C18 columns, as well as by altering the column temperature and mobile phase. Four
different types of C18 columns (Supelco Supelcosil LC18, Phenomenex Luna C18(2),
Merck LiChroCART Supersphere C18, and Phenomenex Phenyl-hexyl), of the same
length and diameter (250 × 4.6 mm) were compared. Each was run with the same mobile
phase (30/70 methanol/ethanol v/v) at the same flow rate (1 mL/min) with the column
temperature set at 40 °C. Under these conditions, back pressure varied between columns,
being 9.9, 8.7, 8.0, and 17.4 MPa for the Luna, Phenyl-hexyl, Supelcosil and Merck
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columns respectively. The particle size in the Supelcosil, Luna, and Phenyl-hexyl columns
was 5 µm and in the Merck column 4 µm.
To compare the columns, the same CoQ10 standard (corresponding to a plasma
concentration of 0.17 µmol/L) and extract of a plasma sample (corresponding to a plasma
concentration of 0.24 µmol/L) were injected into each column. The ratio of water (for
standards) or plasma to 1-propanol was 1 to 5 (v/v). CoQ10 was detected with ultraviolet
detection at 275 nm.
The Phenyl-hexyl column gave the best signal-to-noise ratio when standards were run
(Table 3.5) which is expected given it has the highest bond density (4 µmol/m2, as
compared to a bonding density of 3 µmol/m2 for the Luna and Supelco columns). The
bonding density is the amount of C18 chains per gram of absorbent and is related to the
surface area. It therefore gives a measure of how well the silica surface is shielded.
The Luna column gave better resolution of CoQ10 from interfering compounds when the
plasma sample was injected (Figure 3.6), and hence gave the better signal-to-noise ratio for
plasma samples. Therefore, a Phenomenex Luna C18(2) column was chosen for further
assay development.
Table 3.5 The signal-to-noise ratio for a CoQ10 standard and plasma extract in four
C18 columns.
Column Standard Plasma
Luna 9.0 18.3
Merck 10.6 10.9
Supelcosil 10.1 13.2
Phenyl-Hexyl 13.3 14.2
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Figure 3.6 Chromatograms obtained with different C18 columns, with arrows
indicating the CoQ10 peak. Red trace is the Phenyl-hexyl column, blue trace is the
Merck column, green trace is the Supelco column and black trace is the Luna column.
A column with a smaller diameter allows the flow rate to be reduced without the
chromatography being altered. The advantage is that solvent usage is reduced and better
resolution is obtained. Therefore, a smaller diameter column (Phenomenex Luna C18(2)
column, 250 × 3 mm, 5 µm) was used in the final assay.
3.4.3. Column temperature
The temperature of the column affects resolution (and hence sensitivity) because pressure
in the column and retention are reduced at higher temperatures. Use of very high
temperatures causes safety concerns due to boiling points of solvents and can also cause
evaporation. The mobile phase used was 70% ethanol and 30% methanol with the ratio of
water (for standards) or plasma to 1-propanol being 1 to 5 (v/v).
Comparison of the signal-to-noise ratio when the column (Phenomenex Luna C18(2), 250
× 4.6 mm, 5 µm) was held at 25 °C, 40 °C and 45 °C showed that it increased with
increasing column temperature (Table 3.6). A column temperature of 45 ºC achieves
optimal sensitivity (Figure 3.7) while remaining safe.
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Table 3.6 The signal-to-noise ratio for a CoQ10 standard (corresponding to a plasma
concentration of 1.34 µmol/L) and a plasma sample (corresponding to a plasma
concentration of 0.53 µmol/L) when the HPLC column is held at different
temperatures.
Temperature Standard Plasma
25 ºC 48 25
40 ºC 71 48
45 ºC 74 54
Figure 3.7 Chromatography achieved when the column is held at 25 ˚C (black), 40 ˚C
(red), and 45 ˚C (blue). Arrows indicate the peak corresponding to CoQ10.
3.4.4. Mobile phase
When a 30/70 methanol/ethanol (v/v) mobile phase was used with a Phenomenex Luna
C18(2) column (250 × 3 mm, 5 µm) to measure CoQ10 in plasma, a co-eluting peak on the
tail of the CoQ10 peak caused interference. Attempts to change the mobile phase to
separate this co-eluting peak from the CoQ10 peak are described below.
Reported isocratic CoQ10 assays have used a mobile phase consisting of 10/90 2-
propanol/methanol (v/v) (42); 20/80 1-propanol/methanol (v/v) (25); 5/85 tert-butyl
alcohol/methanol (v/v) (31); 6/17/77 2-propanol/ethanol/methanol (v/v/v) (28); and
4/21/75 ethanol/methanol/2-propanol (v/v/v) (35). The method of Wang et al., (1999) (30)
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used a gradient elution with (a) 100% methanol and (b) 20/80 tert-butanol/ethanol. Initial
conditions were 90% a and 10% b for the first 4 minutes, followed by a linear change over
6 minutes to 50% a and 50% b, and finally an immediate reversion to the initial conditions
for 3 minutes (30).
3.4.4.1. Experimental
The Phenomenex Luna C18(2) column (250 × 3 mm, 5 µm) was held at 45 ˚C for all
mobile phases investigated. Detection was by ultraviolet detection at 275 nm. Plasma
samples were extracted by adding 490 µL 1-propanol and 10 µL of 5 mmol/L 1,4-
benzoquinone in 1-propanol to 100 µL plasma. This mixture was vortexed for 10 minutes
then centrifuged at 8000g for 10 minutes. The supernatant (100 µL) was directly injected
into the HPLC system. The ratio of water (for standards) or plasma to 1-propanol was
therefore 1/5 (v/v) for all extracts.
Changing the mobile phase from 30/70 methanol/ethanol (v/v) to 40/60 ethanol/methanol
(v/v) gave no additional separation (Figure 3.8). A 50/50 acetonitrile/ethanol (v/v) mobile
phase gave sharper peaks than when methanol was used in the mobile phase and a
decreased retention time for CoQ10. However the co-eluting peak was still not resolved
from the CoQ10 peak (Figure 3.8).
Figure 3.8 Chromatography achieved using a 30/70 methanol/ethanol (v/v) mobile
phase (black), a 40/60 ethanol/methanol (v/v) mobile phase (red), and a 50/50
acetonitrile/ethanol (v/v) mobile phase (blue). Arrows indicate positioning of the
CoQ10 peak.
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Replacing the ethanol in the mobile phase with the less polar 1-propanol or 2-propanol (i.e.
using 50/50 1- or 2-propanol/ acetonitrile v/v) resulted in a clean CoQ10 peak in the
chromatogram (Figure 3.9) with retention times of  7 and 9 minutes for 1- and 2-propanol
respectively. A mobile phase of 25% 1-propanol and 75% acetonitrile resulted in a
retention time of around 27 minutes (Figure 3.9) which is too long for a routine assay.
When the 1-propanol content of the mobile phase was 40% (with 60% acetonitrile (v/v))
the retention time was around 10 minutes, but there were co-eluting peaks with the
coenzyme Q10 peak (Figure 3.9).
Figure 3.9 Chromatogram of a plasma extract run with a 50/50 1-
propanol/acetonitrile (v/v) mobile phase (black), a 25/75 1-propanol/acetonitrile (v/v)
mobile phase (blue), a 40/60 1-propanol/acetonitrile (v/v) mobile phase (red), and a
35/65 1-propanol/acetonitrile (v/v) mobile phase (green). CoQ10 peaks are identified
by arrows.
A mobile phase of 35% 1-propanol and 65% acetonitrile (v/v) resulted in a CoQ10 retention
time of around 14 minutes. However, when plasma samples were extracted, it became
evident that a large peak elutes with the solvent front and tails for 15 minutes (Figure 3.9).
This peak masks the CoQ10 peak, and hence does not allow quantification of CoQ10.
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It became evident that the more polar methanol/ethanol mobile phase washes interfering
peaks off the column much faster than the less polar 1-propanol/acetonitrile mobile phase
with less peak tailing. It is possible that the interfering compounds contain hydroxyl
groups, which are solvated by methanol in the mobile phase, and hence washed from the
column. Acetonitrile cannot solvate compounds containing hydroxyl groups which could
be why the interference took so long (15 minutes) to wash off the column when the 1-
propanol/acetonitrile mobile phase was used.
3.5. Assay for CoQ10 using ultraviolet detection
3.5.1. Final assay
A summary of the final assay for CoQ10 using ultraviolet detection is outlined below and
an example chromatogram is shown (Figure 3.10).
3.5.1.1. Extraction
1,4-Benzoquinone (5 mmol/L) in 1-propanol is stored in the –13 ºC freezer for up to one
week. For each assay run, it is diluted into 1-propanol to a concentration of 33 µmol/L, and
used as the extraction solvent. The ratio of plasma to extraction solvent is 1/5 (v/v). After
addition of extraction solvent, samples are mixed on a vortex mixer for 10 minutes,
centrifuged at 8000g for 5 minutes, and the supernatant transferred into an HPLC vial.
3.5.1.2. HPLC set-up
Column: Phenomenex Luna C18(2) (250 × 4.6 mm, 5 µm) at 45 ºC
Mobile phase: 30/70 methanol/ethanol (v/v), flow rate 1 mL/minute
Injection volume: 200 µL
Detector settings: wavelength 275 nm
3.5.1.3. Standards
Standard CoQ10 is made to appropriate concentrations ensuring that the water to 1-
propanol ratio is always 1/5 (v/v).
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Figure 3.10 An example chromatogram obtained from a plasma extract with
ultraviolet detection. Arrow indicates the CoQ10 peak.
3.5.2. Calibration curve and linearity
A calibration curve was constructed using standards containing a ratio of 1/5 (v/v) water to
1-propanol (Figure 3.11). The calibration curve is linear to at least 5 µmol/L which
supports other reports of linearity for CoQ10 with ultraviolet detection (2, 33).
Figure 3.11 A calibration curve for CoQ10 using the assay as outlined in Section 3.5.1,
with ultraviolet detection (R2 = 0.9997).
3.5.3. Comparison of anticoagulants in relation to ultraviolet detection
It is possible that the anticoagulants added to blood during phlebotomy may interfere with
chromatography or oxidation of plasma CoQ10H2 by 1,4-benzoquinone. It is therefore
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important to confirm the effect of anticoagulants on the CoQ10 assay. Serum, lithium
heparinised, and EDTA blood samples were taken from ten volunteers (written informed
consent was obtained from all participants). Samples were analysed as described in section
3.5.1.
The mean ± SD CoQ10 concentration in the lithium heparinised, serum, and EDTA samples
for the 10 participants was 1.3 ± 0.5, 1.4 ± 0.7, and 1.4 ± 0.5 µmol/L, respectively,
suggesting that there was no effect of the different anticoagulants on the measurement of
CoQ10. Therefore, any anticoagulant is acceptable for analysis of total CoQ10 using
ultraviolet detection.
3.6. Assay for CoQ10 using electrochemical detection
After setting up the assay for CoQ10 using ultraviolet detection, an electrochemical detector
became available. The CoQ10 assay was subsequently set up with electrochemical
detection, due to the advantages of this detection method (increased sensitivity, ability to
measure the ratio of reduced to oxidised CoQ10, and cleaner chromatograms). Tang et al.,
(2001) (1) recently reported a simple, robust and rapid method for measurement of either
total CoQ10 or the ratio of CoQ10H2 to CoQ10 using electrochemical detection.
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3.6.1. Further description of the HPLC set-up used by  Tang et al., (2001)(1)
Figure 3.12 The HPLC set-up used by Tang et al., (2001).
A drawback of the assay of Tang et al., (2001) (1) is the use of hexane in the mobile phase.
Because of the low boiling point of hexane, evaporation is a concern so that a mobile phase
that contains hexane needs to be made fresh regularly to eliminate changes in the
composition of the mobile phase due to evaporation. The experience gained from setting
up the assay for total CoQ10 using ultraviolet detection was therefore integrated into the
methodology of Tang et al., (2001) (1), and the final assay is described below.
The HPLC set-up described by Tang et al.,
(2001)(1) involves use of electrochemical
detection, and can measure either total CoQ10,
or reduced and oxidised CoQ10. There is no
pre-extraction oxidation step. Coenzyme Q10 is
extracted from plasma using 1-propanol at a
ratio of 1/9 plasma/1-propanol. For
measurement of total coenzyme Q10, an
electrochemical cell is situated before the
analytical column and set to a potential to
oxidise all CoQ10. For measurement of
oxidised and reduced CoQ10, the two forms are
separated on the analytical column and then a
series of oxidation, reduction, and finally
oxidation at the analytical cell, is employed.
Potentials are set such that only CoQ10 and
compounds requiring potentials less than
CoQ10 for oxidation and reduction undergo
these reactions. The electrolyte used in the
1.5/1.5/27.5/69.5 2-propanol/glacial acetic
acid/hexane/methanol (v/v/v/v) mobile phase is
50 mmol/L sodium acetate trihydrate.
Guard column (RP C18)
Column: Microsorb-MV 
(150 x 4.6 mm, 5 m Rainin)µ
Pump and auto-injector
Mobile phase: 1.5/1.5/27.5/69.5 
2-propanol/glacial acetic 
acid/hexane/methanol (v/v/v/v) 
with 50 mmol/L sodium acetate 
trihydrate
Pulse Dampner
Filter
Guard Cell (G1)
Filter
Guard Cell (G2)
Filter
Analytical Cell (A1)
Analytical Cell (A2)
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3.6.2. Final assay for CoQ10 using electrochemical detection
A summary of the final assay for coenzyme Q10 using electrochemical detection is outlined
below. Example chromatograms showing (a) total CoQ10, and (b) the CoQ10 to CoQ10H2
ratio as measured using electrochemical detection is shown (Figure 3.13).
3.6.2.1. Extraction
The ratio of plasma to 1-propanol is 1/9 (v/v). After addition of 1-propanol, samples are
mixed on a vortex mixer for 10 minutes, centrifuged at 8000g for 5 minutes, and the
supernatant is transferred into an HPLC vial.
3.6.2.2. HPLC setup
A pulse dampener is situated between the pump and the injector. A guard cell (set to a
potential of + 700 mV when measuring total CoQ10) is situated immediately prior to the
analytical column. The first cell of the analytical cell is set to a potential of –700 mV, and
the final analytical cell (from which the chromatogram is obtained) is held at a potential of
+ 550 mV (as determined from the hydrodynamic voltammogram, Chapter 2). When the
ratio of CoQ10H2 to CoQ10 is to be measured, the guard cell is placed immediately after the
analytical column and set to a potential of +700 mV.
Column: Phenomenex Luna C18(2) (250 × 3 mm, 5 µm) at 45 ºC
Mobile phase: 30/70 methanol/ethanol (v/v), 50 mmol/L sodium acetate trihydrate, and 15
mL/L glacial acetic acid, flow rate 0.5 mL/minute
Injection volume: 20 µL
Detector settings: Final analytical cell set to a potential of 550 mV, range setting of 200
nA.
3.6.2.3. Standards
Standard CoQ10 is made to appropriate concentrations ensuring that the water to 1-
propanol ratio is 1/9 (v/v).
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Figure 3.13 Example chromatograms of a 1-propanol plasma extract with CoQ10
detected using electrochemical detection, showing total CoQ10 (black), and the CoQ10
to CoQ10H2 ratio (red).
3.6.3. Calibration curve and linearity
A calibration curve was constructed using standards containing a ratio of 1/9 (v/v) water to
1-propanol (Figure 3.14). The calibration curve is linear to at least 10 µmol/L as has been
previously reported (55).
Figure 3.14 A calibration curve of CoQ10 with electrochemical detection (R2 = 0.9998)
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3.6.4. Comparison of anticoagulants in relation to electrochemical detection
It has been reported that EDTA interferes with the chromatography when using
electrochemical detection to measure CoQ10 (56). Therefore, serum, lithium heparinised,
and EDTA blood samples were taken from ten volunteers (written informed consent was
obtained from all participants). Total CoQ10 was measured as described in section 3.6.2.
The CoQ10 concentration of EDTA samples was on average 4.4 ± 2.9% lower than that in
serum and lithium heparinised samples, which is similar to the 8.8% lower values reported
in EDTA plasma as compared to lithium heparinised plasma by Tang et al., (2001) (1). The
difference between the three anticoagulants was almost significant (p = 0.075). The lower
values in the EDTA samples are due to dilution of the plasma by EDTA forcing water out
of the red blood cells. The cholesterol concentration of EDTA samples was significantly
(6.3 ± 1.8 percent) lower than that in the lithium heparinised samples (p < 0.001), which
supports this theory. Therefore, EDTA samples are acceptable for the described assay
using electrochemical detection, as long as the results obtained from EDTA samples are
not compared with results obtained from lithium heparin samples.
Figure 3.15 Electrochemical detection of an extract of lithium heparin plasma (black),
EDTA plasma (blue), and serum (red).
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3.7. Precision and recovery of ultraviolet and electrochemical methods for CoQ10
detection
Precision and recovery for both the ultraviolet and electrochemical detector based assays,
as described above, were calculated.
3.7.1.1. Experimental
Two pools of human plasma with abnormally low CoQ10 concentrations (total CoQ10 0.15
(for ultraviolet detection) and 0.24 (for electrochemical detection) µmol/L), prepared by
diluting plasma with human serum albumin in saline, were used. Additionally, pooled
plasma was spiked by adding CoQ10 concentrations of 2.75 (for ultraviolet detection) and
0.97 (for electrochemical detection) µmol/L. The mixtures were allowed to equilibrate for
at least 24 hours before use. Precision was calculated by replication at each level, with four
aliquots from each pool being analysed each day (within-run) for six days (between-run).
Recoveries were determined by calculating the difference between a plasma sample and
the same plasma with added CoQ10 (four added concentrations from 0.03 to 0.13 µmol/L
for electrochemical detection, and 0.08 and 0.19 µmol/L for ultraviolet detection).
3.7.1.2. Results
The precision and recovery of both assays is acceptable by clinical standards, and
compares well with previously published methods (Table 3.7).
Table 3.7 The between- and within-run precision, recovery, and the concentration
range of samples used to determine these parameters, for CoQ10 assays using
electrochemical and ultraviolet detection.
Between-Run
%CV
Within-Run
%CV
Recovery (%) Concentration
Range (µmol/L)
Present UV assay 3.2 2.4 93-103 0.24-0.98
Present EC assay 3.3 3.2 98-102 0.15-2.76
Tang et al., (2001) (1) 1.2-4.9 1.2-4.9 96-101 0.01-4.63
Mosca et al., (2002) (2) 2 1.6 96-99 1.02
UV = ultraviolet detection, EC = electrochemical detection.
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The between- and within-run precision of total CoQ10 assays using either ultraviolet or
electrochemical detection is sufficient for clinical use (CV < 3%), though the precision
may be overestimated when using ultraviolet detection at low concentrations since the test
samples had been diluted with albumin, and the effect of minor peaks has therefore been
reduced.
3.8. Discussion
Ultraviolet detectors are more common in an analytical laboratory than electrochemical
detectors which generally leads to them being the preferred detection method when setting
up an HPLC assay to measure total CoQ10 in blood plasma for limited samples. However, a
laboratory aspiring to offer measurement of blood plasma CoQ10 as a routine hospital test,
or to measure the reduced to oxidised CoQ10 ratio, would require an electrochemical
detector. The within- and between-run precision data and the recovery results for both the
electrochemical and ultraviolet detection assays described in this Chapter confirms that
both are simple, accurate and reliable.
Ultraviolet detection allows quantification of normal blood plasma CoQ10 concentrations,
with a 1/5 (v/v) plasma to 1-propanol ratio. The extraction procedure outlined by Mosca et
al., (2002) (2) is rapid and simple, and the high recovery values suggest the extraction is
complete. The addition of 1,4-benzoquinone to oxidise CoQ10 is effective, and does not
greatly complicate the extraction procedure. Simplification of this extraction procedure by
making a large volume of 1,4-benzoquinone in 1-propanol (5 mmol/L) and storing it at –13
ºC is not feasible, since the 1,4-benzoquinone solution is unstable over time at this
temperature (Chapter 2).  Taking into account the 1/5 (v/v) sample to 1-propanol extraction
procedure, the ultraviolet assay as described has a limit of detection in plasma of 62
nmol/L. A plasma CoQ10 concentration of 200 nmol/L would be considered a low result, so
therefore the limit of detection using ultraviolet detection allows distinction of low-normal
from deficient levels of total CoQ10 in human plasma samples. There are many peaks in the
chromatogram obtained using ultraviolet detection, and the baseline tends to be noisy,
which adversely affects the limit of detection. The method using ultraviolet detection
requires a large injection volume (200 µL), however the chromatography is not adversely
affected.
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Electrochemical detection offers the most sensitive assay to determine total CoQ10 in blood
plasma. Extraction of CoQ10 from blood plasma, as outlined by Tang et al., (2001) (1), is
fast and simple. The limit of detection is 20 nmol/L in plasma. The chromatogram obtained
using electrochemical detection allows accurate quantification of the CoQ10 peak due to the
clean baseline, which in turn is due to the ‘screening’ process applied during HPLC
analysis. The oxidation – reduction – oxidation process allows compounds in the extract to
be screened out if the electrochemical potentials at these reduction and oxidation steps are
appropriate. Advantages of electrochemical detection are the requirement for a smaller
sample size (due to the more dilute extracts and smaller injection volumes), and the
increased sensitivity (due to a lower limit of detection, and the cleaner baseline).
Electrochemical detection allows analysis of the ratio of reduced to oxidised CoQ10 in
plasma, with just one injection of the extract. Reduced CoQ10 is unstable in the presence of
air, being easily oxidised. Hence, when measuring this ratio it is crucial that sample
handling is strictly controlled, with samples being frozen to –80 °C as soon as possible if
they are to be stored, or else analysed in the shortest possible timeframe if not to be frozen.
Fluorescence detection is not sensitive enough to measure endogenous blood plasma
CoQ10 unless the extract is concentrated. It is possible that a more sensitive fluorescence
detector (such as a laser-induced fluorescence detector) could provide adequate sensitivity
but these detectors are expensive. The fluorescence detector used in the present study
allows detection of a CoQ10 plasma concentration of 760 nmol/L, where a low sample may
be 200 nmol/L. The chromatogram obtained using fluorescence detection contains many
other peaks, resulting in a noisy baseline, which makes detection of the CoQ10 peak
difficult. Also, the low sensitivity means that it is necessary to inject a large sample
volume, which results in a broad peak.
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Chapter 4. Coenzyme Q10 Reference Interval and Biological Variation
4.1. Introduction
Having developed an assay to measure CoQ10 (Chapter 3), the assay was applied to
determine the characteristics of CoQ10 in the New Zealand population.
As outlined in Chapter 1, decreased CoQ10 levels may occur during disease, ill health, or as
a side-effect of medication. Because CoQ10 is essential for every cell in the body, this
decreased CoQ10 may have important medical consequences. It is therefore important to be
able to estimate CoQ10 concentration in the body, either to ensure sufficient CoQ10 is
present, or to advise supplementation and monitor bioavailability of supplementation if it is
not.
An understanding of the biochemistry of a compound, such as the reference interval in
healthy people and the biological variation, is essential for interpreting concentrations
found in patients.
4.1.1. Reference interval
A reference interval is the range of values that occur in 95% of a given population.
Reference intervals may be influenced by genetic and ethnic factors, although the effect of
these factors is difficult to isolate from endogenous factors which are inherent in
individuals and cannot be modified such as age and sex. Exogenous factors, such as
exercise, pregnancy, habitual use of alcohol or other ‘recreational substances’ can also
affect reference intervals.
Determination of the reference interval provides an understanding of the variability of the
analyte concentration in the population, and often (if sample size permits) some factors
affecting the interval distribution. These include gender, smoking, alcohol and diet (1).
One can also determine whether data have a normal (Gaussian) distribution.
To calculate a reference interval, a reference sample group (a number of individuals taken
to represent the reference population) is selected from the population of possible
individuals. Reference values are obtained on these individuals to give a statistical
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dispersion, termed the reference distribution (1). The upper and lower reference limits (2.5
and 97.5% interfractile intervals) of the reference dispersion are usually used to define the
reference interval.
Ideally, individuals used to determine a reference interval should: be ostensibly healthy,
not be taking oral contraceptives, prescribed or over-the-counter drugs, excessive amounts
of alcohol, or tobacco products and other such recreational substances (1). However, often
one has to select the most appropriate individuals as it is almost impossible to get the ideal
population (1).
When determining a reference interval, one must consider how many people need to be
sampled before a statistically valid reference interval is obtained. The following need to be
taken into account (1) (1) the size of error that the laboratory and clinicians are willing to
accept (2) the magnitude of change that is clinically important and (3) the variability in the
measurements.
The Harris and Boyd criteria (2) may be used to determine whether reference intervals
should be stratified according to an influencing factor such as gender. This method uses a
Gaussian-based z-statistic, with large values indicating that separation is warranted. The
criterion for the standard deviations indicates that separate reference intervals are
necessary if the ratio of the standard deviations is too large. These criteria are
recommended for samples with approximately 60 subjects per group under consideration.
4.1.1.1. Reporting CoQ10 adjusted for lipids
The close association of plasma CoQ10 and lipids is widely accepted, and is expected since
CoQ10 is lipophilic. This association implies that lipids should be considered when
measuring plasma CoQ10 (3, 4) since plasma CoQ10 concentrations may be directly
influenced by the concentration of plasma lipids.
4.1.1.2. The measurement of plasma CoQ10 as opposed to tissue CoQ10
When measuring CoQ10, do plasma and tissue CoQ10 concentrations correlate? If tissue
and plasma concentrations do not correlate, is measurement of plasma CoQ10 relevant? It is
possible that tissue levels may be more than adequate when plasma levels are deficient,
especially when plasma lipid concentrations are low.
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Measurement of tissue CoQ10 is difficult due to the invasive sample collection procedure
required. Measurement of plasma CoQ10 is much more straightforward and routine.
In the study of Laaksonen et al., (1995) (5), median plasma CoQ10 concentrations were
slightly lower in young endurance trained athletes than in healthy controls but muscle
CoQ10 concentrations were almost twice that of healthy controls. Interestingly, there was a
much larger range in plasma CoQ10 concentrations in these athletes compared to that in
controls (5). Statistically significant associations between serum and muscle CoQ10
concentrations were not observed in all subjects or in different subgroups (5).
The decrease in plasma CoQ10 after exercise reported by Kaikkonen et al., (1999) (6)
suggests that plasma concentrations, at least to some degree, reflect the need for CoQ10 by
muscles and other organs.
Niklowitz et al., (2004) (7) report that excessive CoQ10 supplementation did not influence
erythrocyte (a non-mitochondrial containing blood compartment) concentrations, but a
positive correlation existed between plasma content and concentrations in platelets (a
mitochondria containing blood compartment). Therefore, under physiologically normal
conditions, blood cells or organs may regulate their CoQ10 content independently from
environmental supply (7). Because erythrocyte CoQ10 concentration is independent of
supplementation, incorporation into outer cell membranes may be limited, but inner
compartments, like mitochondrial membranes, may be influenced (7).
4.1.2. Biological variation
Biological variation quantifies fluctuation around a homeostatic set point, and variation
when there is no homeostasis. Total variation in measurement of an analyte is a composite
of pre-analytical factors (those related to preparation of the individual for sampling, such
as posture, and those influenced by sample collection itself, such as tourniquet application
time); analytical random error (precision), and inherent biological variation around the
homeostatic set point. If the correct procedures are used, the variation around the set point
itself can be separated from the other sources of variation contributing to total variation.
Chapter 4 151
The difference between homeostatic set points themselves is the between-subject
biological variation (1).
When within-subject variation (CVi) is much smaller than between-subject variation
(CVg), the analyte is said to have marked individuality (1). The index of individuality (II)
for an analyte is calculated as (Equation 4.1)
II = [CVa2 + CVi2]1/2/CVg 4.1
Where CVa is analytical variation. This is most often simplified to CVi/CVg, which is
satisfactory if analytical variation (CVa) is less than the within-subject variation (1).
The individuality of analytes significantly influences reference values (1). Where an
analyte has high individuality (a low index of individuality, II < 0.6), the range of values
from each individual span only a small part of the reference interval. Therefore, an
individual could have values that were very unusual for them (therefore clinically
important) but these results would still lie within the reference interval. In this situation,
the population-based reference interval is of limited utility for detecting unusual results in
most individuals (1). In contrast, when an analyte has little individuality (II is high, II >
1.4) the distribution of values from a single individual cover much of the reference
interval, and conventional reference intervals are of significant value (1). It is possible to
increase II by stratification (stratify the data by, for example, age or gender), thereby
making reference intervals more useful (1).
Sequential analysis of an analyte is required to obtain a reasonable estimate of an
individual’s homeostatic set point as the result does have intrinsic analytical and within-
subject biological variation. To calculate how many samples (N) are needed to ensure that
the estimate of the homeostatic set point is within a certain percentage of the true value
with a stated probability, equation 4.2 can be applied (1).
N = [Z*(CVa2 + CVi2)1/2/D]2 4.2
Where Z is the Z-score appropriate for the probability, usually 1.96 for p < 0.05, and D is
the desired percentage of closeness to the homeostatic set point.
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Lowering the probability, or widening the allowance for the window of acceptability
(increasing D), decreases the number of samples required.
To generate data on components of random biological variation, sequential samples are
required from a small group of subjects, usually healthy people, and preferably of both
genders (1). The number of subjects is a compromise between the large number that is the
ideal for a better estimate, and the smaller number that can be handled in any practical
experimental design (1). To have good precision, and negligible bias, the analyses ought to
be done with one instrument, by one operator, with only one set of calibrators, and a single
lot of reagents and consumables. The best experimental design assays each sample twice,
in random order, in a single analytical run (1). This has the advantage that between-run
analytical variation is eliminated, and the analytical component of variation can be derived
from replicate analyses of subject samples, ensuring that analytical variation is estimated at
the same level as subject samples, and that the matrix is identical throughout (1). However,
the intensive analytical effort required to analyse samples in this manner limits the number
of subjects and samples that can be studied.
Analysing all samples only once in one analytical run allows for a larger number of
subjects and samples to be studied, although analytical variation must be assessed using
quality control samples. This has the disadvantage that for some tests, precision achieved
with quality control samples differs from that obtained with patient samples (1).
Data on within-subject biological variation and analytical precision can be used to
determine the change that must occur in an individual’s serial results before the change is
significant (the reference change value), and also to determine the statistical probability
that a change in an individual’s serial results is significant (1).
Total variation (CVt) is a combination of pre-analytical variation (CVp) (variation related
to preparation of the individual for sampling and those influenced by sample collection
itself), analytical variation (CVa), and within-subject biological variation (CVi) (Equation
4.3).
CVt = (CVp2 + CVa2 + CVi2)1/2 4.3
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To state with confidence that an individual’s serial results have changed, the difference in
results must exceed that which can be explained by the inherent variation due to these three
factors (1). If pre-analytical variation is minimised, then Equation 4.4 is true.
CVt = (CVa2 + CVi2)1/2 4.4
This variation is random, and therefore shows a Gaussian distribution (1). The range in
which the values will lie with a certain probability can therefore be derived.
For a Gaussian distribution:
The found value will lie within the range value ± 1 CV with 68.3% probability.
The found value will lie within the range value ± 2 CV with 95.5% probability.
The found value will lie within the range value ± 3 CV with 99.7% probability.
The multipliers 1,2, and 3 are the z-scores. Thus, the found value for any analyte lies
within ± Z (CVa2 + CVi2)1/2 with a probability appropriate to the z-score (1). Z-scores are
bi-directional, and the 99% and 95% bi-directional Z-scores have probability of 2.58 and
1.96 respectively.
When a sample is analysed in duplicate, total variation is as described in Equation 4.5.
Total variation = 21/2 * Z * (CVa2 + CVi2)1/2. 4.5
For serial results to be significantly different, the difference in numerical results must be
greater than the combined variation inherent in the two results (1). This value is the
‘critical difference’ or the ‘reference change value’ (RCV), derived using Equation 4.6.
RCV = 21/2 * Z * (CVa2 + CVi2)1/2 4.6
Ninety-five percent probability is conventionally regarded as significant, and 99%
probability is conventionally regarded as highly significant.
Alternatively, the probability that a change is significant can be calculated using a
rearranged formula (Equation 4.7),
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Z = change/[21/2 * (CVa2 + CVi2)1/2] 4.7
Comparison of the Z score with the probability table allows determination of whether the
change is significant (1).
Existing databases on biological variation can be used in all laboratories, as there is
evidence that biological variation is constant with ageing, and disease (especially when the
analyte is unaffected by the disease). Thus although the homeostatic set point may change,
the variation around it does not (1). The biological variation of CoQ10 data described below
are the first data describing biological variation of CoQ10.
A reference interval for coenzyme Q10 concentrations in the healthy New Zealand
population, and quantification of the natural biological variation of coenzyme Q10 that
occurs in a healthy individual over time are presented in this Chapter.
4.2. General methods
4.2.1. Ethics
These studies were approved by the Canterbury Ethics Committee, Christchurch, New
Zealand and written informed consent was obtained from all participants.
4.2.2. Biochemistry
For all studies heparinized plasma specimens were analysed for total CoQ10 using HPLC
with electrochemical detection, as described in Chapter 3, Section 3.6.2. Total cholesterol,
triglycerides and HDL-cholesterol were determined by an enzymatic colorimetric method
(Aeroset Analyser Model LN, Abbott Laboratories, Illinois IL, USA). Coefficients of
variation for the total cholesterol, triglycerides and HDL-cholesterol assays were 1.6%,
1.1%, and 5.3% respectively. Direct LDL-cholesterol was measured using Roche
Diagnostics Reagents, with a coefficient of variation of 1.2%. Between and within-run
coefficients of variation for total CoQ10 measurement were approximately 3.3%.
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4.2.3. Statistics
 Statistical analysis was performed using SPSS Base version 10.0 (SPSS, Inc., Chicago,
Illinois), and SigmaStat software (SPSS, Inc., Chicago, Illinois). Statistical significance
was accepted when p < 0.05.
Correlation analysis in the reference interval study was performed with the Pearson
correlation coefficient. Outliers were included in determination of the reference interval
because the nonparametric analysis allows for these. Comparisons were performed with the
Mann-Whitney rank-sum test.
For the study of biological variation of CoQ10, variance estimates for the inter- and intra-
individual and analytical variation were determined with a residual maximum likelihood
ratio (REML) variance decomposition procedure, and are expressed as CVs.
4.3. Reference interval
4.3.1. Aim
To determine a reference interval for total plasma CoQ10, the plasma CoQ10 to LDL-
cholesterol ratio, and the plasma CoQ10 to total cholesterol ratio in healthy New Zealand
adults.
4.3.2. Study design
4.3.2.1. Subjects
Two hundred and five participants, who were self-reportedly healthy and disease free were
enrolled from the electoral roll or from responses to advertisements. A screening
questionnaire was used to determine entry into the study. Mean age of participants was
46.9 years (range 18.0-83.0), and included both males (n = 90) and females. The group
comprised 90% New Zealand Europeans, 5% New Zealand European/Maori, and 5% other
ethnicities. There were few vegetarians or vegans (2.4%). Thirty five percent of the
participants reported taking herbal supplements at some time. These ranged from
multivitamins, minerals and antioxidants to bee pollen, barley juice powder, and deer
velvet. None of the participants reported taking CoQ10 supplements. Thirty two percent of
the group was on medication, with 3% taking hormone replacement therapy, and 11%
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currently taking hormonal contraceptive. Eight percent of the participants smoked one or
more cigarettes per day.
4.3.2.2. Specimen handling
Blood samples were taken between 0750 and 1015 hours, with 115 participants having
fasted overnight. Samples were taken into glass vacuum tubes containing lithium heparin.
Blood was centrifuged within 1 hour of collection, and plasma was stored protected from
light at –30 °C until analysis. The maximal time samples were stored (at –30 ˚C) before
analysis was 112 days.
4.3.2.3. Laboratory assays
Because not all samples in the reference interval study were from fasted subjects, LDL-
cholesterol was measured directly and triglycerides and HDL-cholesterol were not
measured.
4.3.3. Results
4.3.3.1. Demographic variables
The demographic characteristics and lipid profiles of the population sample used to
determine the reference interval are summarised in Table 4.1. There was no significant
difference in any variable (total CoQ10, total cholesterol, LDL-cholesterol, CoQ10 to total
cholesterol ratio, or CoQ10 to LDL-cholesterol ratio) between the fasting (n = 115) and
non-fasting (n = 90) groups. Therefore, fasting and non-fasting data were pooled for
statistical analysis. This lack of difference may be explained by the fact that all samples
were taken between 0750 and 1015 hours, at which time non-fasting subjects would have
consumed breakfast which (for the greater part of the population) would contain low levels
of CoQ10 and lipids. Furthermore, dietary CoQ10 is not well absorbed so that only a very
small amount of the ingested CoQ10 would have been absorbed into the blood stream by
the time of taking blood. Maximum absorption of CoQ10 from supplements is reported to
occur six hours after ingestion, as found in Chapter 5.
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Table 4.1 Demographic characteristics and lipid profiles of population samples. Data
are median (interquartile range). p-Value is for comparison between males and
females.
Females Males p-Value Total Cohort
Age (years) 44.00
(20.80 – 74.60)
45.00
(21.00 – 75.10)
p = 0.918 44.00
(21.00 – 74.80)
BMI (kg/m2) 24.52
(18.69 – 39.98)
26.05
(18.82 – 37.16)
p = 0.122 25.60
(18.79 – 38.99)
Total
Cholesterol
(mmol/L)
5.47
(3.78 – 8.51)
5.61
(3.36 - 8.37)
p = 0.541 5.54
(3.54 – 8.50)
LDL –
Cholesterol
(mmol/L)
2.96
(1.46 – 5.27)
3.24
(1.56 – 4.87)
p = 0.381 3.01
(1.49 – 5.09)
BMI = body mass index.
The lack of significant difference in age, body mass index, total cholesterol, and LDL-
cholesterol between males and females confirms that these two groups were well matched.
4.3.3.2. CoQ10 in the population – distribution
The distribution of total CoQ10 for the complete cohort was not Gaussian, being skewed
toward higher concentrations (Figure 4.1) (Skewness (± standard error) = 1.14 ± 0.17).
Therefore, non-parametric statistics were used to describe the population.
Figure 4.1 Histogram of total CoQ10 levels in the complete population sample (n =
205).
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The distributions of the total CoQ10 to LDL-cholesterol ratio, and the total CoQ10 to total
cholesterol ratio were closer to a normal distribution than that of CoQ10 alone (skewness (±
standard error) = 0.93 ± 0.17). However, some skewness to a higher ratio is evident (Figure
4.2).
Figure 4.2 Histogram of the total CoQ10 to total cholesterol ratio (A) and total CoQ10
to LDL-cholesterol ratio (B) in the complete population sample (n = 205).
4.3.3.3. CoQ10 and gender
The reference interval for total CoQ10, lipids and the ratios of CoQ10 to lipids for males and
females separately and combined are shown in Table 4.2.
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Table 4.2 The 95% interfractile reference intervals for all analytes, ratios, and
subgroups that deserve stratification.
n 95% Interfractile
Reference Interval
Total CoQ10 205 0.46 – 1.78 µmol/L
Total CoQ10 – Males 90 0.45 – 2.05 µmol/L a
Total CoQ10 - Females 115 0.46 – 1.71 µmol/L a
Total CoQ10 – Age 18 – 44 years 105 0.43 – 1.61 µmol/L
Total CoQ10 – Age 45 – 83 years 100 0.57 – 1.95 µmol/L
LDL-Cholesterol 205 1.50 – 4.98 mmol/L
Total CoQ10 to LDL-Cholesterol Ratio 205 158 – 522 µmol/mol
Total Cholesterol 205 3.57 – 8.40 mmol/L
Total CoQ10 to Total Cholesterol Ratio 205 101 – 265 µmol/mol
Total CoQ10 to Total Cholesterol  Ratio - Males 90 121 – 284 µmol/mol
Total CoQ10 to Total Cholesterol Ratio - Females 115 88 – 244 µmol/mol
a These sub-groups are not statistically required to be stratified using Harris and Boyd
criteria (2), but the difference is of interest.
There was a significant difference in total CoQ10 and the CoQ10 to total cholesterol ratio
between males and females (p = 0.008 and p < 0.001, respectively), with males tending to
have a higher total CoQ10 level than females (Figure 4.3) (2.5 – 97.5% ranges for males
and females were 0.45 – 2.05 and 0.46 – 1.71 µmol/L respectively). There was a non-
significant trend for a difference in CoQ10 to LDL-cholesterol ratio between males and
females (p = 0.075). A significant difference in total CoQ10 between males and females has
been previously reported in some studies (6, 8) but not in others (9-11).
Figure 4.3 Histogram of total CoQ10 for females (A) (n = 115) and males (B) (n = 90).
On the basis of the criteria recommended by Harris and Boyd, (1990) (2), and the National
Committee for Clinical Laboratory Standards (NCCLS), (1995, 2001) (12), the reference
interval for total CoQ10 need not be stratified according to gender.
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4.3.3.4. Correlation of CoQ10 and lipids
The correlations of total CoQ10 with both total cholesterol (r = + 0.651) and LDL-
cholesterol (r = + 0.600) were significant (p < 0.001) (Figure 4.4). This significant
correlation is expected due to the lipophilicity of CoQ10 and has been previously reported
(4, 6, 13-17). A strong correlation between total cholesterol and LDL-cholesterol also
existed (Figure 4.5).
Figure 4.4 The correlation of total CoQ10 and total cholesterol (A), and total CoQ10
and LDL-cholesterol (B) for the complete population (n = 205), males (n = 90), and
females (n = 115).
Figure 4.5 The correlation of total cholesterol and LDL-cholesterol in the complete
population sample (n = 205), males (n = 90), and females (n = 115).
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4.3.3.5. CoQ10 and age
Significant positive trends for total CoQ10 (Figure 4.6), LDL-cholesterol and total
cholesterol (Figure 4.7) to increase with increasing age (p < 0.001, r = + 0.277, + 0.385,
and + 0.439 respectively) were evident and have been previously reported (6, 18, 19).
Other reports have described a lack of association between age and CoQ10 (8, 20). The
correlation of CoQ10 and age disappeared when cholesterol was included in a multivariate
analysis, which supports the findings of Wolters et al., (2003) (16). Application of the
criteria recommended by Harris and Boyd (2) and the NCCLS (21) indicates that separate
reference intervals for total CoQ10 according to age are justified (Table 4.2). In the ideal
situation, more data would be collected for each age group, in order to have more
confidence in these results.
Figure 4.6 The correlation of total CoQ10 and age for males (n = 90, p = 0.239),
females (n = 115, p < 0.001).
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Figure 4.7 The correlation of total cholesterol and age for the complete sample
population (n = 205, p < 0.001), males (n = 90), and females (n = 115).
4.3.3.6. CoQ10 and BMI
There was a significant correlation (p < 0.001) between CoQ10 and BMI (r = + 0.246)
(Figure 4.8), as has been previously reported (6, 8, 16, 22). Related to this was a significant
trend for increasing total cholesterol, and LDL-cholesterol (p = 0.007 and < 0.001
respectively) with increasing BMI (r =  + 0.188 and + 0.249 respectively). Wolters et al.,
(2003) (16) reported that the association of CoQ10 and BMI disappeared when CoQ10
values were adjusted for lipids, which suggests that the increased circulating cholesterol
results in more circulating CoQ10. There is, however, no case for stratifying the reference
interval according to BMI (2, 21).
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Figure 4.8 The correlation of total CoQ10 and body mass index for the complete
population sample (n = 205; p < 0.001), males (n = 90), and females (n = 115).
The reference intervals as presented in Table 4.2 can be compared to previously published
reference intervals, as shown in Table 4.3.
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Table 4.3 Other reported reference intervals for CoQ10.
Publication Measuring In Males/
Females
n Age Total CoQ10
(µmol/L)
Total CoQ10/Total
Cholesterol
% Oxidised CoQ10
in Total
(10) Plasma 0.88 ± 0.17
(10) Serum 0.89 ± 0.35
(13) Serum 0.94 ± 0.28
(23) Serum 18 2.41 ± 0.25 44
(24) Plasma Both 2 – 6 days 0.56
(11) Plasma Both 31 18 - 56 0.54 ± 0.21
(0.30 – 1.19)
(5) Serum 1.58
(0.66 – 3.51)
(25) 60
smokers
1.01 ± 0.76
(26) Males 14 23 – 56 4.4 ± 1.6
(27) Plasma Males 256 45-70 1.12 ± 0.29
(0.55 – 2.31)
(27) Plasma Females 264 47 - 70 0.97 ± 0.25
(0.28 – 2.23)
(27) Plasma Males 123 34 - 66 1.22 ± 0.40
(0.54 – 3.44)
(27) Plasma Females 118 42 - 64 1.06 ± 0.27
(0.52 – 1.88)
(27) Plasma Males 11 50 - 67 88.6 ± 1.0
(87.4 – 90.4)
(27) Plasma Females 29 51 - 69 87.3 ± 2.0
(80.9 – 90.9)
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Table 4.3 Other reported reference intervals for CoQ10 (continued).
Author Measuring In Males/
Females
n Age Total CoQ10
(µmol/L)
Total CoQ10/Total
Cholesterol
% Oxidised CoQ10
in Total
(28) 18 0.38 – 0.93 7
(29) Plasma 0.32 – 0.97 3.7 ± 2
(30) Plasma Males 400 25.1 –
70.1
0.40 – 1.72
(30) Plasma Females 305 22.1 –
70.3
0.43 – 1.47
(31) Males 20 19 – 23 1.01 ± 0.56
(0.24 – 2.10)
(7) Plasma Both 50 Children 0.84 ± 0.29 255 ± 91 µmol/mol
(7) Plasma Both 12 Adults 0.96 ± 0.26 199 ± 45 µmol/mol 9.3 ± 2.5
(32) Both 21 M
37 F
45.2 ±
14.8
0.69 ± 0.29
(0.22 – 1.45)
(17) Plasma Children 0.79
(0.62 – 0.95)
(16) 0.16 mmol/mol
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4.4. Biological variation
4.4.1. Aim
To determine the intra- and inter-individual variation of plasma total CoQ10, the plasma
CoQ10 to LDL-cholesterol ratio, and the plasma CoQ10 to total cholesterol ratio.
4.4.2. Study design
4.4.2.1. Subjects
Ten healthy adult male volunteers were enrolled via response to advertisements.
Participants were excluded from the study if they reported taking any CoQ10, vitamin
supplements or other medications within four weeks prior to initiation of the study. All
participants were self-reportedly healthy and disease free throughout the study and did not
smoke. The median age of participants was 23.5 years (range 21-28 years), the median
weight was 69 kg (range 60-100 kg) and the median body mass index was 21.4 (18.5 –
28.6) kg/m2.
4.4.2.2. Study protocol
Seven baseline fasting blood samples were collected, at least one week apart, over a 2-
month period.
4.4.2.3. Sample handling
Blood samples were taken in the morning after a 10 hour overnight fast. Seven samples
were taken in total over the two month period. Blood specimens were collected from the
median cubital vein into glass vacuum tubes containing lithium heparin. Blood was
immediately placed on ice, and tubes were centrifuged within 1 hour of collection at 1800g
for 10 minutes at 4 °C. Plasma was immediately transferred to pre-labelled 5 mL serology
tubes and stored at -80 °C until analysis, which was within 5 months of collection.
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4.4.3. Results
4.4.3.1. Demographic variables
All ten participants had healthy levels of CoQ10 and lipids (Table 4.4). Table 4.4 also
shows the median ratios for total CoQ10 to LDL-cholesterol, and total CoQ10 to total
cholesterol (n = 70).
Table 4.4 Lipid characteristics for the participants in the biological variation of
CoQ10 study (n = 70).
Median (interquartile range)
Total CoQ10 (µmol/L) 0.85 (0.66 – 0.99)
Total Cholesterol (mmol/L) 4.75 (4.10 – 5.70)
LDL-Cholesterol (mmol/L) 2.75 (2.24 – 3.28)
HDL-Cholesterol (mmol/L) 1.12 (0.99 – 1.31)
Triglycerides (mmol/L) 1.20 (1.00 – 1.50)
Total CoQ10 to LDL-Cholesterol (mmol/mol) 289 (252 – 348)
Total CoQ10 to Total Cholesterol (mmol/mol) 169 (147 – 198)
4.4.3.2. Intra- and inter- individual variation
The intra- and inter-individual variation in CoQ10 shows that CoQ10 in an individual is
tightly distributed around a homeostatic set point (Table 4.5). This concept is confirmed by
observing graphs of the range of CoQ10 values reported for each individual over the seven
time points (Figure 4.9). There is greater natural variation in the CoQ10 to lipid (total
cholesterol or LDL-cholesterol) ratio than there is for total CoQ10 alone (Figure 4.10),
suggesting that lipids have a larger natural variation than total CoQ10.
Table 4.5 The intra- and inter-individual variation in CoQ10 parameters.
Intra-individual
%CV
Inter-individual
%CV
Total CoQ10 12 29
Total CoQ10 to LDL-Cholesterol Ratio 15 26
Total CoQ10 to Total Cholesterol Ratio 14 18
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Figure 4.9 Biological variation (median and range) for CoQ10 for each participant.
Blue vertical lines indicate the reference interval, as determined in the healthy New
Zealand population.
Figure 4.10  Biological variation (the median and range) for the CoQ10 to total
cholesterol ratio, and the CoQ10 to LDL-cholesterol ratio for each participant.
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(RCV) or ‘critical difference’ for serial results to be significantly different. Thus, for total
CoQ10, with a CVi of 12% and a CVa of 3.3%, a 95% significant change is 35.0% and a
99% significant change is 46.1%. Significant changes in CoQ10 can therefore occur within
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(a 99% significant change) and still be within the reference interval. Biological variation
and the reference change value therefore need to be taken into consideration when
assessing, for example, whether therapy with statins has resulted in a significant fall in
CoQ10, or conversely, whether supplementation has resulted in a significant increase in
CoQ10.
Furthermore, for total CoQ10, the index of individuality (CVi/CVg) is 12.2 / 29.0 = 0.42
which is low. This further suggests that reference intervals are of little use in deciding
whether a significant change in Q10 values has occurred (be it an increase due to
supplementation or a decrease due to, for example, statin therapy).
Applying Equation 4.2 reveals that seven samples should be evaluated to ensure that the
estimate of the homeostatic set point is within 10% of the true value with 95% probability.
4.5. Discussion
For CoQ10, a deficiency state is important since CoQ10 is required by every cell in the
body. The reference interval gives a basis on which to make medical decisions, since
results lying outside the reference interval deserve attention – either in the form of
continued monitoring or action such as supplementation. Because the lower (2.5%) limits
for males and females in the present study were very similar (0.45 and 0.46 µmol/L
respectively), the statistically significant difference in total CoQ10 between males and
females is not clinically important, and it is therefore valid to use one reference interval for
males and females in a clinical setting. CoQ10 concentrations do not show a Gaussian
distribution. Therefore non-parametric statistics were used since non-parametric (or
distribution-free) statistics require no assumption of the distribution. The disadvantage of
non-parametric statistics is that they are less powerful than the corresponding parametric
tests.
The difference in CoQ10 between genders does not appear to be due to differences in total
cholesterol levels, since the ratio of CoQ10 to total cholesterol was also significantly
different in males and females. However, the association of CoQ10 and age is probably
explained by higher total cholesterol levels found in older people (at least up to 80 years of
age, as in the studied population) since the correlation of age and CoQ10 disappeared when
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cholesterol was included in a multivariate analysis. The association of CoQ10 and BMI is
also probably due to increased total cholesterol levels in people with higher BMI.
The index of individuality of 0.42 for total CoQ10 suggests that individuals have a tightly
homeostatically controlled plasma CoQ10 concentration, and therefore population based
reference intervals are of little use. An individual can have a significant change in their
CoQ10 concentration, but still have a level that falls within the reference interval. The low
index of individuality therefore suggests that monitoring of plasma CoQ10 levels over time
is more informative than comparing a one off value for an individual to a population based
reference interval.
From a clinical perspective, serial changes in CoQ10 should be evaluated against the
reference change value (RCV) to allow for both biological variation and analytical
imprecision. The biological variation study was carried out on young healthy males and it
is possible that variation in CoQ10 may differ for females, older adults, or children. Males
were chosen for this study because males should have more constant biochemistry over a
seven week period than females. Documentation on the effect of the menstrual cycle on
plasma CoQ10 is lacking and may be of interest for interpretation of patient results.
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Chapter 5. Relative absorption of Coenzyme Q10 Supplements, Dose Range for the Coenzyme Q10
Supplement Q-Gel, and the Effect of Statin on Coenzyme Q10 in Patients with Chronic Heart Failure
5.1. Introduction
5.1.1. Coenzyme Q10 supplementation
Deficiency of CoQ10 is important in terms of ill health. Therefore, where medical
intervention is required, supplementation will generally be advised. It has been reported
that the desired concentration of plasma CoQ10 considered to have a therapeutic effect is
2.90 µmol/L (1, 2). CoQ10 supplements are available over the counter from health food
shops and pharmacies in most countries, and different brands differ in bioavailability
because of differing excipients, form of CoQ10 (reduced or oxidised), and the type of
encapsulation (3-8). Information on the bioavailability of various brands of CoQ10 is
limited and may be influenced by uninformed sales representatives. As CoQ10 supplements
are relatively expensive (approximately NZ $1 per day), knowledge of bioavailability is
important. While there are reports comparing various formulations of CoQ10, comparison
of results between studies is complicated by differences in the CoQ10 preparations,
subjects, and dosage. Extrapolation of bioavailability results from animal trials to humans
is hampered by a common trend to supplement animals with doses that are equivalent to
extremely high doses in humans. For example, giving a 75 kg human a 150 mg dose of
CoQ10 is equivalent to 2 mg/kg, whereas Lass et al., (1999) (9) administered 123
mg/kg/day to mice when determining the effect of CoQ10 administration on tissue levels. A
survey of the relative absorption at 6 hours of CoQ10 supplements available in New
Zealand has not been previously reported.
Knowledge of the dose-range for CoQ10 is limited but would be very useful when planning
and designing studies involving CoQ10 supplementation. Therefore, a study investigating
the dose-range for the most bioavailable brand of CoQ10 supplement, Q-Gel, was
completed.
5.2. Coenzyme Q10 and statin therapy in patients with chronic heart failure
As discussed in Chapter 1, Section 1.1.9.6, statin (3-hydroxy-3-methylglutaryl-coenzyme-
A (HMG CoA) reductase inhibitor) therapy is associated with a decrease in plasma CoQ10
concentration (10-15). A multitude of studies have demonstrated that statins can
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profoundly improve both coronary and peripheral endothelial function (16-18) even in
young, healthy and normocholesterolemic males. Chronic heart failure is associated with
endothelial dysfunction (19, 20). The endothelial nitric oxide pathway has been found to be
defective in patients with heart failure (19, 20) and the degree of endothelial impairment is
related to the severity of heart failure (21). The improvement in tissue perfusion is an
important goal in patients with chronic heart failure in terms of both the peripheral and
coronary circulation (22). Although not currently indicated for chronic heart failure, statin
therapy could result in substantial clinical benefits through its endothelium enhancing
properties and other pleiotropic effects. In a retrospective analysis of large statin trials,
statin therapy was associated with improved cardiovascular outcome in subgroups with
heart failure (23). However, statin therapy may potentially be unfavourable in chronic heart
failure patients due to its CoQ10 reducing properties (10, 11, 13, 14). CoQ10 deficiency has
been implicated in chronic heart failure, and the severity of heart failure is correlated with
the degree of CoQ10 depletion.
Therefore, a study was conducted by the Lipid and Diabetes Research Group of
Christchurch Hospital, to investigate the effect of statin therapy on both endothelial
function and plasma CoQ10 concentrations in people with chronic heart failure.
5.3. General methods
5.3.1. Ethics
These studies were approved by the Canterbury Ethics Committee, Christchurch, New
Zealand and written informed consent was obtained from all participants.
5.3.2. Biochemistry
For all studies (unless otherwise specified), heparinized plasma specimens were analysed
for total CoQ10 using HPLC with electrochemical detection, as described in Chapter 3,
section 3.6.2. Total cholesterol, triglycerides, and HDL-cholesterol were determined by an
enzymatic colorimetric method (Aeroset analyser Model LN, Abbott Laboratories, Illinois
IL, USA). Coefficients of variation for the total cholesterol, triglycerides, and HDL-
cholesterol assays were 1.6%, 1.1%, and 5.3% respectively. Direct LDL-cholesterol was
measured using Roche Diagnostics reagents, with a coefficient of variation of 1.2%.
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Between and within-run coefficients of variation for total CoQ10 measurement are
approximately 3.3%.
5.3.3. Statistics
 Statistical analysis was performed using SPSS Base version 10.0 (SPSS, Inc., Chicago,
Illinois), and SigmaStat software (SPSS, Inc., Chicago, Illinois). Statistical significance
was accepted when p < 0.05.
For the bioavailabilty study of coenzyme Q10 supplements, the differences between CoQ10
supplements were tested using the non-parametric Friedman test, and Wilcoxon signed-
rank test, as appropriate.
5.4. Absorption of coenzyme Q10 supplements
5.4.1. Aim
To investigate the absorption of seven different CoQ10 supplements marketed in New
Zealand.
5.4.2. Study design
5.4.2.1. Subjects
Ten healthy adult male volunteers were enrolled. Participants were excluded if they
reported taking any CoQ10, vitamin supplements or other medications within four weeks
prior to the study. All participants were self-reportedly healthy and disease free throughout
the study, and all were non-smokers. The mean age of participants was 24.2 years (range
21 - 28 years), the mean height was 180 cm (range 173 - 187 cm), and the mean weight
was 72 kg (range 60 - 100 kg). The study size (n = 10) was selected based on reported
effects of coenzyme Q10 supplementation, indicating that CoQ10 supplementation would
increase Cmax by 15 – 20% (equates to ± 0.23 - 0.30 µmol/L) at α = 0.5 with a power of
80%.
5.4.2.2. Study protocol
Baseline blood samples were obtained after a ten hour overnight fast and CoQ10
supplements were administered as a single dose of 150 mg (based on the claimed content
on supplement packaging). Supplement brands were given in a randomised order (a
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different randomised order for each participant), with a week long washout period between
trial days. After administration of the supplement, a standardised vegetarian breakfast and
lunch were provided. Lunch was provided as a takeaway package and participants were
permitted to leave the study centre after breakfast. Six hours after administration of the
supplement, participants returned to the study centre for collection of a second blood
sample.
5.4.2.3. Blood collection
Blood specimens were collected from the median cubital vein into glass vacuum tubes
containing lithium heparin. Blood was immediately placed on ice and tubes were
centrifuged within 1 hour of collection at 1800g for 10 minutes at 4 °C. Plasma was
immediately transferred to pre-labelled 5 mL serology tube then stored at -80 °C until
analysis, which was within 5 months of sample collection.
5.4.2.4. Assumptions made in this study
This study assumes that maximum absorption from all of the CoQ10 supplements occurs 6
hours after ingestion. In several studies looking at the pharmacokinetic properties of
CoQ10, tmax occurred at approximately six hours (Table 5.1) (3, 4, 7, 8). Whalqvist et al.,
(1998) (6) reported tmax to occur at 4 hours, and Kaikkonen et al., (1997) (4) reported tmax
for a granule-based supplement to occur at 10 hours, as opposed to 6 hours for an oil-based
supplement. Data presented in Section 5.5.3.5 further support the occurrence of tmax 6
hours after supplementation. It is possible that time to tmax varies more between individuals
than between formulations. This is a limitation of this study, as it is very possible that tmax
occurred at a time other than 6 hours for some individuals and/or some supplement brands.
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Table 5.1 tmax as determined by various authors.
Publication Supplement Formulation tmax (hours)
(3) CoQ and Emcompress
CoQ and soy bean oil
CoQ, soy bean oil,  polysorbate-80 and
phosphatidylcholin
CoQ, soy-bean oil, and polysorbate-80
6a
(24) Q-Gel
Starch-coated nano beadlets containing CoQ
dispersed into a water-soluble gelatin matrix
7
7
(6) CoQ in a complex micelle in an emulsion
CoQ as dry powder
4a
(7) Solubilised CoQ
Reduced CoQ
Fully solubilised CoQ
CoQ as dry powder
6.2 ± 1.6
8.1 ± 6.3
5.8 ± 0.7
6.7 ± 1.0
(8) Biotransformed, reduced CoQ
CoQ as dry powder
6.0 ± 0.3
5.9 ± 3.0
asecondary peak observed at 24 hours.
Evidence of a second (lesser) peak at 24 hours after ingestion of the supplement has also
been reported (3, 6). It has been suggested that this two-peak pattern occurs because the
CoQ10 is administered as the oxidised form, and the first peak is due to the blood content of
this parent compound. While circulating in the blood, the parent compound (oxidised
CoQ10) undergoes reduction somewhere in the peripheral compartment (for example, in the
liver). The oxidised CoQ10 will easily pass biomembranes into the liver, but the increase in
water solubility caused by the reduction of the quinone by the liver enzymes impairs the
ability of the reduced CoQ10 to pass biomembranes. The result will then be a second peak
caused by CoQ10H2 (3, 6). However, one formulation tested by Kurowska et al., (2003) (8)
contained CoQ10H2, and the reported tmax for this formulation was 6.0 ± 1.3 hours, which is
inconsistent with the theory of Whalqvist et al., (1998) and Weis et al., (1994) (3, 6).
Redistribution after incorporation into the VLDL fraction in the liver (25) and hepatic
recycling (26) have also been suggested as causes for the two-peak pattern.
5.4.2.5. Supplement brands
Supplement brands investigated for relative absorption were Blackmores (Blackmores
Ltd), Good Health (Good Health Ltd), Kordel’s (distributed by Nutra-Life Health &
Fitness (NZ) Ltd), Q-Gel (manufactured by Gel-Tec, Tishcon Corp., USA), Radiance
(Health & Herbs International Ltd), Solgar (manufactured by Solgar Vitamin and Herb),
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and Thompson’s (Thompson Nutrition Ltd). These brands were tested because they are
‘popular’ brands (as advised by health food shop assistants), or brands that contain
differing excipients. The formulation of each supplement brand used in this study is
outlined in Table 5.2.
Table 5.2 The excipients and formulation of the seven CoQ10 supplement brands
investigated for relative absorption.
Supplement Excipients Capsule/Tablet Type
Q-Gel Vitamin E, Annato seed extract,
Biosolv® base (lecithin, polysorbate,
sorbitin monoleate, and medium
chain triglycerides)
Softules containing liquid
dispersion
Radiance Rice bran oil, lecithin, selenium and
vitamin E
Softgels containing liquid
dispersion
Blackmores Soy lecithin Capsules containing liquid
dispersion
Solgar Vegetable cellulose, vegetable
magnesium stearate and silica
Vegetable capsules
containing dry powder
Kordel’s Evening primrose oil and salmon oil Capsules containing liquid
dispersion
Thompson’s Vegetable oil Vegetarian capsules
containing liquid
dispersion
Good Health Glucose, sucrose, magnesium
stearate, calcium phosphate, and
natural orange flavour
Chewable tablets
5.4.3. Results
Coenzyme Q10 supplementation with all brands was well tolerated with no reported side
effects.
5.4.3.1. Coenzyme Q10 content of the diet
Participants were fed an identical, vegetarian diet on each study day to limit the effect of
dietary CoQ10. The diet of participants on study days consisted of: (breakfast) weet-bix,
milk and sugar, two slices of toast, and margarine, with two eggs; (Lunch) one sandwich
(white and brown bread, lettuce, tomato, and cheese), apple, and orange juice. This diet
contributed approximately 315 µg of CoQ10 (Table 5.3).
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Table 5.3 The CoQ10 content of the diet given to participants on each study day.
Item Approximate
Weight (g)
CoQ10
Concentration
(µg/g)
Total Contribution
(µg)
Milk 128 0.1a 12.8
Toast 50 0a 0
Jam 10 n.k. n.k.
Weet-bix 31 0 0
Margarine 9 n.k. n.k.
Orange Juice 102 0.3a 30.6
White bread 60 0a 0
Brown bread 60 0a 0
Lettuce 6 n.k. n.k.
Tomato 24 0.9a 21.6
Cheese 40 1.3a 52.0
Apple 152 1.3a 197.6
Total 314.6 µg
 n.k. = not known; a from (27).
5.4.3.2. Supplement adherence
All CoQ10 supplements tested contained 100% or more of the claimed CoQ10 content
(Table 5.4). Six of the seven brands contained approximately 20% more CoQ10 than
claimed. The brand Good Health had a mean of 100% of the CoQ10 concentration claimed
with some tablets containing 10% less CoQ10 than was claimed on the packaging. Some
brands supply a more variable dose than others, Q-Gel being the most consistent (Table
5.4).
Table 5.4 The measured and claimed CoQ10 content of the different supplement
brands (n = 6 capsules or tablets).
mg of CoQ10 per Capsule/Tablet
Brand Claimed Measured
(mean ±SD)
Yield Recovery
(%)
Q-Gel 30 41 ± 1.3 137
Radiance 50 63 ± 2.1 125
Blackmores 50 60 ± 4.1 121
Solgar 30 39 ± 4.4 130
Kordel’s 75 95 ± 5.5 127
Thompson’s 30 36 ± 1.9 121
Good Health 30 30 ± 2.0 100
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Because absorption of CoQ10 is very poor (8, 28), minor differences in the amount of
CoQ10 ingested due to variability in dose in each capsule or tablet probably become
insignificant, and can be considered to have little effect on the results.
5.4.3.3. Demographic variables
Mean baseline lipids (± SD) for all participants were 4.81 ± 1.04, 2.78 ± 0.75, 1.18 ± 0.30,
and 1.28 ± 0.44 mmol/L for total cholesterol, LDL-cholesterol, HDL-cholesterol, and
triglycerides, respectively. Mean baseline CoQ10 (± SD) was 0.85 ± 0.25 µmol/L. There
was no significant change in baseline levels of CoQ10, LDL-cholesterol, HDL-cholesterol,
triglycerides, or total cholesterol during the seven weeks of the trial. This confirms that the
week-long wash-out period was sufficient for a return to baseline levels, and also that there
were no significant dietary changes made by participants during the trial period.
5.4.3.4. Effect of CoQ10 supplementation on plasma lipids/dietary compliance
There was no significant effect of CoQ10 supplementation on total cholesterol (p = 0.539),
triglycerides (p = 0.128) or LDL- and HDL-cholesterol (p = 0.910 and 0.587 respectively).
This suggests that participants were compliant with dietary restrictions on study days, since
the supplements contained little or no lipid and the diet given contained low concentrations
of lipid.
5.4.3.5. Difference in absorption between participants
There was a significant difference (p = 0.003) in CoQ10 absorption between the ten
participants (Figure 5.1). Some participants efficiently absorbed CoQ10 from most
supplements, while others showed inefficient absorption. This difference in absorption
between participants has been previously reported (3, 4, 6, 8, 28).
There was no correlation (p = 0.56) between baseline CoQ10 levels and absorption of
CoQ10 from the seven supplement brands which supports the findings of Zita et al., (2003)
(28). Conversely, Wolters et al., (2003) (29) reported that changes in cholesterol-adjusted
CoQ10 concentrations were inversely related to baseline values.
Chapter 5 183
Figure 5.1 The increase in coenzyme Q10 concentrations at six hours for individual
participants and all supplement brands (n = 7). Horizontal lines show median
increase in CoQ10 for each participant.
This significant difference in absorption between the participants may be explained on the
basis of the significant correlations between baseline LDL-cholesterol concentration and
change in CoQ10 (p = 0.004 ; r = + 0.343), between total cholesterol level and change in
CoQ10 (p = 0.004 ; r = + 0.338), and also between baseline triglycerides and change in
CoQ10 (p = 0.035 ; r = + 0.253). This suggests that higher LDL-cholesterol or triglyceride
concentrations may aid absorption of CoQ10.
There was no significant correlation between HDL-cholesterol, weight, or body mass index
and CoQ10 absorption.
5.4.3.6. Relative absorption of CoQ10 brands at six hours
There was a significant difference in relative absorption at six hours between the seven
CoQ10 brands tested (p < 0.001), with Q-Gel having significantly higher relative absorption
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at 6 hours than any other supplement brand (p = 0.013). These results are summarised in
Table 5.5, which shows the median change in total CoQ10 and CoQ10 ratios, for the
different supplement brands. The significance of these differences is shown in Table 5.6.
There was a significant change in the CoQ10 to LDL-cholesterol and CoQ10 to total
cholesterol ratios between the supplement brands (p = 0.001 for both). The change in these
ratios appeared to mirror the change in total CoQ10 (Table 5.5).
Table 5.5 The median change in CoQ10 at six hours after supplementation with the
different brands.
Brand Change in Total
CoQ10 concentration
(µmol/L)
Change in CoQ10 to
LDL-Cholesterol Ratio
(mmol/mol)
Change in CoQ10 to Total
Cholesterol Ratio
(mmol/mol)
Q-Gel 0.586 (0.349 - 1.424) 0.275 (0.218 - 0.500) 0.125 (0.100 - 0.225)
Radiance 0.321 (0.218 - 1.118) 0.140 (0.120 - 0.373) 0.065 (0.048 - 0.210)
Blackmores 0.229 (0.109 - 0.531) 0.130 (0.072 - 0.253) 0.045 (0.028 - 0.090)
Solgar 0.203 (0.094 - 0.295) 0.075 (0.048 - 0.188) 0.045 (0.020 - 0.075)
Kordel’s 0.177 (0.102 - 0.274) 0.075 (0.050 - 0.173) 0.040 (0.018 - 0.078)
Thompson’s 0.173 (0.106 - 0.442) 0.080 (0.060 - 0.150) 0.028 (0.060 - 0.073)
Good Health 0.139 (0.105 - 0.297) 0.095 (0.040 - 0.165) 0.040 (0.018 - 0.053)
Values shown are median values, with brackets showing the inter-quartile range.
Table 5.6 Statistical analysis of differences in the change in total CoQ10 at 6 hours
after a single oral dosea.
Q-Gel Radiance Blackmores Solgar Kordel’s Thompson’s
Radiance 0.013
Blackmores 0.013 0.059
Solgar 0.013 0.053 0.333
Kordel’s 0.005 0.009 0.203 0.959
Thompson’s 0.005 0.037 0.646 0.386 0.878
Good Health 0.005 0.022 0.203 0.959 0.386 0.508
aNull hypothesis was that there was no significant difference in relative absorption at 6
hours between the seven supplement brands.
As discussed in Chapter 1, different excipients in CoQ10 supplements are likely to affect
the absorption of the CoQ10. Because CoQ10 is lipid soluble, it is likely that administering
it as a dispersion, or solubilised in oil will aid absorption into blood, as has been previously
reported (30, 31). This was supported by the present study. Conversely, Chopra et al.,
(1998) (5) found the absorption from powder-filled hardshell capsules and powder-based
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tablets to be higher (125% and 128% respectively) than that from a standard softgel
capsule containing a CoQ10 suspension in oil. A summary of studies on the absorption and
bioavailability of CoQ10 supplements is shown in Table 5.7.
The high absorption of Q-Gel compared to other coenzyme Q10 supplement brands
supports the findings of Chopra et al., (1998) (5), who found the absorption of Q-Gel to be
319% better than that from a standard softgel capsule containing a CoQ10 suspension in oil,
after 3 weeks of a daily 120 mg dose. Additionally, Ullmann et al., (2005) (24), reported
Q-Gel to have higher bioavailability than a Q-SorB product (which contains rice bran oil,
lecithin, and a beeswax soybean oil mixture as excipients) and slightly higher
bioavailability than a new supplement containing starch-coated nano beadlets encasing
CoQ dispersed into a water-soluble gelatin matrix
It is possible that the high relative absorption at 6 hours of Q-Gel is due to the presence of
both non-ionic surfactants (polysorbate 80) and the natural surfactant lecithin. The brands
Radiance and Blackmores showed the second and third highest absorption respectively,
and also contain lecithin as an excipient. Lecithin (a liposome forming phospholipid) has
been shown to increase the absorption of CoQ10 supplements (32), although Weis et al.,
(1994) (3) reported no increase in bioavailability when micelle and liposome-forming
agents were added to the CoQ10 supplement. As discussed in Chapter 1, it is not only the
presence of liposome and micelle forming agents, but also their concentration that plays a
major role in bioavailability, because of critical micelle concentrations (33).
The effect of the capsule on absorption is not clear, since there are no reported studies
where the same formulation has been encapsulated in different capsules. Therefore, any
perceived differences in absorption due to capsules is actually a combined difference due
to formulation and encapsulation.
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Table 5.7 A summary of studies investigating the absorption and bioavailability of CoQ10 supplements.
Publication Dose Duration Study Design Number of
Subjects
(age)
% Male Baseline Q
(µmol/L)
Supplement Type Final Q
(34) 300 mg
(3 x 100
mg dose
daily)
11 days Simple 3
(31 - 35 y/o)
100 Q10H2 0.8 100 mg Q10 powder
dissolved in 25 mL
milk
Q10H2 3.2 (during
latter half of
supplementation)
(3) 100 mg Single
dose
Randomised,
crossover
10
(24 – 30 y/o)
50 Not given 1)Hard gelatin capsule
with 100mg Q10, 400mg
Emcompress
2)Soft gelatin capsule
with 100mg Q10, 400
mg soy bean oil
3)Soft gelatin capsule
with 100mg Q10, 20mg
polysorbate 80, 100mg
lecithin, 280mg soy
bean oil
4)soft gelatin capsule
with 100mg Q10, 20mg
polysorbate 80, 380mg
soy bean oil
Increase at about six
hours
1) 0.9 µmol/L
2) 1.5 µmol/L
3) 0.9 µmol/L
4) 0.9 µmol/L
(4) 30 mg
3 x daily
(90 mg
total)
2 months Large block,
randomised,
single-blind,
placebo
controlled
(46 ± 7 y/o)
30
30
30
100
(smokers,
23 ± 9
cigarettes/
day)
1.08 ± 0.31
1.07 ± 0.34
0.89  ± 0.33
Granular
Oil-based capsule
Placebo
Change
1.81 ± 0.82
(168% increase)
1.90 ± 0.97
(178% increase)
-0.01 ± 0.26
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Table 5.7 A summary of studies investigating the absorption and bioavailability of CoQ10 supplements (continued).
Publication Dose Duration Study Design Number of
Subjects
(age)
% Male Baseline Q
(µmol/L)
Supplement Type Final Q
(5) 120 mg 3 weeks Randomised,
double-blind
(20 - 56 y/o)
6
6
6
6
Not given 0.579 – 0.602
Oil based capsule
Powder filled capsule
Tablet
Q-Gel
1.586 ± 0.289
1.887 ± 0.243
1.853 ± 0.254
3.833 ± 1.563
(5) 120 mg 4 weeks Randomised,
double-blind
(20 – 56 y/o)
12
12
Not given 0.451 ± 0.127
Oil based capsule
Q-Gel
1.459 ± 0.579
3.242 ± 0.926
(6) 100 mg Single
dose
Randomised,
crossover
23
(20 - 43 y/o)
52 0.630 ± 0.165
0.605 ± 0.121
Dry powder in hard
gelatin capsule
Q in a complex micelle
in an emulsion in soft
gelatin capsule
@4hr 0.730 ± 0.164
(20 ± 35% increase)
@4hr 1.366 ± 0.361
(130 ± 61% increase)
(7) 180 mg Single
dose
Randomised,
crossover
9
(23 – 56 y/o)
89 0.602 (mean) Oxidised in liquid
Reduced in capsule
Q-Gel
powder tablet
1.192 ± 0.428 (Cmax)
1.47 ± 0.764 (Cmax)
1.192 ± 0.579 (Cmax)
0.138 ± 0.057 (Cmax)
(8) 300 mg 1 week Randomised,
two-way
crossover, 3-
week
washout
11
(30.9 ± 10.8
y/o)
55% 2.884 ± 1.089
2.085 ± 1.008
Crystaline Q, hard
gelatin capsule,
powdered ω-3 fatty
acids
Biotransformed reduced
Q10 powder, powdered
ω-3 fatty acids, hard
gelatin capsule
Cmax 0.936 ± 0.645
After 1 week 8.687 ±
3.602
(Change 0.205)
Cmax 2.118 ± 1.050
After 1 week 8.096 ±
3.602
(change 0.367)
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Table 5.7 A summary of studies investigating the absorption and bioavailability of CoQ10 supplements (continued).
Publication Dose Duration Study Design Number of
Subjects
(age)
% Male Baseline Q
(µmol/L)
Supplement Type Final Q
(35) 50 mg
(single
daily
dose)
15 days Randomised (19 – 23 y/o)
10
10
100
0.949 ± 0.37
1.123 ± 0.741
Regular tablet
Sustained release tablet
After 412 hours
1.204 ± 0.359
1.297 ± 0.822
(36) 0.05% Q
in cream,
once
daily
50 mg  +
cream as
above
2 months
2 months
Randomised
25
(35-45 y/o)
25
(35-45 y/o)
0
Q10H2 0.72 ±
0.14
Q10 0.27 ±
0.12
Q10H2 0.73 ±
0.15
Q10 0.24 ±
0.10
25 mg Q10 + 25 mg of
d-RRR-α-tocopherol
acetate + 25 µg
selenium as selenium
aspartate
(2 x daily)
(After 60 days)
Q10H2 0.76 ± 0.13
Q10 0.29 ± 0.08
Q10H2 1.56 ± 0.24
Q10 0.49 ± 0.16
(131% increase Q10 in
sebum)
(29) 30 mg
(plus
other
antioxida
nts)
6 months Double-blind,
placebo-
controlled
220
(>60 y/o,
median 63,
range 60-90)
0 Median
(interquartile
range)
Control  0.98
(0.55 – 1.62)
Treatment
1.02
(0.54 – 1.81)
Soft gelatin capsules,
soy oil and other
antioxiants
After supplementation
Median (interquartile
range)
Control 1.30 (0.99 –
2.46)
Treatment 1.97 (1.06
– 3.50)
(28) 30 mg
and 100
mg
2 months
(single
daily
dose)
Randomised,
double-blind,
placebo-
controlled
99
(20 - 80 y/o)
100 1.459
10 and 90%
fractiles
(0.949 &
2.119)
Soya oil
Soft gelatin capsule
Median increase
(µmol/L)
30mg => 0.637
100mg => 1.575
placebo => -0.266
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5.5. Dose range for the coenzyme Q10 supplement Q-Gel
5.5.1. Aim
To investigate the dose range for the CoQ10 supplement Q-Gel, given at 60, 150, and 300
mg doses.
5.5.2. Study design
5.5.2.1. Subjects
Eight healthy adult male volunteers were enrolled. Participants were excluded if they
reported taking any CoQ10, vitamin supplements, or other medications within four weeks
prior to the study. All participants were self-reportedly healthy, disease free throughout the
study and all were non-smokers. The mean age of participants was 24 years (range 20 - 26
years), the mean height was 185 cm (range 178 - 192 cm), and the mean weight was 75 kg
(range 63 - 86 kg).
5.5.2.2. Study protocol
Baseline blood samples were obtained after a ten hour overnight fast, and the Q-Gel
supplement was administered as a single dose (based on the claimed content on
supplement packaging) of 60, 150, and 300 mg, taken as two, five, and ten, 30 mg
capsules. A dose of 300 mg taken as three 100 mg Q-Gel capsules was also given.
Supplement doses were given in a randomised order (a different randomised order for each
participant), with a week long washout period between trial days. A standardised breakfast
was given after administration of the supplement, and a standardised lunch and afternoon
tea were provided at set time points throughout the day. Blood samples were taken at 2
hourly intervals after administration of the supplement, for 10 hours. Participants were not
permitted to leave the study centre at any time during each study day.
5.5.2.3. Specimen handling
Blood specimens were collected from the median cubital vein into glass vacuum tubes
containing lithium heparin. Blood was immediately placed on ice, and tubes were
centrifuged within 1 hour of collection at 1800g for 10 minutes at 4 °C. Plasma was
immediately transferred to pre-labelled 5 mL serology tubes then stored at -80 °C until
analysis, which was within 2 months of sample collection.
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5.5.3. Results
Coenzyme Q10 supplementation with all doses was well tolerated with no reported side
effects.
5.5.3.1. Coenzyme Q10 content of the diet
Participants were fed an identical, vegetarian diet on each study day to limit the effect of
dietary CoQ10. The diet of participants on study days consisted of: (breakfast) four weet-
bix, milk and sugar, or four slices of toast, with margarine and jam, with a pottle of
preserved fruit and a glass of fruit juice; (Lunch) one filled roll (white bread, lettuce,
tomato, and cheese), an apple, and a muesli bar. This diet contributed approximately  533.2
µg of CoQ10 (Table 5.8).
Table 5.8 The approximate CoQ10 content of the diet given to participants in the dose
range study on each study day.
Item Approximate
Weight (g)
CoQ10
Concentration
(µg/g)
Total Contribution
(µg)
Milk 290 0.1a 29
Toast 100 0a 0
Jam 10 n.k. n.k.
Weet-bix 100 0 0
Margarine 9 n.k. n.k.
Orange Juice 170 0.3a 51
Pottle fruit 140 1.3 182
White bread 60 0a 0
Lettuce 6 n.k. n.k.
Tomato 24 0.9a 21.6
Cheese 40 1.3a 52.0
Muesli bar 31 0 0
Apple 152 1.3a 197.6
Total 533.2 µg
 n.k. = not known; a from (27).
5.5.3.2. Supplement adherence
Both Q-Gel capsules used contained more than 100% of the claimed CoQ10 content. The 30
and 100 mg capsules (n = 6) each contained 44.5 ± 3.4 and 144.3 ± 6.0 mg CoQ10 (mean ±
SD), respectively. Therefore, at a nominal dose of 300 mg, the actual amount ingested was
445 mg and 432 mg, respectively.
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5.5.3.3. Demographic variables
Mean baseline lipids (± SD) for all participants were 4.17 ± 0.59, 2.64 ± 0.41, 1.32 ± 0.29,
and 0.89 ± 0.40 mmol/L for total cholesterol, LDL-cholesterol, HDL-cholesterol, and
triglycerides respectively. Mean baseline CoQ10 (± SD) was 0.66 ± 0.18 µmol/L. There
was no significant change in baseline levels of CoQ10, LDL-cholesterol, HDL-cholesterol,
triglycerides, or total cholesterol during the four weeks of the trial, further confirming that
the week-long wash-out period was sufficient for the CoQ10 level to return to baseline, and
also that there were no significant dietary changes made by participants during the trial
period.
5.5.3.4. Dose range for Q-Gel
The absolute change in CoQ10 for each participant and dose is shown in Table 5.9.
Table 5.9 The absolute change in CoQ10 at six hours for each participant and dose.
Change in CoQ at 6 hours (µmol/L)
Subject 60 mg dose
(30 mg capsules)
150 mg dose
(30 mg capsules)
300 mg dose
(30 mg capsules)
300 mg dose
(100 mg capsules)
1 0.39 1.99 1.79 0.65
2 0.18 0.96 0.69 0.98
3 0.28 0.39 0.57 0.46
4 0.65 0.97 2.14 0.54
5 0.64 0.85 1.58 0.78
6 0.26 0.89 0.32 0.19
7 0.34 0.77 1.22 1.17
8 0.17 1.28 1.11 0.37
The median increase in plasma CoQ10 concentration with time, after supplementation with
four different doseage regimens of CoQ10, is shown in Figure 5.2. The dose vs increase in
CoQ10 concentration curve for Q-Gel given as 30 mg capsules is shown in Figure 5.3.
There was a significantly higher median increase in CoQ10 from the 150 mg dose than the
60 mg dose (p < 0.001). The median CoQ10 increase was not significantly different
between the 150 and 300 mg doses made up from 30 mg capsules (p = 0.114). The median
absorption from the 300 mg doses via 30 or 100 mg capsules was significantly different (p
< 0.001). The median increase in CoQ10 was significantly higher (p = 0.016) from the 150
mg dose (via 5 x 30 mg capsules) than from the 300 mg dose via 3 x 100 mg capsules.
There appears to be no further increase of CoQ10 level from a single dose after
approximately 200 mg (Figure 5.3).
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Figure 5.2 The median increase in plasma CoQ10 after oral supplementation with 60,
150, and 300 mg CoQ10 via 30 mg Q-Gel capsules, and with 300 mg via 100 mg Q-Gel
capsules. Error bars indicate the standard error of the mean.
5.5.3.5. Time to tmax
The median time to tmax for all doses tested was six hours, which confirms the that the six
hour time-point used in the bioavailabilty study was accurate, at least for the Q-Gel
preparation.
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Figure 5.3 The dose range for the coenzyme Q10 supplement Q-Gel, administered as
30 mg capsules.
5.6. Coenzyme Q10 and statin therapy in patients with chronic heart failure
This study was carried out in collaboration with the Lipid and Diabetes Research Group of
Christchurch Hospital.
5.6.1. Aim
To measure the effect of statin therapy on plasma total CoQ10 concentrations in patients
with chronic heart failure, and to investigate the association of statin therapy, CoQ10, and
endothelial function.
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5.6.2. Study design
5.6.2.1. Subjects
Twenty four patients were recruited from the Cardiology Department outpatient clinic at
Christchurch Hospital. All had symptomatic heart failure (New York Heart Association
Functional Class II or III), and reduced left ventricular ejection fraction (<40%) on
echocardiography. Four patients had type 2 diabetes mellitus and 8 had hypertension.
Patients were receiving standard anti-failure medication of a loop diuretic (n = 18),
angiotensin converting enzyme inhibitor (n = 18) or angiotensin II receptor antagonist (n =
4), with or without digoxin (n = 2), a beta-adrenergic blocker (n = 13), and spironolactone
(n = 4). It was a requirement that the dosage of anti-failure treatment had not changed for
at least three months prior to enrolment, and throughout the study period. Fourteen patients
used aspirin throughout the study period.
5.6.2.2. Study protocol
Patients received 40 mg of Atorvastatin or placebo once daily in the evening for 6 weeks in
a randomised, placebo-controlled, double blind, crossover design. Placebo was lactose,
formulated (by Christchurch Hospital Pharmacy) to visually appear identical to the
Atorvastatin. A 2-week wash-out period was used between treatments. Venous blood
samples (lithium heparin) were collected at baseline, and after each treatment arm (statin
and placebo), for the measurement of plasma lipoproteins and total CoQ10.
5.6.2.3. Measurement of resistance vessel function
Endothelium-dependent and endothelial-independent resistance vessel function was
assessed by venous occlusion plethysmography as described by Watts (37) (Hokanson,
Bellevue, WA, USA) and discussed in Strey et al., (2005) (38). Area under the curve
(AUC) for the forearm blood flow curve was calculated as the first 3 valleys (pulses) after
the cuff artefact. An AUC ratio of the infused arm to the non-infused arm was calculated.
5.6.2.4. Measurement of CoQ10
Total plasma CoQ10 was measured in lithium heparinised plasma by reversed-phase HPLC
with ultraviolet detection, as described in Chapter 3, Section 3.5.1.
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5.6.3. Results
Six weeks of Atorvastatin therapy was well tolerated. One patient with longstanding,
slowly progressive myotonic dystrophy developed myalgia, but these symptoms were
tolerable and the participant chose to complete the study. One participant was withdrawn
from the study after the baseline visit due to worsening heart failure. Atorvastatin treatment
was associated with reductions in LDL-cholesterol (50%), triglycerides (26%) and plasma
CoQ10 levels (33%) (Table 5.10). HDL-cholesterol concentrations remained unchanged.
The percentage reduction in CoQ10 was associated with improvement in acetylcholine
induced, endothelium-dependent vasodilation (r = + 0.501, p = 0.034) (Figure 5.4). This
association did not exist during co-infusion with the nitric oxide antagonist NG-
monomethyl l-arginine  (l-NMMA) (p = 0.598), or during sodium nitroprusside infusion (p
= 0.123). Although there was a significant correlation between statin-induced reductions in
CoQ10 and LDL-cholesterol (p = 0.017), multivariate analysis adjusting for reductions in
LDL-cholesterol showed that CoQ10 remained the significant variable predicting change in
endothelial function (p = 0.041).
Table 5.10 Effect of 6-week statin therapy on lipoprotein profiles and plasma CoQ10
levels.
Baseline Placebo Statin
Treatment
% Reduction p-value
Total Cholesterol
(mmol/L)
5.25 ± 0.20
(3.90 – 7.20)
5.50 ± 0.21
(3.90 - 8.00)
3.47 ± 0.15
(2.30 - 5.40)
36.6 ± 1.8
(15.4 – 50.0)
<0.001
LDL-Cholesterol
(mmol/L)
3.32 ± 0.16
(2.04 - 4.84)
3.56 ± 0.16
(2.19 - 5.24)
1.77 ± 0.11
(0.73 – 3.02)
50.4 ± 2.1
(26.6 - 66.8)
<0.001
Triglycerides
(mmol/L)
1.60 ± 0.13
(0.80 - 3.00)
1.70 ± 0.20
(0.60 - 4.70)
1.15 ± 0.09
(0.60 - 2.50)
26.3 ± 3.6
(0.0 - 57.5)
<0.001
HDL-Cholesterol
(mmol/L)
1.22 ± 0.08
(0.67 - 2.16)
1.17 ± 0.07
(0.66 - 2.04)
1.18 ± 0.07
(0.67 - 2.02)
-2.1 ± 2.5
(-24.6 - 30.2)
0.55
Plasma CoQ10
(µmol/L)
1.19 ± 0.09
(0.59 - 2.08)
1.13 ± 0.10
(0.56 - 2.27)
0.74 ± 0.06
(0.42 - 1.63)
33.1 ± 2.6
(12.5 – 52.4)
<0.001
Data are mean ± SEM for n = 24 patients with ranges in brackets, p-value = comparison
between placebo and treatment.
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Figure 5.4 Correlation between absolute reduction in plasma CoQ10 and
improvement in AUC ratio during intra-arterial acetylcholine infusion at 30 µg/min
following statin treatment.
5.7. Discussion
Where supplementation with CoQ10 is warranted, the significant difference in absorption
between participants highlights the need for monitoring CoQ10 concentrations. Results
presented in this chapter also show that not all supplements have equal absorption at 6
hours. The Q-Gel brand showed better absorption at six hours than other brands tested, so
will be the best brand to use in future clinical trials.
It was found that supplements do not all contain the exact nominated dose. The majority of
the supplement brands investigated, with the exception of Good Health, contained more
CoQ10 than stated. This is probably done on purpose by manufacturers to ensure consumers
cannot complain for getting less product than they paid for. This additional CoQ10 in
capsules was not corrected for in our results, because it is minor additional CoQ10, and the
absorption of CoQ10 is so low that this difference was assumed to make little difference to
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the overall results. Additionally, the majority of supplement brands contained 20% more
CoQ10 than nominated, so were relatively consistent anyway.
Absorption of CoQ10 during supplementation correlates significantly with plasma
cholesterol, and statins decrease plasma cholesterol. Therefore, patients on statin therapy
may show reduced absorption of CoQ10 from exogenous sources, due to the low
concentration of circulating cholesterol. This needs further investigation.
The dose range results suggest that the maximum single dose of CoQ10 (as the supplement
brand Q-Gel) that should be administered for effective supplementation is approximately
200 mg. A significantly better absorption is achieved when a 300 mg dose is administered
as 10 x 30 mg capsules, as opposed to 3 x 100 mg capsules. The increased absorption from
the 30 mg capsules may be due to a lower ratio of CoQ10 to oil in these capsules.
Additionally, it has been suggested that co-supplementation with vitamin E may decrease
absorption of CoQ10 (39, 40), and the vitamin E content of the 300 mg dose via 10 x 30 mg
capsules was 60 international units, whereas that of the 300 mg dose via 3 x 100 mg
capsules was 450 international units.
The results presented in this Chapter show the response to a single dose of CoQ10. Further
studies are required to confirm the plasma response to repeated CoQ10 dosing over time. It
is probable that plasma levels rise over time, possibly until a plateau is reached. If plasma
levels plateau with supplementation, it is possible that lower levels of supplementation
may maintain levels at the plateau value, once it has been reached. Most people who are
supplemented with CoQ10 will be supplemented with repeated dosing, which makes this
information important.
The 33% decrease in plasma CoQ10 due to statin therapy is consistent with that previously
reported (10-15). Changes in plasma CoQ10 levels correlated with changes in LDL-
cholesterol levels, as has been previously reported (13). Other statin trials have been
unable to demonstrate any significant association between reductions in CoQ10 and LDL-
cholesterol concentrations (11). In patients with type 2 diabetes, there is emerging evidence
that supplementation with CoQ10 may improve endothelial function in conduit vessels (41)
and in resistance vessels in combination with fenofibrate (42). In a recently published
study, CoQ10 or Cerivastatin therapy alone, and the combination of both, improved
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endothelial function in conduit vessels of dyslipidemic males with poor endothelial
function. Interestingly, the combination did not result in additional benefits for
endothelium-dependent vasodilation when compared to each treatment alone (43). Our
results show that CoQ10 reductions did not eliminate the beneficial effects of statin therapy
on endothelium-dependent vasodilation. It remains to be tested whether CoQ10
supplementation in statin treated heart failure patients would translate into additional
clinical benefits. In our study, participants with the greatest reduction in CoQ10 had the
most pronounced improvement in endothelium-dependent vasodilation after statin therapy.
It is possible that statin-induced reduction of CoQ10 levels may limit the maximum
favourable effects of Atorvastatin on the microcirculation.
In addition, if our findings that improvements in endothelial function correlate well with
CoQ10 change can be confirmed, CoQ10 measurement could potentially serve as a
biochemical marker for statin pleiotropism.
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Chapter 6. Coenzyme Q9 – Reference Interval, Biological Variation, and Change with Coenzyme Q10
supplementation
6.1. Introduction
Coenzyme Q9, a homologue of CoQ10, is a benzoquinone unit with nine isoprenoid units.
As discussed in Chapter 1, CoQ9 is the predominant CoQ homologue found in rodents
(mice and rats), while most other mammals (including humans) have predominantly
CoQ10. There are conflicting reports as to whether CoQ9 is present in humans. Human
serum has been reported to contain (1-4), and not contain (5, 6) CoQ9. Tang et al., (2001)
(7) reported the presence of CoQ9 in only one individual, a patient with glycogen storage
disease, Type I. They found no measurable CoQ9 in 25 healthy individuals, and 24 other
individuals with illness.
If CoQ9 is present in human plasma in both the reduced and oxidised forms, as CoQ10 is, it
is possible that the reason why Tang et al., (2001) (7) did not detect CoQ9 in human
plasma is because their method quantifies both reduced and oxidised forms of CoQ9 and
CoQ10, and the limit of detection may not be low enough to measure the low
concentrations of endogenous CoQ9 and CoQ9H2.
The presence of CoQ9 in human plasma has no known medical significance. It is possible
that CoQ9 originates as a metabolite of CoQ10 catabolism, as a product of incomplete
CoQ10 biosynthesis (where the last isoprenoid unit is not added during the biosynthesis of
CoQ10), or from the diet.
It has been estimated that the daily dietary CoQ9 intake is 0 – 1.3 µmol/day (8, 9), but this
estimate is unreliable because of the large number of food items that contained CoQ9 at
levels below the detection limit (8). The main dietary sources of CoQ9 are cereals and
edible fats (Table 6.1) (8, 9). If 10% of the dietary intake of CoQ9 is absorbed, the CoQ9
plasma level would increase by approximately 50 nmol/L (9).
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Table 6.1 The CoQ9 concentration in various foods.
Food Item CoQ9 (nmol/g food)
Weber et al., (1997)
(8)
CoQ9 (nmol/g fresh weight)
Mattila and Kumpulainen, (2001)
(9)
Pork heart 4.9 (2.1 – 7.7) 3.9
Beef 3.3 0.5
Chicken 1.0 0.5
Pork chop 1.3 n.d.
Ham 0.4 1.1
Herring b.l. b.l.
Rainbow trout b.l. 0.4
Salmon b.l. n.d.
Bread (rye) 5.9 5.9
Bread (wheat) 1.4 2.6
Rice b.l. n.d.
Broccoli 0.8 (0.7 – 0.9) n.d.
Cauliflower b.l. 0.1
Potato b.l. b.l.
Tomato b.l. b.l.
Carrot b.l. b.l.
Cucumber 0.1 n.d.
Orange 0.6 b.l.
Apple b.l. 0.3
Kiwifruit 0.4 n.d.
Yoghurt 0.4 b.l.
Hard cheese b.l. b.l.
Cream cheese b.l. n.d.
Hens egg 0.5 (0.4 – 0.6) b.l.
Reindeer n.d. 10.7
Beef Heart n.d. b.l.
Beef liver n.d. 1.8
Pork liver 1.5
Rapeseed oil n.d. b.l.
Tuna (canned) n.d. 0.4
Crispbread, rye n.d. 5.9
Pea 0.1
Bean n.d. 0.1
Blackcurrant n.d. 1.0
Ligonberry n.d. 3.6
Strawberry 0.1
Clemintine b.l.
Orange juice n.d. b.l.
Ligonberry juice n.d. 0.1
Milk (1.5%fat) n.d. n.d.
n.d. = not determined, b.l. = below limit of detection.
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There are published methods for measurement of CoQ10 in human plasma that use CoQ9 as
an internal standard (Table 6.2). The presence of endogenous CoQ9 in human plasma
would rule out this compound as an internal standard.
Table 6.2 Assays for CoQ10 in human plasma that use CoQ9 as an internal standard.
Publication Measuring Sample Type Internal Standard
(7) CoQ10
CoQ10H2
Human plasma CoQ9
(10) CoQ10
CoQ10H2
Human plasma CoQ7, CoQ9,
CoQ9H2
(5) CoQ10 Human plasma CoQ9
(11) CoQ10
CoQ10H2
Human plasma CoQ9
This chapter describes work that defines the concentration of endogenous total CoQ9 in
human plasma, establishing a reference interval, biological variation, and the influence of
CoQ10 supplementation on CoQ9 concentrations. This is essential information to underpin
investigations of the possible clinical significance of a change in the proportion of CoQ9,
and for estimating its quantitative effects on many assay methods for CoQ10.
6.2. Coenzyme Q9 measurement
The assay for CoQ9 is as described for CoQ10 using electrochemical detection as described
in Chapter 3, Section 3.6.2. The assay quantifies both total CoQ9 and total CoQ10
simultaneously. The method gives 100 ± 2% recovery of CoQ9 (7).
The standard curve for CoQ9 in 1-propanol is linear from at least 0.5 to 250 nmol/L (Figure
6.1), r = + 0.998.
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Figure 6.1 Standard curve for coenzyme Q9 in 1-propanol.
A chromatogram of a CoQ9 standard, an extract of rat plasma, an extract of human plasma,
and an extract of a human plasma that has been spiked with CoQ9, confirms that a peak for
CoQ9 is evident in human plasma (Figure 6.2).
Figure 6.2 Chromatogram of a CoQ9 standard (0.01 µmol/L) (black), a rat plasma
extract in 1-propanol, 163 nmol/L (green), a human plasma extract in 1-propanol,
40.1 nmol/L (blue), and a 1-propanol extract of human plasma spiked with CoQ9
(red).
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Confirmation that the CoQ9 peak is free of interference was obtained by running the same
HPLC system as described, but replacing the analytical column with a Phenomenex
Develcosil C30 column (250 × 4.6 mm, 5 µm) and slowing the flow rate to 0.8 mL/minute
with the column at 22 ºC. CoQ9 and CoQ10 were retained for longer on the C30 column
(retained for 25.2 and 35.3 minutes respectively) than on the C18 column. The plasma and
standard CoQ9 and CoQ10 had identical retention times when the C30 column was used
(Figure 6.3), confirming the identity of the CoQ9 peak. Additionally, the CoQ9 and CoQ10
concentrations calculated for 4 plasma samples using both the C18 and C30 columns were
very similar (Table 6.3), further confirming that it is CoQ9 that is being measured.
Figure 6.3 Chromatograms of a CoQ9 standard (0.02 µmol/L) (black), a human
plasma extract in 1-propanol, 50 nmol/L (blue), and a CoQ10 standard (0.02 µmol/L)
(red), using a Phenomenex C30 analytical column
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Table 6.3 The concentration of CoQ9 in four random human plasma samples, as
measured using a Phenomenex Luna C18(2) column, and a Phenomenex Develcosil
C30 column.
Phenomenex Luna
C18(2) Column
(CoQ9 in nmol/L)
Phenomenex Develcosil
C30 Column
(CoQ9 in nmol/L)
11.5 7.6
46.7 50.0
14.4 16.4
18.2 18.2
Further confirmation of the identity of the CoQ9 peak was achieved by spiking a plasma
sample with standard CoQ9, and ensuring that a single peak was obtained from the spiked
plasma sample (Figure 6.4) when run on the C30 column.
Figure 6.4 A plasma sample spiked with CoQ9 (black), and the same sample unspiked
(red). Endogenous CoQ9 concentration was 50 nmol/L, and the total CoQ9 in the
spiked sample was 70 nmol/L.
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A chromatogram showing reduced and oxidised CoQ10 (no oxidation or reduction of the
extract before the analytical column) in human plasma, as is used in the method of Tang et
al., (2001) (7), reveals a very small peak for CoQ9 (Figure 6.5). This is approximately the
size of the CoQ9 peak observed in the method of Tang et al., (2001) (7). Of concern,
however, is that when using CoQ9 as an internal standard for measurement of CoQ10, the
concentration of CoQ9 in different individuals will not be identical. This would lead to
error in the CoQ9 concentration, which would transfer to error in the calculated CoQ10
concentration when using CoQ9 as an internal standard. For example, Tang et al., (2001)
(7) added 1260 nmol/L CoQ9 to each plasma sample, which would lead to a 1 to 7%
(depending on the endogenous CoQ9 concentration) underestimation of the actual CoQ10
concentration when the peak height or area of the internal standard is used to calculate
CoQ10 concentration.
Figure 6.5 Chromatograph showing reduced and oxidised CoQ10 in a human plasma
sample (black), and the same sample as total CoQ10 (red). The concentration of total
CoQ9 and total CoQ10 in this sample is 19 nmol/L, and  0.60 µmol/L, respectively.
6.3. Reference interval for Coenzyme Q9
The endogenous plasma total CoQ9 concentration was determined in 205 healthy New
Zealanders, as described in Chapter 4, Sections 4.3.2 and 4.3.3.
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6.3.1. Results
6.3.1.1. Reference interval for CoQ9 in complete cohort, and in males and
females separately.
The distribution of plasma CoQ9 is skewed to the right (Figure 6.6), as found for CoQ10.
Therefore, non-parametric statistics were used to determine the reference intervals. The
reference interval (2.5 and 97.5 interfractile intervals) for the complete population is 8.8 –
47.0 nmol/L (n = 193), with the median CoQ9 concentration being 20.7 nmol/L. There is a
non-significant trend (p = 0.350) for males to have a higher CoQ9 level than females, with
the medians (reference interval) for CoQ9 in males and females being 21.2 (8.3 – 71.8)
nmol/L (n = 80) and 19.9 (8.8 – 43.5) nmol/L (n = 113), respectively.
Figure 6.6 A histogram for CoQ9 in the complete reference cohort (n = 193).
6.3.1.2. Correlation of CoQ9 with CoQ10 and lipids.
Approximately 33% of the variation in CoQ9 is explained by variation in CoQ10, and the
correlation between CoQ9 and CoQ10 in the complete reference cohort (Figure 6.7) was
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highly significant (r = + 0.577, p < 0.001). The median ratio of CoQ9 to CoQ10 was 23.9
mmol/mol, with the absolute range of the ratio being 7.6 – 60.1 mmol/mol. The median
total CoQ9 to LDL–cholesterol ratio in the complete reference population was 689
nmol/mol, with the reference interval being 290 – 1880 nmol/mol. The median total CoQ9
to total cholesterol ratio in the complete reference population was 385 nmol/mol, with the
reference interval being 158 – 890 nmol/mol.
Figure 6.7 Correlation of CoQ9 and CoQ10 in the complete reference cohort (n = 205).
The weak but highly significant correlation of CoQ9 and CoQ10 supports the hypothesis
that CoQ9 is made during CoQ10 biosynthesis by an isoprenoid unit being left off.
However, this correlation also supports the hypothesis that CoQ9 is a metabolite of CoQ10
catabolism, since it is feasible that a person with high CoQ10 has more CoQ10 degradation,
and hence increased levels of CoQ9.
Plasma CoQ9 concentrations correlated weakly, but significantly, with total cholesterol (r =
+ 0.316, p < 0.001) and direct LDL-cholesterol (r = + 0.245, p = 0.001).
Total CoQ10 (umol/L)
2.52.01.51.0.50.0
To
ta
l C
oQ
9 
(n
m
ol
/L
)
80
70
60
50
40
30
20
10
0
Chapter 6 213
6.4. Biological variation of Coenzyme Q9
The biological variation of plasma total CoQ9 was estimated by measuring CoQ9 in the ten
healthy male volunteers used to study the biological variation of CoQ10, as discussed in
Chapter 4, Sections 4.4.2, and 4.4.3.
6.4.1. Results
6.4.1.1. Demographic variables
The median ratios for total CoQ9, the total CoQ9 to LDL-cholesterol, and the total CoQ9 to
total cholesterol ratio (n = 70) are shown in Table 6.4.
Table 6.4 Lipid characteristics for the participants in the biological variation of CoQ9
study (n = 70).
Median (interquartile range)
Total CoQ9 (nmol/L) 18.03 (7.65 – 31.51)
Total CoQ9 to LDL-Cholesterol (nmol/mol) 6.76 (3.61 – 1.58)
Total CoQ9 to Total Cholesterol (nmol/mol) 0.37 (0.23 – 0.74)
Observation of the change in CoQ9 over the two month period in the 10 healthy males
showed that 8 of the 10 participants had CoQ9 levels that were tightly distributed around a
homeostatic set-point, and 2 participants (5 and 6) had less tightly controlled plasma total
CoQ9 concentrations (Figure 6.8). The CoQ10 level correlated with the CoQ9 level in the 10
volunteers (Figure 6.9). The ratios varied widely (Figure 6.10).
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Figure 6.8 Median (·) and range (bars) of CoQ9 concentrations of seven
measurements taken over 2 months from 10 healthy males. Red vertical lines
represent the reference interval determined for CoQ9.
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Figure 6.9 Biological variation (median (·) and absolute range (bars)) for CoQ9 vs
CoQ10 for each participant.
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Figure 6.10 Biological variation (the median and range) for the ratio of CoQ9 to
CoQ10 for each participant. Red vertical lines indicate the reference interval, as
determined in the healthy New Zealand population.
6.5. Effect of CoQ10 supplementation on CoQ9
6.5.1. Study design
Ten healthy male volunteers were supplemented with 150 mg of various CoQ10 supplement
brands, as outlined in Chapter 5, Section 5.4.
6.5.2. Results
6.5.2.1. Demographic variables
Mean baseline CoQ9 (± SD) was 19.1 ± 6.8 nmol/L. There was a significant increase in
CoQ9 after supplementation with CoQ10 (p < 0.001). The median (2.5 – 97.5 percentiles)
CoQ9 concentration increased from 18.0 (7.7 – 39.5) nmol/L to 24.1 (11.7 – 42.1) nmol/L.
There was a weak but significant correlation (r = + 0.380, p = 0.001) between the change
in CoQ9 and the change in CoQ10 after CoQ10 supplementation (Figure 6.11).
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Figure 6.11 Correlation of the change in CoQ10 and CoQ9 after supplementation with
150 mg CoQ10 (n = 70). Red lines indicate the 95% confidence intervals.
There was no significant change in the ratio of CoQ9 to CoQ10 after CoQ10 supplementation
(p = 0.351). However, there was much greater variation in the ratio after supplementation
than before (Figure 6.12).
Figure 6.12 The ratio of CoQ9 to CoQ10 at baseline and after supplementation with
CoQ10 (n = 70).
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Analysis of the formulation contents revealed the presence of CoQ9 in all formulations, at
an approximate concentration of 4 – 26 µg (5 - 32 nmol) per unit. It is not expected that
this very low concentration of CoQ9 would affect plasma concentrations substantially.
6.6. Discussion
The question of whether CoQ9 is present in human plasma has been controversial. These
studies have shown that CoQ9 is present endogenously in humans, with the median CoQ9
concentration in the reference population being 20.7 nmol/L. This value is lower than the
mean CoQ9 concentration of 46.4 ± 7.8 nmol/L reported in 18 healthy participants by
Wakabayashi et al., (1994) (2). It is also lower than the CoQ9 concentration reportedly
found in one patient with a rare glycogen storage disease (Type I) of 31 nmol/L by Tang et
al., (2001) (7). However, Tang et al., (2001) (7) report that no detectable CoQ9 was found
in the 25 samples from healthy subjects and 24 samples from other subjects with various
illnesses.
The concentration of CoQ9 in the rat plasma sample was 163 nmol/L which compares with
published values of 252 ± 12.6 nmol/L in the blood of 12 month old rats (n = 6) (12). The
CoQ10 concentration in the rat plasma sample measured here was 46 nmol/L, which
compares with the published value of 51.0 ± 4.6 in the blood of 12-month old rats (n = 6)
(12).
It can be assumed that CoQ9 circulates in both the reduced and the oxidised forms since the
CoQ9 peak was larger when all CoQ9 was oxidised before detection than when the reduced
and oxidised forms were separated on the analytical column.
The results presented here provide evidence that CoQ9 is not an ideal internal standard for
measurement of CoQ10, and may result in 1 to 7% underestimation of CoQ10
concentrations as compared to methods not using CoQ9 as an internal standard.
The increase in plasma total CoQ9 after supplementation with CoQ10 agrees with animal
data on the effect of CoQ10 supplementation on CoQ9 concentrations in mice and rats. In
rats supplemented with CoQ10, an increase in plasma CoQ9 has been reported (13), but in
other studies no change was seen (14). An increase of CoQ9 in rat tissues after CoQ10
supplementation has been reported for spleen (14), liver (14), and cerebral tissues (15). No
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change in CoQ9 concentrations in rat tissues after CoQ10 supplementation was reported for
brain (14, 16), liver (13), kidney, (13, 14), and heart (14). A decrease in CoQ9 after CoQ10
supplementation in rats has been reported in skeletal muscle (14).
In rat and mouse mitochondria, an increase in CoQ9 after CoQ10 supplementation has been
reported in heart muscle (16), skeletal muscle (13, 16), brain (16) and kidney (13). No
change in CoQ9 after CoQ10 supplementation was seen in rat liver mitochondria (13).
Whether the effect of CoQ10 supplementation on CoQ9 levels in rats and mice is
comparable to the effect in humans is questionable since CoQ9 is the predominant CoQ
homologue in rats and mice. In rats, plasma CoQ9 is 5-fold higher than CoQ10, tissue CoQ9
is 3-11-fold higher than CoQ10, and skeletal muscle mitochondrial CoQ9 is 20-fold higher
than CoQ10 (13). During CoQ10 supplementation of rats, the ratio of CoQ9 to CoQ10 has
been reported to remain unaltered in all tissues except skeletal muscle (16).
The increase in CoQ9 during CoQ10 supplementation is not likely to arise from the low
concentration of CoQ9 in the supplements. It may be due to the in vivo modification of the
isoprene moiety, and/or the antioxidative protection of mitochondrial CoQ9 by endogenous
CoQ (17). It is also possible that the various tissues possess the ability to trim off an
isoprenoid unit. The possibility that exogenous CoQ10 stimulates the synthesis of
endogenous CoQ9 in rats has been ruled out by Dallner et al., (2000) (18) and Bentinger et
al., (2003) (19). Additionally, it is possible that supplemental CoQ10 exchanges with tissue
CoQ, thus displacing some CoQ9 into the plasma.
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Chapter 7. Determination of Vitamin K
7.1. Introduction
The plethora of papers describing assays for measurement of vitamin K suggests that it is
difficult to develop a simple, accurate, and reliable assay for its measurement. As discussed
in Chapter 1, plasma vitamin K is difficult to quantify because (1) it is present at very low
levels (approximately 0.2 – 5 nmol/L), and (2) it is associated with the lipid constituents of
plasma. Assays to date have used long and tedious sample preparation (Appendix 3),
involving liquid-liquid extraction and solid phase purification, with concentration of
extracts by evaporation and reconstitution.
The most promising assays for vitamin K to date utilise HPLC (Appendix 3). Because
vitamin K deficiency is mostly associated with haemorrhagic disease of the new-born, the
sample-size requirements of the assay need to be considered to ensure it can be applied for
measurement of vitamin K in this population.
Detection of vitamin K in HPLC is most commonly achieved using fluorescence detection
which has been applied for measurement of vitamin K in milk products (1, 2), foods (3-5),
animal and human tissues (6-8), and plasma (9-20) (Appendix 4). Early reports of HPLC
determination of vitamin K used ultraviolet detection for measurement in plasma (12) and
milk products (21-23) although sensitivity was not high. Electrochemical detection has also
been used for determination of vitamin K in milk (24), foods (25), and plasma (26). There
is one report of the use of gas chromatography to measure vitamin K in plant material after
HPLC separation (27), and another reporting the use of GC/MS for measurement of plasma
vitamin K (28).
As discussed in Chapter 2, fluorescence detection for vitamin K requires the reduction of
naphthoquinone. Because vitamin K naphthoquinol is readily oxidised in the presence of
atmospheric oxygen, this reduction is most efficient if carried out online immediately prior
to the fluorescence detector. This reduction has been achieved using zinc metal in the
presence of zinc ions during extraction (9), using tetramethylammonium
octahydridotriborate added to the HPLC column effluent before detection (29) or to the
mobile phase (11), using photochemical reduction (12, 30), and using sodium borohydride
in ethanol added to the HPLC column effluent before the detector (15). Coulometric
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reduction has also been employed (6). Reduction with zinc, utilising a small on-line
column packed with zinc powder and zinc ions in the mobile phase, has been the most
common reduction method reported when measuring vitamin K with fluorescence
detection (1, 2, 4, 5, 13, 17, 18, 20, 31). On-line reduction of vitamin K by alcohol
catalysed by platinum (packed in a small on-line column) has also been reported, using
10% platinum-on-alumina (16), platinum-black (7, 8, 19), and platinum oxide (14). In the
method of Usui et al., (1989) (7), the platinum-black column and the analytical column
were heated to 50 ºC, but this heating was applied solely to improve the chromatography,
and was not a necessity for the reduction of vitamin K.
The disadvantage of chemical reduction, for example with sodium borohydride, is that the
solution of sodium borohydride degrades and therefore has to be made fresh regularly.
Coulometric reduction is sensitive to residual oxygen and in the absence of an oxygen
scrubber, the reduction efficiency achieved by a coulometric cell is only approximately
60% (9) as discussed in Chapter 2. Reduction by zinc is efficient, but the zinc powder
needs to be replaced on a regular basis and there is a requirement for zinc ions in the
mobile phase. Additionally, Lambert et al., (1986) (29) suggested that packed-bed reactors
cause serious peak broadening and therefore a loss of assay sensitivity as was confirmed in
Chapter 2.
In this Chapter, platinum-black was used as a catalyst for the reduction of vitamin K by
alcohol. Platinum catalysed reduction of vitamin K by alcohol is preferred over zinc
reduction because it is highly efficient (as shown in Chapter 2) and the reduction efficiency
does not decrease over time (7, 14, 16, 32). Therefore, upon exposure to an alcohol mobile
phase, the lifetime of the platinum-black catalyst appears indefinite as long as the mobile
phase does not contain acetonitrile or tetrahydrofuran, which poison the reactor (7, 16, 32).
Additionally, there is no requirement for modifiers in the mobile phase, the only
requirement being for alcohol. The results presented in Chapter 2 show that the
fluorescence response of the vitamin K hydroquinone is highest in protic solvents so this
requirement is more of an advantage than a disadvantage.
Daines (2001) (32) investigated the relative effectiveness of various methanol/metal
catalyst systems at reducing vitamin K. Eight different metal catalysts were investigated
including 5 different forms of platinum, silver powder, copper (I) oxide, and palladium
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black. Each catalyst was packed into a 20 × 2 mm refillable guard column and flushed with
methanol at a flow rate of 0.5 mL/min for at least one hour. Platinum compounds had
superior reducing efficiency when compared to the other metal catalysts tested (32). The
only exception was platinum-on-carbon which, supporting the findings of MacCrehan and
Schönberger (1995) (16), showed no reduction activity. It is possible that platinum-on-
carbon completely adsorbs the reactants and products yielding no fluorescence or
absorbance signal (16, 32). Palladium black gave a much lower fluorescence response than
the platinum compounds (32). Silver powder and copper oxide catalysts did not bring
about any reduction because these catalysts require high temperatures to reduce (32).
Daines (2001) (32) also investigated the reducing ability of a series of different alcohol
mobile phases, and found the order of reducing ability in the presence of platinum-black
was methanol>ethanol>2-propanol>butanol>1,2-ethanediol.
The analytical columns used in HPLC assays of vitamin K are almost always C18, with the
exception of Cook et al., (1999) (33) who utilised a C30 column. The C30 column allowed
the separation of the cis and trans isomers of vitamin K1, present in margarines and oils
(33). The trans-isomer of vitamin K1 is biologically active, whereas the cis-isomer is
relatively inactive (34, 35). It is therefore only necessary to be able to separately quantify
these two forms when measuring vitamin K in processed food samples. The assay of Shino
(1988) (14) quantified vitamin K1 and menaquinone-4-8 in plasma as single peaks using a
C18 column with a methanol/ethanol/60% perchloric acid (600/400/1.2 v/v/v) mobile
phase.
The mobile phases used in HPLC assay of vitamin K usually contain various combinations
of methanol, dichloromethane, ethanol, hexane, ethyl acetate, acetonitrile, 2-propanol and
water (Appendix 4). Methanol, ethanol and dichloromethane are the three most often used
solvents in the mobile phase. As discussed in Chapter 2, the fluorescence of vitamin K
naphthoquinol in dichloromethane and ethyl acetate is not as high as in methanol, ethanol
or some other protic solvent.
Recovery of vitamin K is often low (Appendix 3). This is in part due to the long and
tedious extraction and purification procedures required, and partly because the highly
lipophilic material in the crude hexane extract is not readily soluble in a reversed-phase
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eluent, and tends to occlude both vitamin K1 and the menaquinones (12) as discussed in
Chapter 3, Section 3.1.1. Even when a less polar alcohol such as 2-propanol is used as the
solvent instead of methanol, only 50% of the vitamin K1 present in a sample is recovered
(12).
Many of the purification steps used during extraction use silica/normal-phase
chromatography (6-10, 12, 14, 16, 19, 20, 26) (Appendix 3). Alternatively, Cham et al.,
(1989) (15) and Jakob and Elmadfa (2000) (18) ‘washed’ the hexane extract with
methanol/water (9/1 v/v). Davidson and Sadowski (1997) (17) report the purification of the
extract using C18 solid phase extraction. When using GC/MS for measurement of vitamin
K, concentration of the hexane extract was necessary but no additional sample purification
was required (28).
The concentration and form of vitamin K present in plasma is dependent on diet (14).
Shino (1988) (14) showed that in 5 healthy males, the concentration of menaquinone-7 was
higher than that of all other forms of menaquinone (Table 7.1).
Table 7.1 The concentration of the various forms of vitamin K in human plasma
(from Shino, (1988) (14)).
Form Mean
Concentration
(nmol/L)
Concentration Range
(nmol/L)
Vitamin K1 6.5 1.6 – 18.4
Menaquinone-4 0.7 0 – 2.0
Menaquinone-5 1.8 0.4 – 3.9
Menaquinone-6 0.4 0 – 2.1
Menaquinone-7 5.9 1.2 – 11.4
Menaquinone-8 0.4 0 – 1.0
Additionally, Kamao et al., (2005) (19) reported the plasma concentration of
menaquinone-4, menaquinone-7 and vitamin K1 in 20 healthy subjects (mean ± SD) to be
0.76 ± 0.85, 38.63 ± 71.31, and 8.92 ± 5.41 nmol/L respectively. In osteoporotic patients
treated with menaquinone-4, plasma menaquinone-4 was significantly elevated and levels
of vitamin K1 and menaquinone-7 were significantly lowered (19). Plasma concentrations
of phylloquinone epoxide are increased when patients are on warfarin treatment (17), and
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phylloquinone epoxide is converted to vitamin K1 via reduction (9).  The question of what
forms of vitamin K should be measured in a routine assay to measure the vitamin K status
of individuals therefore remains controversial.
This chapter describes the steps taken to develop a rapid and robust assay to measure
vitamin K1 and menaquinone-4 in the minimum volume of plasma (as requested by
clinicians). A range of columns and mobile phases were investigated and a comparison of
detection methods after HPLC separation was made.
7.2. Experimental
Unless otherwise stated, all HPLC analysis with fluorescence detection was carried out
using a system made up of the following components: a Shimadzu SCL-10A system
controller, a Shimadzu SIL-10AXL auto injector, a Shimadzu LC-10AT liquid
chromatograph pump, a Shimadzu DGU-14A membrane degasser and a Shimadzu-RF-551
spectrofluorometric detector. Fluorescence detection used an excitation wavelength of 249
nm and an emission wavelength of 408 nm.
HPLC with electrochemical detection was carried out using a system made up of the
following components: a Shimadzu-10Advp auto injector, a Shimadzu LC-10AD pump, a
Uniflows Degasys DG-2410 degassing system, an ESA model 5020 guard cell, an ESA
model 5011 analytical cell and an ESA Coulochem III electrochemical detector. All cell
potentials are with respect to an α-hydrogen/palladium electrode.
Platinum-black was used as received from the supplier. Platinum-black was packed into an
Alltech refillable guard column (20 × 2 mm) and flushed thoroughly with methanol at a
flow rate of 0.1 mL/minute overnight before use. The platinum-black filled column is
referred to in this Chapter as a ‘platinum-black reactor’.
The HPLC systems were interfaced through Delta 5.0 Chromatography software for data
collection. All solvents used were HPLC grade and used as received from the supplier.
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7.3. Comparison of detection methods after HPLC
7.3.1. Limit of detection for vitamin K1 using fluorescence detection
7.3.1.1. Experimental:
Standards (0.2 – 18 nmol/L) were made up in a solvent mixture consisting of 11% water
and 89% 1-propanol. Injection volume was 200 µL. The mobile phase was 30/70 (v/v)
methanol/ethanol, pumped at a flow rate of 0.5 mL/minute. The analytical column was a
Phenomenex Develosil RPAqueous C30 (250 × 4.6 mm, 5µm), at ambient temperature.
The fluorescence detector was an Agilent (1100 series) with the PMT gain set to 12. A
platinum-black reactor was placed between the column and the fluorescence detector.
Noise was determined by calculating the standard deviation of the data points collected in a
clean patch of baseline and the limit of detection taken as the concentration when the peak
height was three times the noise.
 The calibration curve for determination of vitamin K1 (in ethanol) using fluorescence
detection was linear (Figure 7.1). The average limit of detection from a range of standards
(in ethanol) from 0.2 to 18 nmol/L, was 0.28 ± 0.16 nmol/L (mean ± SD).
Figure 7.1 The calibration curve for vitamin K1 using fluorescence detection.
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7.3.2. Limit of detection for vitamin K1 using electrochemical detection
7.3.2.1. Experimental
Standards were as used for fluorescence detection (Section 7.3.1.1) and 50 µL was
injected. The analytical column, flow rate and mobile phase were also the same except
sodium acetate trihydrate (50 mmol/L) and glacial acetic acid (15 mL/L) were added to the
mobile phase as electrolytes. A platinum-black reactor was placed between the pump and
the injector, and a second platinum-black reactor was placed between the column and the
analytical cell. An electrochemical guard cell (set to a potential of –700 mV) was placed
after the first platinum-black reactor, and before the pulse-dampener and injector. The first
cell of the analytical cell was set to a potential of 325 mV and the second to a potential of
700 mV. Noise and the limit of detection were determined as for fluorescence detection.
The calibration curve for vitamin K1 (in ethanol) using electrochemical detection was
linear (Figure 7.2). The limit of detection calculated on standards (in ethanol) from 0.2 to
18 nmol/L) was 0.12 ± 0.04 nmol/L (mean ± SD).
Figure 7.2 The calibration curve for vitamin K1 with electrochemical detection.
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The advantage of using electrochemical detection is that specificity can be increased by
using the multiple electrochemical cells in a ‘screening’ mode, as discussed in Chapter 2,
Section 2.2.4. However, there is a requirement for an electrolyte in the mobile phase and,
additionally, residual oxygen in the system decreases the efficiency of reduction of vitamin
K1 by electrochemical cells, as discussed in Chapter 2. Removal of residual oxygen has
been achieved using a platinum oxide catalyst (36). A platinum-black reactor placed online
between the pump and the injector will also scrub oxygen from the system leading to an
improved efficiency of reduction.
7.4. Extraction
In a routine clinical assay, the extraction procedure must be relatively quick and
straightforward. The extraction must also be efficient as shown by spiking plasma with a
vitamin K1 standard, and measuring recovery.
Liquid-liquid extraction of vitamin K1 from plasma with hexane, after precipitation of
proteins with ethanol, and concentration of the extract by evaporation and reconstitution,
was investigated. Plasma (200 µL) was mixed with ethanol (200 µL), before vitamin K
was extracted with hexane (400 µL). The hexane layer (300 µL) was evaporated and the
residue reconstituted in 1-propanol (200 µL). This method resulted in approximately 87%
recovery of the vitamin K1 from a 50 nmol/L spiked plasma extract (Figure 7.3). However,
when the same procedure was applied to an unspiked plasma sample, the vitamin K1 peak
was too small to be quantified. This method has the advantage that the vitamin K can be
reconstituted in a range of solvents that are compatible with the HPLC system. However,
the disadvantage of this method is that evaporating the supernatant to dryness can result in
degradation of vitamin K due to exposure to light and air. Additionally, as discussed in
Chapter 3, Section 3.1.1, the recovery of this extraction procedure is dependent on the
concentration of lipids in the extract.
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Figure 7.3 Evaporation method for extraction of vitamin K1 from plasma.
The practicalities of analysing vitamin K in plasma by adding 500 µl of 1-propanol to an
equal volume of plasma was investigated. After thorough mixing, the sample was
centrifuged, and the supernatant injected directly into the HPLC. Most of the vitamin K
remained bound to proteins (determined by the low recovery achieved using this method),
making this procedure inefficient. Because vitamin K is lipophilic, large volumes of 1-
propanol are required to release plasma vitamin K from the lipids into the 1-propanol.
However, because vitamin K is present in plasma at such low concentration, the large
volume of 1-propanol required for extraction gives a vitamin K concentration that is too
low to measure. There was no phase separation between 1-propanol and water, so the
lipophilicity of the 1-propanol is reduced, and the vitamin K1 is therefore more soluble in
the protein pellet than the 1-propanol/water mixture.
A liquid-liquid extraction of vitamin K1 from plasma using 1- and 2-butanol was
investigated by adding 500 µl of 1- or 2-butanol to 500 µl of plasma, vortexing and
centrifugation. The top layer (1- or 2-butanol) was removed and injected into the HPLC
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system. A problem with this method is that the precipitated plasma proteins form a layer in
between the aqueous constituents of plasma and the 1- or 2-butanol organic phase.
Therefore, some of the 1- and 2-butanol is associated with the proteins. Three compounds,
urea, sucrose and ammonium sulfate, were investigated to determine whether their addition
to plasma before the 1- or 2-butanol would decrease the thickness of the protein layer, and
reduce the volume of 1- or 2-butanol associated with the protein layer. The addition of a
small amount of urea decreased the thickness of the protein layer, possibly because urea
denatures plasma proteins. Of the two solvents (1- and 2-butanol), the protein layer was
thinner when 2-butanol was used as extraction solvent. Hence this solvent is preferred over
1-propanol.
A possible extraction procedure therefore involves addition of a small amount of urea
(approximately 15 mg) to 500 µl plasma, followed by addition of 500 µl 2-butanol. After
vortexing and centrifugation, the organic phase can be injected directly into the HPLC.
Using this protocol, 72-78% recovery of standards (in an aqueous phase) was achieved.
However, when this procedure was applied to plasma, the lipids in the 2-butanol extract
complicated quantification of vitamin K in the extract, so additional purification of the
extract was still necessary.
7.4.1. PRP column
As described in the column section below (Section 7.5), an HPLC polymer reversed-phase
column (PRP) (Phenomenex PolymerX) retained vitamin K when methanol, ethanol, and
2-butanol were used as the mobile phase. It was proposed that PRP could therefore be used
as a solid phase extraction medium for purification prior to HPLC analysis.
Plasma (100 µL) was mixed with 900 µL of 1-propanol. The solid phase extraction
columns (Phenomenex Strata 100 µm SDB-L syrene Divinyl Benzene 100 mg/mL) were
conditioned with 1 mL 1-propanol. The 1-propanol plasma extract was applied to the PRP
column and eluted using vacuum. The column was washed with 2 mL 1-propanol, and the
vitamin K1 then eluted with 0.5 mL hexane. The hexane was evaporated at 35 ºC under a
stream of nitrogen. The residue was reconstituted in 100 µL 1-propanol, diluted 1/8 (v/v)
with water, and injected (50 µL) into the HPLC system (Phenomenex Develosil C30
analytical column (250 × 4.6 mm, 5 µm), 30/70 methanol/ethanol (v/v) with 50 mmol/L
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sodium acetate trihydrate and 15 mL/L glacial acetic acid mobile phase, flow rate 0.5
mL/minute) with electrochemical detection.  An impurity co-eluted with the vitamin K1
peak, hence this extraction protocol was not taken any further.
7.5. HPLC columns
The protocol for the vitamin K assay using a platinum-black reactor and fluorescence
detection does not enable the use of normal-phase columns, since the quantity of alcohol
required to reduce the quinone would wash vitamin K through without retention. Vitamin
K is lipophilic and therefore more soluble in non-polar solvents. However, vitamin K
cannot be injected onto a reversed-phase column in a non-polar solvent as this would
minimise retention and compromise fluorescence yields. The chromatography offered by
four different reversed-phase columns was briefly investigated (using fluorescence
detection), in order to identify the column with the most promising attributes for the
development of a routine vitamin K assay:
(a) A C18 column (Merk Supersphere 100 RP-18 endcapped, 150 × 4.6 mm, 5 µm)
retained vitamin K1 (standard in ethanol) for about 20 minutes when methanol (run at
0.5 mL/min) was used as the mobile phase (Figure 7.4). For practical reasons, vitamin
K extracted from biological samples needs to be injected in a polar solvent otherwise
retention on the column will be compromised. It is not ideal to inject vitamin K in polar
solvents since its solubility is poor.
(b) A Phenyl-Hexyl column (3 µm, 50 × 3 mm, Phenomenex) incorporating a phenyl
phase with a hexyl alkyl linker as opposed to the traditional propyl chain, did not retain
ethanoic vitamin K1 when a 60/40 methanol/ethanol (v/v) mobile phase was run at 0.2
mL/min. This column reputedly has an increased retention for polar aromatic
compounds, but vitamin K1 is not polar and its retention was not significant on this
column (Figure 7.4). Therefore, no further work was carried out with this column, due
to the lack of retention with a polar mobile phase.
(c) A reversed-phase C30 column (Phenomenex Develosil RP aqueous, 250 × 4.6 mm, 5
µm) retained vitamin K1 for about 18.5 minutes with a 30/70 (v/v) methanol/ethanol
mobile phase (Figure 7.4).
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(d) A polymer reversed-phase (PRP) column from Phenomenex, PolymerX  (150 × 4.6
mm, 5 µm) consists of microporous polystyrene divinylbenzene and is reported to have
similar selectivity characteristics to a C18-bonded silica column. This column retained
vitamin K1 when washed with methanol, ethanol, 2-propanol, and 2-butanol, all at a
flow rate of 0.5 mL/minute. Vitamin K was eluted from this column by heptane. Figure
7.4 shows a chromatogram of a vitamin K1 standard (500 nmol/L, low sensitivity on
the fluorescence detector) with a 20/40/40 hexane/methanol/2-propanol (v/v/v) mobile
phase, retention time approximately 7 minutes. The strong affinity of this column for
vitamin K is probably due to a strong interaction between the styrene-divinylbenzene
copolymer beads of the stationary phase and the aromatic group of vitamin K. Further
work was therefore carried out to determine the most practical mobile phase to use with
this column.
Figure 7.4 Vitamin K1 standard (50 nmol/L) on a C18 column (black), and a Phenyl
Hexyl column (blue), a 500 nmol/L vitamin K1 standard on a Polymer Reversed-
Phase column (red), and a 20 nmol/L vitamin K1 standard on a C30 column (green).
Arrows point to vitamin K peaks.
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7.6. Mobile phase
Requirements of the mobile phase are that first a primary or secondary alcohol must be
present to act as a reducing agent for the platinum-black catalysed reduction. Secondly,
vitamin K must be retained on the column while any co-extracted interfering substances
are washed through. Thirdly, run time for the assay needs to be reasonable (such as 30
minutes or less) for it to be practical as a routine clinical test. Fourthly, protic solvents
should predominate in the mobile phase since the solvent effect on fluorescence described
in Chapter 2 demonstrated that protic solvents result in a greater fluorescence response
from vitamin K1. Finally, it is desirable that the mobile phase separates vitamin K1 and
menaquinone-4.
The Phenomenex PolymerX column (150 × 4.6 mm, 5 µm) described above was used for
the study of the mobile phase since of the columns tested, it retained vitamin K most
strongly.
(a) Vitamin K1 eluted at 29 minutes when the mobile phase consisted of 10/90
heptane/methanol (v/v) (flow rate of 0.4 mL/min). Analysis of an extract of a spiked
(50 nmol/L) plasma sample, (ethanol (200 µl) was mixed with 500 µl spiked plasma,
450 µl of hexane was then added, and the sample vortexed and centrifuged. The
supernatant was removed and evaporated and the sample reconstituted in ethanol)
showed that interfering compounds are also extracted from plasma and continue to be
eluted from the column at 26 minutes. The interfering compounds masked the vitamin
K1 peak so that it could not be accurately quantified (Figure 7.5).
(b) Vitamin K1 eluted at 18 minutes when a 60/20/20 hexane/methanol/2-propanol (v/v/v)
mobile phase was run. The peak was broad in time and also showed some tailing.
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Figure 7.5 Chromatogram of vitamin K1 spiked plasma with 10/90 heptane/methanol
mobile phase on a PRP column (black), and a vitamin K1 standard (50 nmol/L) with a
60/20/20 hexane/methanol/2-propanol mobile phase (red).
(c) Tetrahydrofuran (THF) was added to the mobile phase to investigate what effect it
would have on the chromatography. Vitamin K1 was not eluted from the column after
30 minutes by a 50/50 THF/methanol (v/v) mobile phase run at 0.5 mL/minute.
Vitamin K1 was eluted without retention when the mobile phase was both 40/40/20
(v/v/v) THF/methanol/heptane, and 20/20/60 (v/v/v) heptane/THF/methanol, run at 0.5
mL/minute. A mobile phase of 5/20/75 THF/heptane/methanol (v/v/v) (run at 0.5
mL/min) resulted in elution of menaquinone-4 at 10 minutes, and vitamin K1 at 11
minutes. However, the vitamin K1 and menaquinone-4 peaks overlapped so the two
forms could not be quantified separately (Figure 7.6). A 10/10/80
THF/heptane/methanol (v/v/v) mobile phase (at 0.5 mL/minute) eluted vitamin K1 and
menaquinone-4 at 12 minutes with no separation of the vitamin K1 and menaquinone-4
peaks. A 5/20/75 (v/v/v) heptane/THF/methanol mobile phase (at 0.5 mL/minute)
retained vitamin K1 (retention time 8.2 minutes) for slightly less time than
menaquinone-4 (retention time 8.7 minutes). A 25/75 THF/methanol (v/v) mobile
phase (at 0.5 mL/minute) retained menaquinone-4 (retention time 9 minutes) slightly
Time (minutes)
0 10 20 30
Fl
uo
re
sc
en
ce
 (m
V
)
-5
0
5
10
15
20
25
Chapter 7 235
longer than vitamin K1 (8.5 minutes). Therefore, THF in the mobile phase results in
menaquinone-4 being retained for longer than vitamin K1 on a polymer reversed-phase
column. However, heptane in the mobile phase results in vitamin K1 being retained for
longer than menaquinone-4 on a polymer reversed-phase column. The concentration of
THF has to be kept low since THF poisons the platinum-black reactor (7, 16, 32).
Figure 7.6 Chromatogram of 50 nmol/L vitamin K1 (black) and 50 nmol/L
menaquinone-4 (red), with a 5/20/75 THF/heptane/methanol mobile phase.
(d) When propylene carbonate was added to the mobile phase (50/50 (v/v) propylene
carbonate/methanol, at 0.5 mL/minute), no vitamin K1 peak was seen either with or
without a column. It is possible that propylene carbonate may have some intrinsic
ultraviolet absorbance, which masked the vitamin K1 peak.
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(e) A 20/80 (v/v) cylcohexane/methanol mobile phase (at 0.5 mL/minute) eluted vitamin K
from the column in a similar manner to heptane. As a mobile phase constituent,
heptane is preferred over cyclohexane since heptane is less volatile.
These results indicate that a mobile phase consisting of methanol, ethanol, and heptane in
various proportions may be most useful for a vitamin K assay, on a Phenomenex polymerX
reversed-phase column. The proportions of each solvent in the mobile phase can be altered
to lengthen or shorten retention times of vitamin K (for example, to separate vitamin K1
and menaquinone-4).
(f) Using a 20/80 heptane/methanol (v/v) mobile phase (run at 0.3 mL/min),
menaquinone-4 was eluted at 21 minutes and vitamin K1 at 23 minutes. The vitamin K1
and menaquinone-4 peaks overlapped slightly so could not be accurately quantified
using peak areas (Figure 7.7).
Figure 7.7 Chromatogram of the separation of vitamin K1 (black, VK1) and
menaquinone-4 (blue, MK), both 50 nmol/L, and of a solution containing 25 nmol/L
K1 and 25 nmol/L menaquinone-4 (red). Mobile phase 20/80 (v/v) heptane/methanol.
Detector set on high sensitivity.
MK VK1
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(g) A mobile phase of 20/40/40 heptane/methanol/ethanol (v/v/v) (at a flow rate of 0.5
mL/minute) eluted vitamin K1 (retention time 9.5 minutes) before menaquinone-4
(retention time 10.5 minutes) and the peaks were not baseline separated. A mobile
phase of 20/60/20 (v/v/v) heptane/ethanol/methanol (0.4 mL/minute) also did not
separate vitamin K1 (retention time 11 minutes) from menaquinone-4 (retention time
12 minutes).
(h) Replacing ethanol with 1-propanol, (a mobile phase of 20/40/40 heptane/methanol/1-
propanol (v/v/v) run at 0.4 mL/minute) separated the vitamin K1 (retention time 9.5
minutes) and menaquinone-4 (retention time 11 minutes) peaks slightly more but they
were still not baseline resolved (Figure 7.8).
Figure 7.8 Chromatogram of 50 nmol/L vitamin K1 (black, VK1), 50 nmol/
menaquinone-4 (blue, MK), and 25 nmol/L vitamin K1 and 25 nmol/L menaquinone-
4, in a 20/40/40 heptane/1-propanol/methanol (v/v/v) mobile phase. Detector set on
low sensitivity.
VK1
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(i) The 1-propanol was replaced with 2-propanol and similar peak separation to that
achieved in (h) was evident. Further work used 2-propanol rather than 1-propanol,
since 2-propanol is kept in stock at Canterbury Health Laboratories.
(j) Since heptane is the solvent eluting vitamin K from the column, the heptane content of
the mobile phase was reduced to 15% to investigate whether the vitamin K1 and
menaquinone-4 peaks were better separated. A 15/45/40 heptane/methanol/2-propanol
(v/v/v) mobile phase did increase the resolution but still not sufficiently for a
quantitative assay.
(k) The concentration of 2-propanol was increased, so the mobile phase was 15% heptane,
35% methanol and 50% 2-propanol. The two peaks were now baseline resolved
allowing quantification of both vitamin K1 and menaquinone-4. Therefore, a 15/35/50
heptane/methanol/2-propanol (v/v/v) mobile phase (at a flow rate of 0.4 mL/minute)
was chosen to quantify vitamin K1 and menaquinone-4 (Figure 7.9).
Figure 7.9 Chromatogram of 50 nmol/L vitamin K1 (black), 50 nmol/L menaquinone-
4 (blue), and 25 nmol/L vitamin K1 and 25 nm menaquinone-4 (red), with mobile
phase of 15/50/35 (v/v/v) heptane/2-propanol/methanol.
VK1
MK
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7.7. Discussion
This Chapter describes attempts to develop a rapid, reliable, and robust assay for
quantification of vitamin K1 and menaquinone-4 in human plasma using minimal sample
volume. The extraction procedure and the HPLC system in terms of detection, column and
mobile phase were investigated. An extraction procedure consisting of a simple liquid-
liquid extraction of vitamin K1 from plasma appears to be insufficient because impurities
that interfere with the chromatography are also extracted and, additionally, the extract
needs to be concentrated. Washing a hexane extract with methanol/water, as described by
Jakob and Elmadfa (2000) (18) would be a good, simple purification technique which
needs to be investigated further. Additionally, the assay of Yamashita et al., (1997) (37),
(measuring CoQ10), describes the injection of 5 µL of the hexane extract directly onto a C8
column with a tert-butyl alcohol/methanol mobile phase. Because the injection volume is
very small, the incompatible solvent does not appear to adversely affect the
chromatography.
The Phenomenex PolymerX HPLC column allowed more scope for altering the mobile
phase than the traditionally used C18 columns. Of the mobile phases investigated, only
15/35/50 (v/v/v) heptane/methanol/2-propanol gave baseline separation of the vitamin K1
and menaquinone-4 peaks.
The sensitivity of fluorescence detection is increased by finding the optimal emission and
excitation wavelengths for vitamin K1 in the mobile phase. As discussed in Chapter 2,
there is a small Stokes shift with different solvents for vitamin K1.
MacCrehan and Schönberger (1995) (16) compared deuterium and xenon light sources for
the fluorometer. The detection limits (S/N = 3) for a 50 µL injection were 50 and 7 pg for
the deuterium and xenon-source fluorometers respectively. The detection limit for
oxidative amperometric detection of hydroquinone at a glassy carbon electrode following
on-line catalytic reduction was approximately 200 pg injected, and therefore less sensitive
than fluorometric detection.
Menaquinone-7 may also be an important vitamin K homologue that requires
determination (14, 19). The retention time of phylloquinone epoxide should also be known,
to ensure that the assay is measuring vitamin K1 as opposed to vitamin K1 plus
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phylloquinone epoxide. If the latter is true, then knowledge of whether the patient is
currently receiving Warfarin therapy is essential since Warfarin significantly elevates
phylloquinone epoxide (17). Additionally, the measurement of vitamin K1 and
menaquinone-4 as separate entities is desirable, since menaquinone-4 is significantly
elevated when patients (usually with osteoporosis) are treated with menaquinone-4.
The work described in this Chapter provides a basis on which to further develop a practical
vitamin K assay that meets the demands of clinicians. Electrochemical detection using
coulometric cells has been shown to provide the highest sensitivity of the detection
methods available, especially when combined with platinum-black filled columns for
catalysis of alcohol reduction of vitamin K on-line.
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Chapter 8. Conclusions and Future Work
Coenzyme Q10 (CoQ10) and vitamin K are quinones whose electron and proton transfer
functions are essential for all life forms. The work described in this thesis was initiated by
a demand from clinicians for a rapid, reliable and robust assay to determine vitamin K in
biological samples in order to investigate and monitor the prevalence of haemorrhagic
disease of the new born. Initial work on developing this assay was carried out by Daines
(2001) (1), and further developed in an attempt to meet the needs of clinicians.
During work on the vitamin K assay, demand for a rapid, reliable and robust assay to
determine the chemically similar CoQ10 increased. CoQ10 deficiency is implicated in the
increasingly popular statin therapy, as well as in heart failure and various other
pathologies. Additionally, CoQ10 has become increasingly popular as a nutritional
supplement, with many claims for health benefits of supplementation being made with
little scientific backing.
The work described in this thesis was carried out to develop assays for vitamin K and
CoQ10 that meet the desires of clinicians, and to form a solid basis of knowledge of the
biochemistry of CoQ10 on which to build future clinical trials.
8.1. Vitamin K
? For measurement of vitamin K, the forms to be quantified need to be defined since the
final assay (including the extraction procedure) depends on what is to be measured. For
example, if measuring phylloquinone epoxide, the sample cannot be subjected to
reducing conditions before separation on the HPLC column, since phylloquinone
epoxide is reduced to phylloquinone (vitamin K1). Additionally, Warfarin therapy
significantly elevates the level of phylloquinone epoxide, and patients being treated for
osteoporosis are often supplemented with menaquinone-4.
? The low endogenous concentration of vitamin K, combined with its lipophilicity, make
it a difficult analyte to quantify in biological samples. With the fluorometer available,
fluorescence detection could not meet clinical requirements for determination of low
vitamin K levels in small samples (less than 50 µL). Electrochemical detection gave
scope to meet clinical requirements but further developmental work is necessary.
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? For measurement of vitamin K in plasma, an extraction procedure consisting of simple
liquid-liquid extraction of vitamin K1 appears to be inadequate because impurities,
which interfere with the chromatography, are also extracted. Additionally, the extract
needs to be concentrated.
? A Phenomenex PolymerX HPLC analytical column allows more scope for altering the
mobile phase than the traditionally used C18 columns and will be a good tool to use in
further assay development work.
8.2. Coenzyme Q10
? Coenzyme Q10 in biological samples can be analysed by HPLC using either ultraviolet
or electrochemical detection. Ultraviolet detection allows measurement of total CoQ10
(after oxidation of endogenous CoQ10H2 during extraction). Electrochemical detection
is required for determination of both reduced and oxidised CoQ10. Fluorescence
detection of CoQ10 after alcohol reduction with platinum-black as a catalyst (a more
efficient reduction technique than electrochemical or zinc reduction) does not allow
adequate sensitivity to measure biological levels of CoQ10 even when aprotic solvents
(which give the highest fluorescence yield for CoQ10) are used in the mobile phase.
? Coenzyme Q9 (CoQ9) is present in human plasma with a reference interval of 8.8 –
47.0 nmol/L. These results provide evidence that CoQ9 is not an ideal internal standard
for measurement of CoQ10, and its use leads to erroneous results. The origin of plasma
CoQ9 in humans, be it from catabolism of CoQ10 or a minor product of CoQ10
synthesis, is not clear. There was a weak but highly significant correlation between
plasma total CoQ9 and CoQ10 concentrations and a significant increase in plasma total
CoQ9 concentrations after CoQ10 supplementation.
? Coenzyme Q10 in biological samples is stable for at least 18 months when stored at –80
ºC. It is not, however, stable at –13 ºC. Coenzyme Q10 is photochemically degraded,
and exposure to light for periods of longer than 2 hours leads to significant
degradation.
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? The reference interval for plasma total CoQ10 in the healthy New Zealand population
was determined to be 0.47 – 1.90 µmol/L. Coenzyme Q10 concentrations in healthy
young males were shown to be tightly distributed around a homeostatic set point which
suggests that interpretation of CoQ10 values for a given individual should be based on
previously determined values for that individual as opposed to comparison with a
reference interval.
? Coenzyme Q10 supplements have varied bioavailability and inter-individual differences
in absorption of CoQ10 are marked. Therefore, plasma CoQ10 concentrations should be
monitored during supplementation to ensure efficacy.
? There is a plateau in absorption of CoQ10 from a single oral dose of the supplement Q-
Gel (the most bioavailable brand of the CoQ10 supplements tested) which occurs at
approximately 200 mg. Therefore, the maximum single oral dose to be taken for
maximum absorption efficiency should be 200 mg. The Q-Gel supplements containing
30 mg CoQ10 per capsule give approximately twice the plasma levels of those
containing 100 mg CoQ10 per capsule when equivalent doses are given.
? There is a highly significant 33% reduction in plasma total CoQ10 when patients with
chronic heart failure are given 40 mg per day Atorvastatin therapy for six weeks. This
reduction in plasma CoQ10 correlates with an improvement in endothelial function,
suggesting that plasma CoQ10 concentrations may be a marker for statin-mediated
improvements in endothelial function.
8.3. Further work
Further work is needed to investigate whether there is any correlation between tissue and
plasma CoQ10 levels. This work is essential to ascertain whether measurement of plasma
CoQ10 levels indicates the CoQ10 status in muscle tissue such as myocardium and brain.
Collection of muscle tissue for analysis of CoQ10 involves an invasive sampling technique,
hence is undesirable, however it may be essential if plasma CoQ10 levels do not indicate
tissue status.
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Studies investigating the changes in plasma CoQ10 with multiple sequential CoQ10 dosing,
including bioavailability studies, would be logical next steps from the bioavailability study
reported in this thesis.
Further work is also necessary to elucidate the role of CoQ10 in the many disease states in
which it has been implicated, and hence the benefits of CoQ10 supplementation.  To
complete this further work, it is necessary to have reliable assay methods and reliable data
on normal circulating concentrations of CoQ10 and how these are affected by disease, drug
interactions and supplementation. The work described in this thesis provides an essential
basis of background information from which this further work can evolve.
The significant association of reduction in CoQ10 and improvement in acetylcholine-
induced, endothelium-dependent vasodilation suggests the need for an investigation into
whether acetylcholine-induced endothelium-dependent vasodilation is further improved
with CoQ10 and statin co-therapy, or whether the improvement is negated by CoQ10
supplementation.
The well-known hypotheses that CoQ10 depletion is the cause of statin-induced myalgia,
and that co-therapy of CoQ10 and statins will eliminate myalgia symptoms, remain to be
thoroughly explored, and a study investigating this would answer a very important
question that has remained unanswered for some time now.
Langsjoen and Langsjoen (1999) (2) completed an interesting review of over 40 studies
that have been published that relate information on the benefit of CoQ10 supplementation
in cardiovascular disease. Langsjoen and Langsjoen (1999) (2) concluded that there is
some benefit, particularly lowering of New York Heart Association (NYHA) class,
improved left ventricular ejection fraction, and 6-minute walk test in heart failure patients
who are supplemented with CoQ10. There is currently a large international multicenter
study being conducted into the effect of CoQ10 supplementation in patients with heart
failure, called Q-SYMBIO (3). The principle centre for this study is Denmark, and the
results of this study will be very interesting.
Rauchaus et al., (2003) (4) recently published an interesting finding that survival in heart
failure patients is predicted by their total cholesterol levels, with low levels of total
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cholesterol being associated with worse survival. Various potential mechanisms for this
association were postulated, including lower metabolic reserve in patients with low total
cholesterol, and a protective role for lipoproteins in chronic heart failure.   One potential
mechanism for this association that was not discussed by Rauchaus et al., (2003) (4) was
that CoQ10 levels in these patients may be deficient, if their total cholesterol levels are low.
This potential explanation for the association would be easily explored in stored samples
from a cohort of heart failure patients with a long follow-up period recording survival.
Further work is required to develop a rapid and reliable assay to measure plasma vitamin
K. The first step in development of this assay must be to determine exactly what forms of
vitamin K are to be quantified. It is possible that laser-induced fluorescence detection will
give scope to measure the low plasma concentrations of vitamin K in small sample
volumes. Alternatively, electrochemical detection may allow measurement of vitamin K in
these small samples after further improvement of the assay extraction procedure.
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Appendix 1. Summary of extraction procedures used in published assays of CoQ10 in biological specimens.
Publication Sample
Type
Measuring Detection Anticoag
ulant
Sample
volume
Extraction Evapor
ation?
Recovery Injection
volume
Comments
(1) Plasma CoQ10 UV Heparin 500 µL Liquid –liquid with
hexane then TLC
Yes 103.6 ± 3.3% 10 Two evaporation
steps. Final
reconstitution in
ethanol.
(2) Plasma CoQ10
CoQ10H2
ECD
Ox
UV
Heparin 200 µL Liquid-liquid with
hexane and 5/95 2-
propanol/ethanol
Yes 88.5% for
CoQ10H2 and
111.1% for CoQ10
20 µL Added SDS and
BHT to plasma
before extraction.
Reconstitute in
mobile phase
(3) Plasma CoQ10
CoQ10H2
ECD
Ox-red-ox
Heparin 300 µL Liquid-liquid with 1-
propanol (1 mL)
No 101 ± 3.7% 100 µL Use ferric
chloride to
oxidise plasma
CoQ10H2 to
measure total
CoQ10
(4) Tissue CoQ10
Other
analytes
Diode
array
1g Liquid-liquid with
methanol/chloroform
Yes 92% Reconstitute in
chloroform then
SPE with bond-
elute column,
evaporation and
reconstitute in
0.1% 2-propanol
in heptane
(5) Plasma CoQ10
CoQ10H2
ECD None
(Serum)
100 µL Liquid-liquid with
ethanol and hexane
Yes 97.8 ± 4.4% 10 µL Reconstitute in
ethanol
(6) Plasma CoQ10
CoQ10H2
Carotenoids
tocopherols
ECD
Red-partial
ox-
complete
ox
Heparin 5-10
µL
Liquid-liquid with
hexane
Yes >97% 20 µL Reconstitute in
2.5/47.5/50 2-
propanol/ethanol/
methanol
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Publication Sample
Type
Measuring Detection Anticoag
ulant
Sample
volume
Extraction Evapor
ation?
Recovery Injection
volume
Comments
(7) Plasma CoQ10 UV Heparin 1000
µL
Liquid-liquid with
methanol and hexane
SPE with silica and C18
cartridges
Yes 64 ± 6% Reconstitute in 2-
propanol
(8) Plasma CoQ10H2
CoQ10
ECD
ox-red-ox
EDTA 300 µL Liquid-liquid with 1-
propanol (1 mL)
No 80 µL
(9) (10) Tissues CoQ10H2
CoQ10
CoQ9H2
CoQ9
Vitamin E
homologues
ECD
UV
50 –
100 mg
tissue
50/50 ethanol/hexane (4
mL)
Yes >90 % Antioxidants are
added before and
during extraction
procedure
(11) Plasma CoQ10H2
CoQ10
ECD
ox
Heparin 50 µL Liquid-liquid with 33/66
(v/v) methanol/hexane
No 99 – 104 % 5 µL 5 µL of the
hexane extract
injected directly
(12) Tissue CoQ10H2
CoQ10
CoQ9H2
CoQ9
Vitamin E
and α-
tocopherol
oxidation
products
ECD
ox
100 mg Liquid-liquid with
hexane (2 × 3 mL)
Yes >95% reconstituted
extract in 1/3
(v/v)
chloroform/metha
nol
(13) Plasma CoQ10
CoQ10H2
ECD
Red-ox
EDTA or
heparin
500 µL Liquid-liquid with
methanol and hexane
SPE with either solid
phase silica and C18
cartridges, or silica and
C18 powders
Yes 69.9% with
cartridges
79.5% with
powders
(13) Plasma CoQ10
CoQ10H2
ECD
Red-ox
EDTA or
heparin
50 µL Liquid-liquid with
ethanol and hexane
Yes 80.7%
(14) Plasma CoQ10H2
CoQ10
ECD
ox
EDTA 50 µL Liquid-liquid with
ethanol (500 µL)
No 90.7 – 107.7 %
(mean 99.2 %)
25 µL
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Publication Sample
Type
Measuring Detection Anticoag
ulant
Sample
volume
Extraction Evapor
ation?
Recovery Injection
volume
Comments
(15) Plasma CoQ10H2
CoQ10
and
tocopherols
ECD
Red-red-ox
Heparin 10 µL Liquid-liquid with
hexane (500 µL)
Yes 93 – 97 % Reconstituted
extract in
2.5/47.5/100
(v/v/v) 2-
propanol/ethanol/
methanol
(16) Plasma CoQ10
CoQ10H2
ECD
ox-red-ox
Heparin 100 µL Liquid-liquid with 1-
propanol (900 µL)
No 95.8 - 101.0 % 20 µL
(17) Plasma CoQ10 UV Heparin 200 µL Liquid-liquid with 1-
propanol (1 mL)
No 96 - 98.5 % 200 µL 1,4-benzoquinone
oxidation pre-
extraction
(18) Plasma CoQ10H2
CoQ10
ECD and
UV
EDTA 200 µL Liquid-liquid with
methanol (2 mL) and
hexane (4 mL)
Yes 20 µL Reconstituted
extract in 0.3 mL
ethanol
(19) Plasma CoQ10 UV Heparin 300 µL Liquid-liquid with 1-
propanol (1 mL)
No 100.9 ± 2.1 % 400 µL Sample clean-up
pre-analytical
cell, using column
switching
(20) Erythro
cytes
and
platelets
CoQ10 ECD
Red-red-ox
EDTA 2 mL
blood
Liquid-liquid with
methanol and hexane
(800 µL)
Yes 91 – 100 % Reconstitute in 40
µL ethanol
(21) Tissue CoQ10
CoQ9
Other
analytes
UV 25 mg Liquid-liquid with
hexane
Yes 10 µL Reconstituted
extract in 50 µL
25/75 (v/v)
hexane/methanol
(22) Mouse
tissues
CoQ10H2
CoQ10
CoQ9H2
CoQ9
ECD
Ox-red-ox
Approx
1.1 g
Liquid-liquid with 1-
propanol and water
No 90% for CoQ9H2
117% for CoQ9
86% for CoQ10H2
256% for CoQ10
CoQ10 = coenzyme Q10; CoQ10H2 = coenzyme Q10H2 quinol; CoQ9 = coenzyme Q9; CoQ9H2 = coenzyme Q9 quinol; TLC = thin layer chromatography; UV = ultraviolet
detection; ECD = electrochemical detection; Ox = oxidation; Red = reduction; SDS = sodium dodecylsulfate; BHT = butylated hydroxytoluene; SPE = solid phase extraction;
EDTA = ethylenediaminetetraacetic acid ; v/v = volume to volume.
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Appendix 2. Summary of chromatography systems used in published assays of CoQ10 in biological specimens.
Publication Sample
type
Measuring Detection Mobile Phase Column LOD % CV Comments
(1) Plasma CoQ10 UV 25/75 n-hexane/methanol Finepak SIL C18-5
(250 × 4.6 mm, 5
µm)
10 ng (S/N =
5)
Used potassium
hexacyanoferrat
e (III) to oxidise
tissue CoQ10H2
but not plasma
(2) Plasma CoQ10
CoQ10H2
ECD
Ox
UV
4.5/10/85.5 2-
propanol/methanol/ethanol + 20
mmol/L lithium perchlorate, 1
mL/min
Altex Ultrasphere
ODS (250 × 4.6
mm, 5 m) or Altex
Ultrasphere octyl
(250 × 4.6 mm, 5
µm)
2 pmol
(correspondi
ng to a
concentratio
n of 0.1
µmol/L in
the extract)
<10%
(3) Plasma CoQ10
CoQ10H2
ECD
Ox-red-ox
15/85 1-propanol/methanol +
33 mmol/L perchloric acid and
57 mmol/L sodium perchlorate
for CoQ10H2 measurement,
proportion of 1-propanol
increased to 25 for
measurement of total CoQ10
Column 1
Spherisorb ODS-2
(100 × 4.6 mm, 3
µm)
Column 2
Chromspher C18
(100 × 3 mm, 5 µm)
10% Dual columns
on HPLC –
compounds
strongly retained
on the first
column are
washed off to
waste – CoQ10
goes to second
column
(4) Tissue CoQ10
Other
analytes
Diode
array
0.1/99.9 2-propanol/heptane Cyanopropyl
(5) Plasma CoQ10
CoQ10H2
ECD 0.8/1.0/8.2 v/v/v
methanol/water/ethanol + 0.05
mol/L sodium perchlorate
Capcell Pak C8 (SG
120, 150 × 4.6 mm,
5 µm)
100 pg (S/N
= 3)
Intra- 3.1 and
Inter- 4.0 % for
CoQ10
Post-column
platinum
catalyst
reduction.
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Publication Sample
type
Measuring Detection Mobile Phase Column LOD % CV Comments
(6) Plasma CoQ10
CoQ10H2
Carotenoids
tocopherols
ECD
Red-partial
ox-
complete
ox
10/24/88 2-
propanol/ethanol/methanol
(v/v/v) + 13.4 mmol/L lithium
perchlorate
SuperPac Pep-S
RPC2/C18 (250 × 4.0
mm, 5 µm
51 and 60
fmol/20 µL
inject for
CoQ10H2 and
CoQ10
respectively
(S/N = 3)
Intra- and inter-
12 and 32% for
CoQ10H2 and 9
and 55 for
oxidised CoQ10
Large inter-run
precision
Requires
minimal sample
volume
(7) Plasma CoQ10 UV 15/85 hexane/methanol C18 RP column,
Sepharon C18 (150
× 3 mm, 5 µm)
90 µg CoQ10
per Litre
plasma
(8) Plasma CoQ10H2
CoQ10
ECD
ox-red-ox
20/80 1-propanol/methanol +
32.5 mmol/L perchloric acid
and 57 mmol/L sodium
perchloric
Phase Sep s 5 ODS
2 (50 × 4.6 mm)
Inter- 9.3 –
12.3%, Intra-
3.4 – 7.9%
(9, 10) Tissues CoQ10H2
CoQ10
CoQ9H2
CoQ9
Vitamin E
homologues
ECD
UV
Gradient of (a) 20/80
water/methanol + 0.2% (w/v)
lithium perchlorate and (b)
ethanol with 0.2 % (w/v)
lithium perchlorate
Beckman
Ultrashpere ODS
C18 column (250 ×
4.6 mm, 5 µm)
0.3 pmol/L
for
ubiquinols
0.2 pmol/L
for quinones
(11) Plasma CoQ10H2
CoQ10
ECD
ox
15/85 (v/v) tert-butyl
alcohol/methanol + 50 mmol/L
sodium perchlorate
Supelcosil LC-8
(250 × 4.6 mm, 5
µm)
4 nmol/L
(detection
limit of
plasma
CoQ10 and
CoQ10H2)
(12) Tissue CoQ10H2
CoQ10
CoQ9H2
CoQ9
Vitamin E
and α-
tocopherol
oxidation
products
ECD
ox
Gradient of (a) 2/98 (v/v)
water/methanol + 5 mmol/L
zinc chloride, 2.5 mmol/L
sodium acetate, and 2.5 mmol/L
acetic acid, and (b) 2/49/49
(v/v/v) water/ethanol/methanol
+ 7.5 mmol/L zinc chloride,
3.75 mmol/L sodium acetate,
and 3.75 mmol/L acetic acid
LiChrocart Merck
RP column (125 × 4
mm, 5 µm),
LiChrosorb 100 RP-
18, Merck
0.6 pmol/L
for CoQ10H2
1 pmol/L for
CoQ10
Inter- 8 – 13%
for CoQ10H2
3-5 % for CoQ10
Solid-phase
post-column
reactor dry
packed with zinc
particles (20 ×
4.6 mm stainless
steel column)
was used for on-
line reduction
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Publication Sample
type
Measuring Detection Mobile Phase Column LOD % CV Comments
(13) Plasma CoQ10
CoQ10H2
ECD
Red-ox
2.2/660/660/880 (v/v/v/v) 70%
perchloric
acid/acetonitrile/methanol/ethan
ol + 0.05 mol/L sodium
perchlorate
SuperPac Pep-S
(250 × 4 mm, 5µm)
or SuperPac
Sephasil (250 × 4
mm, 5 µm)
(13) Plasma CoQ10
CoQ10H2
ECD
Red-ox
(14) Plasma CoQ10H2
CoQ10
ECD
ox
Gradient of (a) 100% methanol
+ 50 mmol/L sodium
perchlorate and 10 mmol/L
perchloric acid and (b) 20/80
(v/v) tert-butanol/ethanol
Hewlett-Packard
Hypersil C18 (125 ×
4.0 mm, 5 µm)
2.5 nmol/L Inter- 5.1%
Intra- 3.3%
Chromatography
is not very good,
baseline is not
stable
(15) Plasma CoQ10H2
CoQ10
and
tocopherols
ECD
Red-red-ox
6/17/77 (v/v/v) 2-
propanol/ethanol/methanol +
31.7 mmol/L ammonium
formate
Prontosil 120-3-
C18-SH PEEK
column (150 × 4
mm, 3 µm)
CoQ10H2 25
fmol/20 µL
injection
volume
CoQ10 28
fmol/20 µL
injection
volume
Intra- 3-13% for
all measured
substances
(16) Plasma CoQ10
CoQ10H2
ECD
ox-red-ox
1.5/1.5/27.5/69.5 Glacial acetic
acid/2-
propanol/hexane/methanol
+ 50 mmol/L sodium acetate
trihydrate
RP Microsorb MV
(150 × 4.6 mm, 5
µm) Rainin.
11.6 nmol/L Inter- and intra-
1.20 – 4.9 %
(17) Plasma CoQ10 UV 30/70 methanol/ethanol Supelcosil LC18
(Supelco) (250 ×
4.6 mm, 5 µm)
1.23
nmol/inject
Inter- 2%, Intra-
1.6%
(18) Plasma CoQ10H2
CoQ10
ECD and
UV
4/21/75 ethanol/methanol/2-
propanol + 20 mmol/L lithium
perchlorate
Inertsil ODS-2
column (2 × 100 ×
3.0 mm, 5 µm)
Inter- 5.9 % for
CoQ10H2 and 3.1
% for CoQ10
No limit of
detection or
recovery data
given
(19) Plasma CoQ10 UV 10/90 2-propanol/methanol Hypersil ODS2 (150
× 4.6 mm, 5 µm)
116 nmol/L Inter <3%, Intra-
<2%
Column
switching
eliminated polar
and strongly
retained solutes
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Publication Sample
type
Measuring Detection Mobile Phase Column LOD % CV Comments
(20) Erythroc
ytes and
platelets
CoQ10 ECD
Red-red-ox
6/17/77 (v/v/v) 2-
propanol/ethanol/methanol +
31.7 mmol/L ammonium
formate
Prontosil 120-3-
C18-SH PEEK
column (150 × 4
mm, 3 µm)
Intra- and inter-
5% for total
CoQ10 and 12%
for oxidised
CoQ10
(21) Tissue CoQ10
CoQ9
Other
analytes
UV 25/75 (v/v) hexane/methanol 3.6 ± 0.25 ng
for CoQ10
3.3 ± 0.15 ng
for CoQ9
Measured lots of
things on a
single tissue
sample, so not
optimised for
CoQ.
(22) Mouse
Tissues
CoQ10H2
CoQ10
CoQ9H2
CoQ9
ECD
Ox-red-ox
1.5/1.5/14/83 (v/v/v/v) glacial
acetic acid/2-
propanol/hexane/methanol +
51.2 mmol/l sodium acetate
anhydrous
RP Microsorb-MV
(150 × 4.6 mm, 5
µm) Rainin
17 nmol/L Intra- 2.7 –
5.6% for CoQ9
and CoQ10
Inter 4.6 – 8%
for CoQ9 and
CoQ10
CoQ10 = coenzyme Q10; CoQ10H2 = coenzyme Q10H2 quinol; CoQ9 = coenzyme Q9; CoQ9H2 = coenzyme Q9 quinol; UV = ultraviolet detection; ECD = electrochemical
detection; Ox = oxidation; Red = reduction; EDTA = ethylenediaminetetraacetic acid ; w/v = weight to volume; S/N = signal to noise.
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Apendix 3. The extraction procedures used in various methodologies for determining vitamin K.
Publication Sample Meas
uring
Detection Sample
volume
Extraction Recovery Injection
volume
Comments
(23) Infant
formulas
K1 Reflectance
densiometry
N/A Liquid-liquid, with diethyl ether and petroleum ether,
then preparative column chromatographic separation
then TLC
91 ± 3%
(24) Plant K1 GC N/A Liquid-liquid with hexane, purified on alumina
column
(25) Human
and cow
milk and
infant
formula
K1 UV N/A Liquid-liquid with chloroform and methanol (2/1
v/v). Washed extract with water, chloroform layer
was evaporated to dryness. Solid phase extraction
with silica, washed with light petroleum and eluted
with light petroleum/diethyl ether (97/3 v/v).
Evaporation and reconstitute residue in 50 – 100 µL
mobile phase
Sample clean-up on
first HPLC system,
followed by second
(analytical) HPLC
(26) Serum K1
and
mena
quino
nes
Fluorescence
and UV in
series
2 mL Precipitate proteins with ethanol, then liquid-liquid
with hexane, evaporation, reconstitute in hexane
Complet
e extract
Sample clean-up on
first HPLC system,
followed by second
(analytical) HPLC
(27) Infant
formulas
K1 UV N/A Enzymatic hydrolysis of lipids, using lipase (1.5
hours incubation)
84 – 103% 10 µL
(28) Animal
feed
K3 Fluorescence N/A Aqueous extraction, then K3 is converted to
menadione.
94.4 ±
6.8%
(mean ±
SD)
100 µL
(29) Plasma K1 ECD 3 mL Liquid-liquid with hexane, and further purified with
semi-preparative HPLC
30 µL
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Publication Sample Meas
uring
Detection Sample
volume
Extraction Recovery Injection
volume
Comments
(30) Plasma K1 Fluorescence 0.5 –
1.0 mL
Liquid-liquid with ethanol and hexane, evaporate
hexane and reconstitute residue in hexane. Purify
extract with silica ‘Sep-Pak’ column, which was
washed with hexane, and vitamin K1 eluted with
diethyl ether/hexane (3/97 v/v) and evaporate.
Redissolve residue in hexane, reduce vitamin K1 and
inject.
100 µL ‘Reductive
extraction’.  Add to
exract 70 mmol/L
zinc chloride in 3/97
(v/v) acetic
acid/acetonitrile (pH
2.1). Add 5-10 mg of
zinc metal for 2
minutes, discard
hexane layer, and
evaporate acetonitrile
layer, redissolve in
hexane/water (75/25
v/v). Evaporate
hexane and
reconstitute in mobile
phase
(31) Plasma
or serum
K1(20)
and
K1(21)
Fluorescence 2mL Liquid-liquid with ethanol and hexane. Hexane
evaporated and residue redisolved in
hexand/diisopropyl ether (98.5/1.5 v/v).
94% Semi-preparative
HPLC prior to
analytical HPLC
(32) Plasma K1 Fluorescence
(33) Plasma K1 Fluorescence 2mL Liquid-liquid with ethanol and hexane. Hexane
evaporated and residue redissolved in
hexand/diisopropyl ether (98.5/1.5 v/v).
94% Semi-preparative
HPLC prior to
analytical HPLC
(34) Human
and cow
milk
K1
and
mena
quino
nes
ECD N/A Enzymatic hydrolysis of milk (incubate with lipase
for 1.5 hours), then extract hydrolysate with 1-
pentane, evaporate and redissolve residue in 2-
propanol, subject to semi-preparative then analytical
HPLC.
>93% Semi-preparative
HPLC prior to
analytical HPLC
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Publication Sample Meas
uring
Detection Sample
volume
Extraction Recovery Injection
volume
Comments
(35) Plasma K1
and
mena
quino
nes
Fluorescence 1 mL Denature proteins with ethanol, liquid-liquid
extraction with hexane and diethyl ether. Addition of
water then evaporate hexane, reconstitute residue in
hexane and apply to a silica gel column, which is
washed with hexane/benzene (3/2 v/v). Vitamin K
eluted with hexane/benzene (1/2 v/v) and the eluate
evaporated. Residue redissolved in hexane, and
applied to an alumina column, washed with
hexane/benzene (6/1 v/v) then elute with
hexane/benzene (3/1 v/v). Eluate evaporated and
redissolved in ethanol.
50 µL Reduction post-
column by platinum
oxide catalyst column
(36) Human
serum
K1
and
vitam
in E
Fluorescence 0.5 – 3
mL
Denature proteins with ethanol, extract lipids into
hexane. Wash hexane layer with methanol/water (9/1
v/v). Evaporate hexane layer and reconstitute residue
in 120 µL 2-propanol.
80% 100 µL Reduction post-
column with sodium
borohydride in
ethanol (21 nmol/L)
(37) Animal
tissues
K1
and
mena
quino
nes
Fluorescence 1 g
tissue
sample
Tissue homogenised with 66% 2-propanol, then
mixed with hexane. Hexane layer is evaporated and
the residue redisolved in hexane, and applied to a
Sep-Pak silica cartridge, which is washed with
hexane and K vitamins are eluted with hexane/diethyl
ether (96/4 v/v). Eluate is evaporated and
reconstituted in hexane, which is then subjected to
TLC on a silica gel 60 F254 plate. The vitamin K-
containing spot is removed and extracted with
chloroform, which is then evaporated, the residue
redissolved in ethanol for injection
>73.5% 50 µL Coulometric
reduction
(38) Plant
extracts
K1 Fluorescence N/A Dichloromethane extraction of the plant using a
soxhlet apparatus. Evaporation (not to completion)
and reconstitution of the extract in methanol.
Photochemical
reduction
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Publication Sample Meas
uring
Detection Sample
volume
Extraction Recovery Injection
volume
Comments
(39) Human
liver
K1
and
mena
quino
nes
Fluorescence 1g
tissue
Tissue homogenised with 66% 2-propanol, then
mixed with hexane. Hexane layer is evaporated and
the residue redisolved in hexane, and applied to a
Sep-Pak silica cartridge, which is washed with
hexane and K vitamins are eluted with hexane/diethyl
ether (96/4 v/v). Eluate is evaporated and
reconstituted in hexane, which is then subjected to
TLC on a silica gel 60 F254 plate. The vitamin K-
containing spot is removed and extracted with
chloroform, which is then evaporated, the residue
redissolved in ethanol for injection
107.5 ±
3.0%
(%CV)
50 µL Platinum-black
reduction column
(40) Foods K1 Fluorescence N/A Liquid-liquid extraction into 2-propanol and hexane,
then solid-phase extraction on Silica gel column.
Sometimes an extra step of reversed-phase solid-
phase extraction on C18 was required.
Post-column zinc-
reduction
(41) Infant
formulas
and milk
produces
K1 UV N/A Lipase in phosphate buffer to digest lipids. Semi-
preparative normal-phase HPLC prior to reversed-
phase HPLC and quantitation.
(42) Serum K1 Fluorescence 500 µL Proteins were precipitated with 2-propanol, and
sample extracted with hexane. Hexane was
evaporated, and the residue redissolved in hexane.
The residue was subjected to solid-phase extraction,
which was washed with hexane, and vitamin K1 was
eluted with ether/hexane (3/97 v/v), which was
evaporated, and the residue reconstituted in ethanol
70 ± 34%
(mean ±
SD) (n =
30)
50 µL Reduction catalysed
by 10% platinum-on-
alumina
(43) Plasma K1 GC/MS 1 mL Proteins precipitated with methanol (addition of a
small amount of water), followed by liquid-liquid
extraction with hexane. Evaporated hexane, and
redissolve residue in hexane.
10 µL
(44) Fluorescence Zinc reduction
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Publication Sample Meas
uring
Detection Sample
volume
Extraction Recovery Injection
volume
Comments
(45) Plasma K1
and
phyll
oquin
one
2,3-
epoxi
de
Fluorescence 1 mL Proteins precipitated with ethanol (addition of small
amount of water), then liquid-liquid extraction with
hexane. Hexane evaporated, residue reconstituted in
2-propanol (heated to 50 ºC to help dissolution) and
subjected to solid-phase-extraction - C18 column,
washed with water/methanol (5/95 v/v), and
acetonitrile, and vitamin K eluted with
dichloromethane/methanol (20/80 v/v). Eluent
evaporated. Redissolve residue in 20 µL of 100%
dichloromethane (added first) and 180 µL methanol
containing 10 mmol/L zinc chloride, 5 mmol/L acetic
acid, and 5 mmol/L sodium acetate (1 L methanol + 5
mL aqueous solution).
75.0 ±
5.0%
(mean ±
SD)
100 µL Post-column zinc
reduction (50 × 2 mm
stainless steel column
dry-packed with zinc
metal).
100 × 4.6 mm ID
column packed with
10% platinum on
alumina placed pre-
injector
(46) Infant
formulas
and milk
K1
and
mena
quino
nes
Fluorescence N/A Enzymatic digestion, then extraction >98% 20 µL Zinc reduction
(47) Oils and
margarin
es
K1 ECD N/A Extraction with hexane, followed by straight-phase
semi-preparative HPLC for margarine extracts.
98 – 102% 40 µL ECD reduction
(48) Human
liver
K1
and
mena
quino
nes
Fluorescence 1g
tissue
Tissue homogenised with 66% 2-propanol, then
mixed with hexane. Hexane layer is evaporated and
the residue redissolved in hexane, and applied to a
Sep-Pak silica cartridge, which is washed with
hexane and K vitamins are eluted with hexane/diethyl
ether (96/4 v/v). Eluate is evaporated and
reconstituted in hexane, which is then subjected to
TLC on a silica gel 60 F254 plate. The vitamin K-
containing spot is removed and extracted with
chloroform, which is then evaporated, the residue
redissolved in ethanol for injection
89 – 107% 50 µL Platinum-black
catalysed reduction,
held at 50 ºC
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Publication Sample Meas
uring
Detection Sample
volume
Extraction Recovery Injection
volume
Comments
(49) Milk
powders
and milk
K1 Fluorescence N/A Samples digested with lipase and extracted into
hexane, an alliquot is evaporated, reconstituted into
methanol and injected
Post-column reactor,
20 × 4 mm, dry-
packed with zinc
powder.
(50) Plasma K1 Fluorescence 1 mL The hexane extract, if necessary after evaporation of
non-hexane solvents, was washed with a mixture of
methanol and water, as previously described.
Zinc-powder
reduction
(51) Medical
foods
K1 Fluorescence N/A Sample enzymatically digested with lipase and α-
amylase, and extracted with 1% sodium bicarbonate
solution/isoporpanol (1/1 v/v). Then C18 solid phase
extraction.
101.6 ±
2.85%
Post-column zinc
reduction
(52) Plasma K1 Fluorescence 0.1 –
0.5 mL
Proteins precipitated with ethanol, then hexane
extraction. Hexane layer put onto silica cartridges,
which are washed with hexane, and vitamin K is
eluted with diethylether/hexane 3.5/96.5 v/v). Eluate
is evaporated, and the residue reconstituted in 25 µL
dichloromethane followed by 75 µL mobile phase
component A.
92.3 ±
1.9% (n =
12)
45 µL Zinc reduction
(53) Serum or
plasma
K1,
mena
quino
nes 4
and 7
Fluorescence 0.5 mL Plasma diluted with water, internal standards added,
and sample extracted with ethanol and hexane.
Hexane layer applied to Sep-Pak silica cartridge,
which is washed with hexane, and K vitamins eluted
with hexane/diethyl ether (97/3). Eluate evaporated
and residue redissolved in ethanol.
>92% 40 µL Platinum-black
reduction. One HPLC
system for
menaquinone 4 and
another for K1 and
menaquinone 7.
TLC = Thin-Layer Chromatography
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Appendix 4. HPLC assays previously described for the determination of vitamin K.
Publication Sample
type
Measu
ring
Detection Mobile phase Column LOD %CV Comments
(25)
[part 1]
Human
and cow
milk and
infant
formula
K UV Methanol/dichloromethane (8/2 v/v) Either
microparticulat
e silica or an
amino-cyano-
bonded phase
Collect eluant containing K,
evaporated and reconstitute in
50-100 µL mobile phase
(25)
[part 2]
Human
and cow
milk and
infant
formula
K UV (254 nm
or 270 nm)
Methanol/dichloromethane (8/2 v/v) (1
mL/min)
OR
Methanol/dichloromethane (9/1 v/v)
OR
Acetonitrile/dichloromethane (7/3 v/v)
OR
Acetonitrile/dichloromethane 17/3 (v/v)
Zorbax-ODS
Hypersil-ODS
Zorbax-ODS
Hypersil-ODS
(26)
[part 1]
Serum K1 UV 3% diisopropyl ether in hexane Silica column
(200 × 7 mm,
Rsil 5 µm)
Collected elutant containing K1,
evaporated and reconstitute in
40 µL methanol, inject 20 µL
(26)
[part 2]
Serum K1 UV (248
nm)
100% Methanol, 1 mL/min RP C18 0.5
ng/mL
serum
Within-day
5.3%
(mean
conc 5.5
ng/mL)
Photochemical induction for
reduction, hydroquinone
stabilised with ascorbic acid
(27) Infant
formulas
K1 UV (254
nm)
Acetonitrile/methanol/tetrahydrofuran/wat
er (39/39/16/6 v/v/v/v)
(28)
Animal
feed
K3 Fluorescence
(ex 325 nm,
em 425 nm)
Water/ethanol 4/6 (v/v) (0.6 mL/minute) ODS-Hypersil 0.02
µg/g
Reduced K3 using sodium
borohydride in ethanol, 21
mmol/L
(29)
[part 1]
Plasma K1 ECD (red –
ox)
1 mL/min Normal- phase
HPLC
Residues dissolved in 70 µL
mobile phase
(29)
[part 2]
Plasma K1 ECD (red –
ox)
1 mL/min 50 pg 10% (n=6),
mean value
was 330
pg/mL.
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Publication Sample
type
Measu
ring
Detection Mobile phase Column LOD %CV Comments
(30) Plasma
(EDTA)
K1 Fluorescence
(ex 248 nm,
em 418 nm)
20/80 (v/v) dichloromethane/methanol to
each litre of which was added 5 mL of a
solution containing 2 mol/L zinc chloride,
1 mol/L sodium acetate, 1 mol/L aceic
acid. Flow rate 1 mL/min.
Hypersil-ODS
column. (250 ×
4.6 mm, 5 µm)
0.05
µg/L
10% Reduction with dry-packed zinc
particles in a 20 × 3.9 mm
stainless-steel column, placed
post-column.
(31)
[part 1]
Plasma
or serum
K1(20)
and
K1(21)
Fluorescence Hexane/diisopropyl ether (98.5/1.5 v/v).
0.85 mL/min
Semipreparativ
e silica
column,
RoSIL 5 µm
200 × 4.6 mm)
50
pg/mL
Within-run
3.6% (n =
5, mean
311
pg/mL)
(31)
[part 2]
Plasma
or serum
K1(20)
and
K1(21)
Fluorescence
(ex 325 nm,
em 430 nm)
Methanol/ethy acetate (96/4 v/v) at 0.85
mL/min
RSIL C18 HL
5 µm (150 ×
3.2 mm)
Reduction after column by
adding reducing agent (a
methanolic solution of
tetramethylammonium
octahydridotriborate, 600
mg/100 mL), which is mixed
with the column effluent at a
flow rate of 0.3 mL/min. This
reaction is performed at 80 ºC in
a ‘knitted coil reactor’.
(32) Plasma K1 Fluorescence 20/80 (v/v) dichloromethane/methanol,
with 10 mmol/L zinc chloride.
Hypersil ODS
(250 × 4.6
mm)
25 pg Solid-phase reactor is high-
purity 200-mesh zinc particles
dry-packed into a 20 × 3 mm
stainless steel column.
(33) Plasma K1 Fluorescence Methanol/ethyl acetate (96/4 v/v)
containing 130 mg tetramethylammonium
octahydrotribotate per 100 mL) flow rate
0.7 mL/minute
RP C18
(RoSIL
C18HL, 5 µm,
150 × 3.2 mm)
Post-column reactor was an
open tubular knitted coil, total
volume 980 µL) placed in a
silicane bath at 80 ºC.
(34)
[part 1]
Human
and cow
milk
K1 and
menaqu
inones
ECD Methanol/acetonitrile (1/1 v/v), flow rate 4
mL/minute
Nucleosil C18
(5 µm, 300 × 8
mm), held at
35 ºC
8.3 –
15.2%
Semi-preparative HPLC prior to
analytical HPLC.
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Publication Sample
type
Measu
ring
Detection Mobile phase Column LOD %CV Comments
(34)
[part 2]
Human
and cow
milk
K1 and
menaqu
inones
ECD Methanol/ethanol/60% perchloric acid
(600/400/1.2 v/v/v) containing 0.05 mol/L
NaClO4 in total solution. Flow rate 1
mL/minute
Partisil ODS-2
(5 µm, 250 ×
4.6 mm) for K1
and
menaquinone-
4.
Partisil ODS-3
(5 µm, 250 ×
4.6 mm) for
menaquinones
6,7,8, and 9.
(35) Plasma K1 and
menaqu
inones
Fluorescence
Ex 254 nm,
em 430 nm
Methanol/ethanol/water (1/2/0.06 v/v/v),
hydrogen gas saturated. Flow rate 1.2
mL/min
Nucleosil
5C18 (250 ×
4.6 mm)
25 pg
injected
4.8%
(1.7
ng/mL, n =
4)
(36) Human
serum
K1 and
vitamin
E
Fluorescence
(ex 320 nm,
em 430 nm)
Ethanol/water (92/8 v/v), flow rate 0.9
mL/minute.
C18 Resolve
column (150 ×
3.9 mm, 5 µm)
30 pg
per
injectio
n
Within-run
8.1%
Between-
run 12.9%
Stainless steel coil (0.8 mm ID ×
1m) used as the reactor, held at
55 ºC, ethanolic sodium
borohydride added to effluent
from analytical column. Flow
rate of reducing agent 0.6
mL/min.
(37) Animal
tissues
K1 and
menaqu
inones
Fluorescence
(ex 320 nm
and em 430
nm)
92.5 or 97.5 % ethanol containing 0.25%
sodium perchlorate. Flow rate 1
mL/minute
Nucleosil C18
(150 × 4.6
mm, 5 µm)
40 pg/g
(38) Plant K1 Photoreducti
on
fluorescence
Methanol/2-propanol (60/40 v/v) Du Pont
Zorbax ODS
column (250 ×
4.6 mm, 5 µm)
Solvent resovior equipped with a
gas dispersion tube so the
mobile phase could be sparged
with ‘oxygen-free’ nitrogen.
Reactors prepared from 30-
gauge PTFE tubing (0.30 mm
ID).
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Publication Sample
type
Measu
ring
Detection Mobile phase Column LOD %CV Comments
(39) Human
liver
K1 and
menaqu
inones
Fluorescence
(ex 320 nm
and em 430
nm)
Gradient – A: 100% methanol and B: 2-
propanol/ethanol (4/1 v/v). 100% A for 15
minutes, then B from 0 - 80% from 15 –
90 minutes. Flow rate 1 mL/min
Nucleosil
5C18 (250 ×
4.6 mm)
10 pg
(S/N
=3) for
standar
d, 100
pg in
liver
(40) Foods K1 Fluorescence Methanol/methylene chloride (90/10 v/v),
to each litre of which was added 5 mL of a
solution containing 2 mol/L zinc chloride,
1 mol/L acetic acid, and 1 mol/L sodium
acetate, flow rate 1 mL/minute.
Inter- and
intra-day
precision
ranged
from 6.6 –
13.6%
Reduction with post-column
chemical reactor (2 × 50 mm)
packed with zinc metal (-200
mesh).
(42) Serum K1 Fluorescence
(ex 242 nm,
em 430 nm)
Ethanol/methanol 40/60 (v/v), flow rate 1
mL/minute
RP bonded-
phase silica
column
(210TP 54,
250 × 4.6 mm,
5 µm) Vydac
Hesperia
Relative
standard
deviation
32% (n =
30, 420
pg/mL)
Reduction catalysed by 10%
platinum-on-alumina (50 × 2
mm column bed), an oxygen
reducer column (10% platinum-
on-alumina, 100 × 4.6 mm)
placed pre-injector
(45) Plasma K1 Fluorescence
(ex 244 nm,
em 418 nm)
Dichloromethane/methanol (10/90 v/v) to
each litre of which is added 5 mL of an
aqueous solution of 2 mol/L zinc chloride,
1ol/L glacial acetic acid, and 1mol/L
sodium acetate. Flow rate 0.6 mL/minute
BDS-Hypersil
(150 × 3 mm,
3 µm)
33
pmol/L
Within-run
5.6%
(n=12),
between-
run 11.8%
(n = 14)
(46) Infant
formulas
and milk
K1 and
menaqu
inones
Fluorescence
(ex 243nm,
em 430 nm)
Dichloromethane/methanol (100/900 v/v)
to which was added a methanolic solution
of zinc chloride (10 mmol/L), anhydrous
sodium acetate (5 mmol/L), and glacial
acetic acid (5 mmol/L). Flow rate 1.5
mL/min
C18 resolve
cartridge
column (100 ×
8 mm ID, 5
µm)
30 pg
on
column
(47) Oils and
margarin
es
K1 ECD 95% Methanol/sodium acetate buffer
(0.05M, pH3). Flow rate 1 mL/minute
Vydac 201
TP54 column
(250 × 4.6
mm, 5 µm)
50
pg/inje
ction
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Publication Sample
type
Measu
ring
Detection Mobile phase Column LOD %CV Comments
(48) Human
liver
K1 and
menaqu
inones
Fluorescence
(ex 320 nm
and em 430
nm)
Gradient – A: 100% methanol and B: 2-
propanol/ethanol (4/1 v/v). 100% A for 15
minutes, then B from 0 - 80% from 15 –
90 minutes. Flow rate 1 mL/min
Nucleosil
5C18 (250 ×
4.6 mm).
Column held
at 50 ºC.
5 pg for
MK-4,
10 pg
for
vitamin
K1, and
MK-5
and –6,
20 pg
for
MK-7-
9, and
40 pg
for
MK-
10-13
(49) Milk
powders,
milk
formula,
and milk
K1 Fluorescence
(ex 243nm,
em 430 nm)
Dichloromethane/methanol (100/900 v/v)
+ 5 mL methanol containing 2 mol/L zinc
chloride, 1 mol/L anhydrous sodium
acetate, and 1 mol/L glacial acetic acid.
Any C18
column
(monomeric or
polymeric,
containing 5
µm spherical
particle silica
with >10%
carbon
loading.
(50) Plasma K1 Fluorescence Methanol/dichloromethane, with zinc
chloride, sodium acetate, and acetic acid.
0.09
nmol/L
(51) Medical
foods
K1 Fluorescence Methanol/methylene chloride (900/100
v/v) + 10 mL of 2 M zinc chloride, 1 M
sodium acetate, and 1 M acetic acid in
methanol
Zorbax C18
(250 × 4.6
mm, 5 µm)
8 pg
Limit
of
quantit
ation
27 pg
on
column
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Publication Sample
type
Measu
ring
Detection Mobile phase Column LOD %CV Comments
(52) Plasma K1 Fluorescence
(ex 244nm,
em 430 nm)
Stepwise gradient: Component A: 994.5
mL methanol and 5.5 mL aqueous solution
of 2 mol/L ZnCl, 1 mol/L acetic acid, and
1 mol/L sodium acetate. Component B:
100% dichloromethane. 95% component
A and 5% B for 10 minutes, then 65% A
and 35% B for 13 minutes, and finally
95%A and 5% B for 5 minutes. Flow rate
0.6 mL/minute.
Hypersil BDS
C18 column
(3.2 × 150
mm, 3 µm)
held at 22 ºC.
4 fmol
per
injectio
n (S/N
= 3).
Limit
of
quantit
ation
for 0.25
mL
plasma
was
0.04
nmol/L
Intra-assay
8.2% (n =
6) and
inter-assay
12% (n =
21) for
mean K1
concentrati
on of 1.4
nmol/L
(53) Serum or
Plasma
K1,
menaqu
inones
4 and 7
Fluorescence For menaquinone-4: 95/5 (v/v)
methanol/water
For menaquinone-7 and vitamin K1: 95/5
(v/v) methanol/ethanol. Flow rates 1
mL/minute
CAPCELL
PAK C18
uG120 (250 ×
4.6 mm, 5
µm). Column
held at 35 ºC.
LOD
for
menaqu
inone-
4,
vitamin
K1, and
menaqu
inone-7
was 4,
2, and
4 pg
respecti
vely
Inter-and
intra-assay
%CV was
5.7-9.2%
for
menaquino
ne-4, 4.9-
9.6% for
vitamin K1
and 6.3-
19.3% for
menaquino
ne-7
Platinum reduction column: 15 ×
4 mm, RC-10, Irica Kyoto,
Japan.
UV = ultraviolet detection, HPLC = high-performance liquid chromatography, ECD = electrochemical detection, K1 = vitamin K1, red = reduction, ox = oxidation, em =
emission wavelength, ex = excitation wavelength, MK = menaquinone.
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